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Abstract 
Development and Application of pH-sensitive Fluorescent Probes to 
Study Synaptic Activity in the Brain 
 
Matthew R. Dunn 
 
 This thesis describes efforts at the interface of chemistry and neuroscience to design and 
characterize fluorescent probes capable of tracing neurotransmitters from individual release sites 
in brain tissue. As part of the Fluorescent False Neurotransmitters (FFNs) program, small organic 
fluorophores have been developed that undergo uptake into specific presynaptic release sites and 
synaptic vesicles by utilizing the native protein machinery, which can then be released during 
neuronal firing. The most advanced generation of FFNs are pH-sensitive, and display an increase 
in fluorescence when released from the acidic vesicular lumen into the extracellular space, called 
a “FFN Flash.” In Chapter 2, the utility of the dopamine-selective and pH-sensitive functionality 
of FFN102 to study the mechanisms that regulate changes in pre-synaptic plasticity, a critical 
component of neurotransmission was explored. This included using the FFN flash to quantitatively 
trace dopamine release, changes in the release probability of individual release sites, and changes 
in vesicular loading that can affect quantal size. 
 The second goal of this thesis research, as detailed in Chapters 3 and 4, sought to expand 
the substrate scope of the FFN program to neurotransmitter systems other than dopamine. 
Described in Chapter 3, is the identification of a fluorescent phenylpyridinium, APP+, with 
excellent labeling for dopamine, norepinephrine, and serotonin neurons, however, the properties 
of the probe were found to be ill-suited for measuring neurotransmitter release. As a result, it was 
concluded that this class of compounds was not suitable for generating viable FFN leads. In 
contrast, Chapter 4 highlights the design, synthesis, and screening towards generating the novel 
noradrenergic-specific FFN, FFN270. This probe was further tested for application in acute murine 
brain slices where it labeled noradrenergic neurons, and was demonstrated to release upon 
stimulation. This chapter also describes the application of this compound in a series of in vivo 
experiments, where the ability to measure norepinephrine release from individual release sites was 
demonstrated in a living animal for the first time. This work opens the possibility for many exciting 
future FFN experiments studying the presynaptic regulation of neurotransmission in vivo. 
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Chapter 1: An Introduction to Neurotransmission 
 
1.1 Preface 
 Studying the organizational complexity interconnecting the ~ 100 billion neurons1 that 
comprise the human brain is proving to be one of the most difficult challenges faced by the 
scientists of this generation. Since the coining of the term in 1960’s2, “neuroscience” has rapidly 
expanded as a field over the past few decades. With the number of neuroscience publications in 
the past year (2014) almost doubling that of the previous year3, every new discovery creates 
more questions to explore. Undaunted by this overwhelming complexity, however, 
neuroscientists continue to push forward. Just as every neuron has a specific function, this thesis 
describes my role in developing novel tools to augment this endeavor. Observation has always 
been the foundation of science, and through the creation of new ways to observe previously 
undetectable neurological phenomenon we can continue to add new pieces to the seemingly 
endless puzzle. 
1.2 The Neuron 
 One of the best ways to start understanding how the brain functions as a whole is to look 
at one of its primary individual elements, the neuron (Figure 1). The neuron is a highly 
specialized cell capable of transferring information across potentially large distances. In general, 
signals are collected in the cellular branches extending off the cell body, called dendrites. Based 
on the information collected by the dendrites, an all-or-nothing signal is then initiated at the axon 
hillock and then propagated down the axon through a change in the electrical potential across the 
axonal membrane. Ultimately, the signal reaches structurally defined locations along the axon, 
2 
 
called synapses, which are capable of releasing neurotransmitters. These “pre-synaptic” release 
sites then chemically transfer the signal across the synaptic cleft through the use of 
neurotransmitters to the dendrites, cell bodies, or synapses of the next neurons in the circuit. 
 
Figure 1. A general illustration of a neuron. A signal is received in the dendrites, which the receiving neuron then 
can continue or not. Its own signal is initiated in the axon hillock and travels down the axon, which can be 
myelinated, to the individual release sites, where the signal is then sent across the extracellular space to the target 
neuron. 
 
 While this general mechanism holds true for most neurons, there can be a great amount of 
diversity between each of the steps along this process. The illustration in Figure 1 highlights 
release sites found after arborization of the axon, but in reality, neurotransmitters can also be 
released by dendrites and cell bodies depending on the neuronal cell type. There is also 
retrograde neurotransmission, in which signals are sent in reverse, from the postsynaptic side to 
communicate back to the presynaptic release site. Using just structural characteristics, it is 
possible to classify different types of neurons into specialized groups. For example, most 
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GABAergic inhibitory neurons are called “interneurons” because they have very short axons that 
only affect a local area, while other neurons are called “projection neurons” that have long 
myelinated axons and connect different brain regions to each other4. Some neurons, like in the 
olfactory bulb, process a whole collection of signal inputs and then send out an organized 
convergent signal onto only a few targets5. These neurons have very little axonal branching, 
which is contrary to other types of divergent neurons, such as the dopaminergic neurons that 
project to the striatum. Each individual dopaminergic neuron in this area of the brain has 
extensive arborization of its axons, which allows its signal to be sent to an estimated ~75,000 
other neurons6. While Figure 1 depicts a generic neuronal structure, simply examining the 
diversity of structures occurring with specialized neurons reveals an added layer of complexity to 
understanding neuronal function, which is just the tip of the iceberg. 
 
Figure 2. The members of the monoamine neurotransmitter family. Those members that are part of the 





1.3.1 The Monoamine Family 
 Just as different neurons come in different shapes and sizes, the language in which they 
communicate with other neurons differs as well. The actual identity of the neurotransmitter that 
creates the chemical connectivity with their neighbors can range from small molecules to peptide 
chains of up to 30 amino acids. While each neurotransmitter is important in its own right, the 
majority of the Fluorescent False Neurotransmitter (FFN) program, and the bulk of this thesis, 
focuses on a particular class of neurotransmitters, the monoamines. This family of 
neurotransmitter is named for the common ethylamine side chain present in all its members: 
dopamine (DA), norepinephrine (NE), epinephrine, histamine, and serotonin (Figure 2). The 
catecholamines, DA, NE, and epinephrine are a further sub-class of this neurotransmitter family, 
which share a catechol moiety and biosynthetic pathway (Figure 3). I will describe the DA 
(Chapter 2) and NE (Chapter 3 and 4) neurotransmitter systems in more detail later in this thesis, 
but will provide a general overview of this neurotransmitter family here. 
 
Figure 3. Shared biosynthetic pathway for dopamine (DA) and norepinephrine (NE). Ortho-hydroxylation of the 
amino acid, tyrosine, by tyrosine hydroxylase forms dihydroxyphenylalanine (DOPA). Decarboxylation of DOPA 
by aromatic L-amino acid decarboxylase (AAAD) forms DA, which can by oxidized by dopamine β-hydroxylase 





 The synthesis of catecholamines starts with the amino acid tyrosine. Tyrosine first 
undergoes an ortho-hydroxylation through the enzyme tyrosine hydroxylase (TH) to produce 
dihydroxyphenylalanine (DOPA). DOPA is then decarboxylated by aromatic L-amino acid 
decarboxylase (AAAD) to produce DA. In dopaminergic neurons this would be the final step of 
synthesis, but in noradrenergic neurons dopamine is further converted to NE through dopamine 
β-hydroxylase (DBH) (Figure 3)7. The amine on NE can be further methylated by 
phenylethanolamine-N-methyltransferase to form epinephrine, but the main focus of this thesis 
will be directed towards NE and DA. 
1.3.3 Synaptic vesicles 
 After synthesis, the neuron then packages the neurotransmitter into synaptic vesicles 
where it is stored until the neuron is ready to send its chemical signal. In catecholamine neurons 
this process is controlled by the vesicular monoamine transporter (VMAT2)8. VMAT2 is a 
member of the solute carrier 18 (SLC18) family of proteins, specifically SLC18A2, and is found 
both in the brain and peripheral tissue9. In catecholamine neurons, VMAT2 pumps 
neurotransmitters into the synaptic or large dense core vesicles using a proton electrochemical 
gradient, generated by the vacuolar H+-ATPase (vATPase), as an energy source10. vATPase 
hydrolyzes ATP to pump protons into the vesicle creating a concentration difference of 
approximately 1.5 pH units. For every individual neurotransmitter pumped into the vesicles, two 
protons are pumped out, in an antiport mechanism11. This electrochemical proton gradient is 
strong enough to generate a 104 increase in catecholamine concentration in the vesicle10. A 
summarized schematic of the vesicle life cycle, and the process of neurotransmission described 




Figure 4. General summary of the processes involved in dopamine (DA) neurotransmission from a dopaminergic 
neuron in the striatum, although the process is very similar for NE. Highlighted in green is the life cycle for vesicles. 
1) A vesicle loaded with DA docks at the membrane through the help of the SNARE complex. 2) After calcium 
influx, the vesicle fuses with the membrane and releases its contents. 3) The vesicle is then recycled, 4) where it is 
again loaded with DA. Highlighted in red is the life cycle of DA. 1) DA is first loaded into vesicles through the 
vesicular monoamine transporter 2 (VMAT2). This process is powered by the proton gradient generated by the 
vesicular-ATPase (inset). 2) After release, DA then fills the synaptic cleft and binds to dopamine receptors (DR) 
both pre-, post-, and extrasynaptically. 3) DA is then cleared from the synapse through reuptake by the dopamine 
transporter (DAT) or metabolism by monoamine oxidase (not shown). 
 
After neurotransmitter loading, the vesicle then needs to be docked near the cellular 
membrane before it can be released. This task is performed by a complex of proteins that make 
up the soluble NSF-attachment protein receptor (SNARE) machinery. Synapotobrevin bound to 
the vesicular membrane complexes with other members of the complex attached to the cellular 
membrane, such as SNAP-25, Syntaxin, and Munc1812. Conformational changes of this complex 
then open a fusion pore that allows for the release of neurotransmitters. Once they perform 
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exocytosis, the vesicles then recycle through three possible mechanisms, “kiss and stay”, “kiss 
and run”, or full recycling13. Kiss and stay involves refilling with neurotransmitters without the 
vesicle ever undocking. Kiss and run also keeps the vesicle intact, but it undocks from the 
membrane and SNARE complex before refilling. Lastly, full recycling of the vesicle involves 
binding and reforming through an endosomal intermediate13. Once the vesicle has undergone one 
of these recycling pathways it is then ready for the next release signal. 
1.3.4 Signaling 
 The vesicle fusion process is initiated by the opening of voltage-gated calcium channels 
due to changes in the membrane potential from the electrical signal traveling down the axon. 
Once calcium enters the release site, it binds to the synaptotagim calcium sensor on the vesicular 
membrane. This then leads to the activation of the SNARE complex and neurotransmitter release 
during vesicular fusion14. After the neurotransmitter is released into the synaptic cleft it can then 
bind to pre- or postsynaptic receptors completing the signaling process between neurons. The 
catecholamine binding targets are metabotropic G-protein-coupled receptors (GPCRs)15. These 
receptors have three main structural motifs, an extracellular neurotransmitter binding site, a 
seven transmembrane helices domain, and an intracellular G-protein binding domain16. When an 
agonist of these receptors occupies the binding pocket, the GPCR undergoes a conformational 
change that affects the G-protein binding domain intracellularly. This then changes the affinity of 
this domain for the heteromeric G-protein complex, which initiates an intracellular signaling 
cascade. Depending on the specific neurotransmitter-GPCR pair, this binding leads to a number 
of different intracellular pathways with different downstream targets. 
Catecholamines are classified as modulatory neurotransmitters because their receptors 
can lead to either downstream activation or inhibition. I will briefly discuss DA receptors (DRs) 
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as an example here. More information on NE and adrenergic receptors can be found in Chapter 4 
(4.1.2). There are two main groups of DRs, ones that activate adenylyl cyclase (D1-family) and 
those that inhibit adenylyl cyclase (D2-family). Members of the D1 family lead to the activation 
of the Gs-protein pathway, an increase of cAMP production, and activation of protein kinase A 
(PKA), and include the receptors D1 and D5. Members of the D2 family lead to the activation of 
the Gi- and Go-protein pathways, a decrease in cAMP production, and deactivation of PKA, and 
include the receptors D2, D3, and D417. There is evidence that DA can also influence the Gq-
protein pathway, which can lead to increases in intracellular calcium18, but this process is still 
not fully understood (The Gq pathway is described in more detail in 4.1.2 with adrenergic 
receptors). While the downstream consequences of activating these second messengers is highly 
variable depending on the particular example, it is important to note that DA, or NE, can either 
enhance or inhibit a particular connection. This modulating effect can also be strengthened or 
weakened through pre-synaptic changes in neurotransmitter release. 
After a release event, the duration and extent of this signaling process is also tightly 
controlled by regulating the amount of available neurotransmitter in the synaptic cleft and 
surrounding area. Free extracellular neurotransmitter can either be cleared from the cleft through 
enzymatic degradation or primarily through the reuptake by a specific monoamine transporter 
(Figure 4). Each catecholamine has its own corresponding membrane transporter (MAT), 
dopamine transporter (DAT) for DA or norepinephrine transporter (NET) for NE, although there 
are cases of promiscuity between these transporters and their neurotransmitter substrates19. 
Depending on the environment around a specific release site, the neurotransmitter signal can be 
considered “wired” or “volume” transmission20. Wired transmission is the direct and discrete 
communication of one presynaptic synapse to a specific postsynaptic target. For this type of 
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neurotransmission, the most common type found in the brain, postsynaptic target receptors are 
found primarily right in the synaptic cleft, with the majority of neurotransmitter molecules never 
escaping from the synaptic junction due to MAT activity. The catecholamines, however, are also 
known to undergo volume transmission in most cases. This is where the extracellular 
neurotransmitter concentration is relatively long-lived and potentially affects the receptors on 
multiple target neurons in the area20. This is particularly true for monoamines, such as NE or 
DA, which have been shown in certain cases to exist extracellularly in the cortex for seconds, 
orders of magnitude longer than that typically observed in wired transmission21. The reasoning 
behind this type of transmission, and its biological significance in affecting neurotransmission, 
will be covered more in Chapter 2 (2.1.3). Once the neurotransmitter is cleared from the 
extracellular space and re-enters the neuron, it can then be repackaged into vesicles or 
metabolized by monoamine oxidase (MAO) or catechol-O-methyl transferase (COMT). This 
uptake process is tightly regulated and occurs after every vesicle fusion event. 
1.4 Studying neurotransmission 
1.4.1 The Connectome 
 The connectome is a comprehensive map that would describe all the neuronal wiring and 
connections in the brain22. Understanding this intricate network of billions of neurons is thought 
to be one of the most important goals along the path to understanding the brain. If the whole 
network is the ultimate puzzle, then its smallest piece would be a single synaptic connection. 
Recent advancements in mapping the functional connectivity of the brain have relied on imaging 
the activity of whole neurons and the connection between a particular neuron and its local 
neighbors through intracellular calcium indicators23. The activity of a specific individual neuron 
can be artificially induced using light activated membrane dyes24, caged glutamate25, or 
genetically encoded membrane channels26. While these techniques, and others like them, are 
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very powerful at obtaining general information about neuronal circuits, they still do not directly 
look at all the synapses that make up that connection, or the regulation of those synaptic 
connections that ultimately control firing patterns and circuit function27. 
One of the reasons studying neurotransmission at individual synaptic connections is so 
important is because these connections are not static. There are multiple biological changes that 
can occur in a synaptic connection that alter the way the individual neurons communicate with 
each other. Post-synaptic dendritic spines are highly dynamic and undergo pruning and 
formation as part of normal development28 or behavioral learning29. Dysregulation of this 
process has been linked to mental disorders, such as autism30. Further, post-synaptic changes in 
receptor expression levels can drastically affect the downstream outcome of the same 
neurotransmitter signal.  
On the pre-synaptic side of the connection, there are also regulatory mechanisms in place 
that can affect neuronal signaling. The neurotransmission of particular synapses can be fairly 
plastic over time, either increasing or decreasing their amount of neurotransmitter released. In 
hippocampal mossy fiber neurons, there is a drastic decrease in the failure rate of their firing 
after undergoing long trains of activation (>30min), an observation termed long-term 
potentiation (LTP)31. Additionally, these same mossy fiber neurons under different activation 
conditions can actually demonstrate long-term depression (LTD)32, or even forms of short-term 
plasticity33. The ultimate effect of each of these changes is an alteration in how that particular 
neuron communicates with its targets. It is important to note that these changes in synaptic 
activity are part of normal neuronal function, and synaptic impairment or degeneration is 
common during the progression of many diseases or disorders34. Some examples that involve 
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catecholamine synapses in particular are addiction35, depression36, as well as, Parkinson’s37 and 
Alzheimer’s38 diseases.  
Therefore, to truly understand how the circuits of the brain function, it is important to 
study exactly how neurotransmission at a particular synaptic connection can be regulated over 
time and under different physiological conditions or disease states. Due to the nature of this 
project, a particular focus will be placed on the pre-synaptic modulation that leads to changes in 
neurotransmission, with a particular emphasis on catecholamines.  
1.4.2 Electrochemistry 
 Historically, one of the most common ways to directly measure neurotransmitter release 
is through cyclic voltammetry and amperometry. These techniques work by sending a small 
electric potential to the area of interest and oxidizing certain analytes with an appropriate redox 
potential. This technique works for catecholamines, since these neurotransmitters have redox 
potentials within the typical -0.4 to 1V scanning range39. Electrochemical techniques are highly 
sensitive to analyte concentrations with excellent temporal resolution (up to 1ms)40, but lack 
sufficient spatial resolution. It is estimated that typical carbon-fiber electrodes measure 
neurotransmitter release from hundreds of release sites depending on the density of the 
projections (Figure 5)41. In particular to measuring catecholamine release, these techniques are 
also limited in their ability to distinguish between DA and NE signals, due to the similarities of 
their redox potentials. Advancements in the standard electrochemical techniques have designed 
multiple special electrode surface modifications that preferentially enhance DA detection40, 
however, specificity for NE remains difficult42,43. Electrochemical recordings have also been 
paired with other biosensors, such as liquid chromatography, capillary electrophoresis, and mass 
spectrometry, using newly designed dual-functioning sensors40. These techniques have helped 
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with the collection of information from multiple analytes, but still do not address the problems 
with spatial resolution. 
 
Figure 5. A) Representation of an electrode in a 1 mm3 volume of brain tissue (grey matter), which is expected to 
contain ~1 billion synapses. B) Zoomed in area surrounding the representative tip of the electrode. Surrounding the 
tip are all the dopaminergic release sites (labeled with the DA label, FFN102, described in 1.4.4) in the expected 
volume measured with current electrochemical methods (estimated to be ~100’s of release sites for DA in the 
striatum)44. Scale bars are in µm. 
 
1.4.3 Previous Optical Techniques 
 While electrochemistry has provided a wealth of knowledge about bulk neurotransmitter 
release patterns and regulatory mechanisms, to further the understanding of how the individual 
members of that bulk population operate, the field turned to optical imaging. Advancements in 
imaging techniques now allow for the collection of information from areas as small as the single 
synapse with excellent temporal resolution. As a result, there has been a wealth of imaging 
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techniques developed to study neurotransmitter exocytosis, each with their own benefits and 
limitations. Almost each step along the neuron activation pathway can now be mapped optically; 
(1) voltage dyes measuring the electrical potential change traveling down the axon, (2) calcium 
indicators measuring the influx of calcium after the electrical potential opens their channels, (3) 
membrane bound dyes measuring vesicular membranes fusing to the outer cellular membrane, 
(4) intravesicular pH sensors measuring vesicular content being exposed to the extracellular 
space, and (5) receptor-based sensors measuring neurotransmitter binding. 
(1) Voltage dyes:  
 Neurons are tightly held at a resting electrochemical potential that changes up to 100mV 
upon the opening of voltage gated sodium channels and subsequent potassium and calcium 
channels. This voltage change across the relatively narrow plasma membrane results in a huge 
electric field of 107-108V/m 45. As a result, several imaging tools have been developed that 
harness this change in electric field to create an optical signal change. One example of how these 
sensors work is through redistribution, which requires a dye that maintains an equilibrium 
between two environments (for example, Rhodamine-6G: extracellular vs intracellular)46. When 
the membrane potential changes, this concentration equilibrium can shift drastically resulting in 
more uptake or release of the dye. While redistribution in general is slow, non-specific, and has 
poor signal to noise, advancements in this field have developed many other ways to harness this 
change in electric field, such as membrane reorientation47, electrochromic dyes48, FRET-
based49,50, genetically encoded protein sensors51, and even other methods. However, I describe 
only one common example here, due to the fact that even as this field progresses further and 
overcomes some of its earlier limitations, measuring voltage is still an upstream reporter of 
neurotransmission, and does not always lead to neurotransmitter release. Actual release at a 
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synapse is a dynamic probabilistic event that can change depending on conditions52, and even 
release sites along the same axon can have different release probabilities53. As a result, there may 
be functionally different strengths of neurotransmission occurring, but distinguishing this with a 
voltage sensor would be impossible. 
(2) Calcium indicators: 
 Following the previously described large change in membrane potential, there is a 
subsequent opening of voltage gated calcium channels, which increases the intracellular Ca2+ 
concentration in active neurons. In tandem, there are also intracellular stores of Ca2+ that can 
participate in generating a transient Ca2+ concentration spike54,55. Increased Ca2+ concentration 
near the active zone of the synapse causes activation of vesicular membrane bound proteins, such 
as synapototagmin-1, which leads to initiation of the SNARE complex56. As such, measuring 
these transient Ca2+ concentration spikes has been a widely used tool to study neuron activity. 
This can be done with calcium sensitive organic fluorophores, as well as genetically encoded 
calcium indicators (GECIs). 
 Synthetic calcium indicators combine a fluorophore with a calcium coordinating motif. 
One example, fura-2, combines a stilbene fluorophore with an octacoordinate, tetracarboxylate 
calcium coordinating motif57. Binding of calcium to fura-2 results in a ratiometric and 
measurable wavelength shift that can be used to measure intracellular Ca2+ concentrations. In 
practice, these dyes can be loaded into neurons using a membrane permeable AM-ester form, 
which is then cleaved by cytosolic esterases and then locked inside. The requirement of this 
loading method has proven to be a major drawback in the application of this technology, as it is 
time consuming and non-specific (i.e. labels all cells). 
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 Calcium sensors have gained neuron-type-specific labeling through genetic control with 
the introduction of genetically encoded calcium indicators (GECIs). Sensors in this class 
commonly combine the Ca2+ binding domain of calmodulin (CaM) and circularly permuted GFP 
(cpGFP). cpGFP, in its native state, is not fluorescent, but can be turned on by the 
conformational change that occurs when Ca2+ binds to the linked CaM domain58. While GECIs 
have improved targeted selectivity, they have historically had poorer Ca2+ sensitivity or kinetics 
than the synthetic calcium sensors. Recent advancements in this class of sensors has led to the 
availability of GECIs, such as GCaMP6f, which can now compete with synthetic calcium 
sensors while maintaining selective neuron control59. However, like the voltage dyes previously 
described, intracellular Ca2+ concentration levels are still an upstream reporter for actual 
neurotransmission, and not all Ca2+ transients cause the same response. The relationship between 
Ca2+ and neurotransmitter release is dependent on the availability of readily releasable vesicles, 
the actual Ca2+ concentration at the active zone, and the molecular coupling between Ca2+ and the 
vesicular fusion machinery52. The mechanisms that regulate these parameters will be discussed 
in more detail in Chapter 2, but it is clear that while release probability and calcium transients are 
related, this factor is not uniform for all synapses, and can be dynamic over time. As a result, a 
tool for measuring actual neurotransmitter release will be more useful when studying 
neurotransmission than calcium sensors. 
(3) Vesicular membrane dyes: 
 In an attempt to more directly measure the kinetics and understand vesicular fusion, a 
series of endocytic membrane dyes have been used. These dyes are structurally designed to have 
a high affinity for the cellular phospholipid bilayer membrane. The most successful example of 
this is FM1-43, a styryl pyridinium molecule that has a hydrophobic tail and charged head group, 
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similar to a phospholipid60,61. After this dye is bath applied and inserted into all membranes, the 
neurons are stimulated, causing vesicle recycling. As a result, some of the dye is incorporated 
into the vesicular membranes inside the neuron through endocytosis. The remaining dye on the 
extracellular membranes is then washed away with a β-cyclodextrin derivative, ADVASEP-7. 
This is possible due to the higher affinity binding between FM1-43 and ADVASEP-7 over the 
membrane61,62. After these loading steps, synaptic vesicle fusion kinetics can be correlated with 
an observed loss of FM1-43 fluorescence when it washes away after it is re-exposed to the 
extracellular ADVASEP-7. 
 While this optical technique is even closer to measuring direct neurotransmission, it is 
limited by many drawbacks. First, the dye can only be loaded into vesicles after long neuronal 
stimulation protocols, which have been shown to cause drastic changes in synaptic behavior63. 
Additionally, this means that FM1-43 will also only label the synaptic vesicles in currently active 
release sites, making it difficult to study functionally plastic release sites64. This is a potentially 
important parameter when studying dopamine neurotransmission, and will be further discussed 
in Chapter 2 (2.1). Another problem with FM1-43 loading is the requirement of the presence of 
ADVASEP-7, which further makes the use of FM1-43 in vivo impractical. Second, the change in 
fluorescence associated with a single vesicular recycling event is very small relative to the total 
fluorescence in all the vesicles in the whole synapse. As a result, the dye is typically used to 
observe kinetics over a large number of action potentials, and is poorly suited to study single 
synaptic events65,66. Lastly, the measurement of vesicular recycling is only correlative to actual 
neurotransmission. While this technique can be paired with electrochemistry67, inherently, it does 




 Similar to the endocytic dyes, synaptopHluorin (SpH) also measures vesicular behavior. 
SpH is a genetically encoded protein that contains a pH-sensitive GFP variant linked to the 
vesicular membrane bound protein, synaptobrevin68. The pH-sensitive GFP used has a 
ratiometric fluorescence excitation spectrum, which changes in acidic environments, such as the 
loaded vesicle (pH ~ 5.5), and more basic environments, such as the extracellular environment 
(pH ~ 7.4)69. This technique improves upon the endocytic dyes in both specificity and sensitivity. 
As a genetically encoded protein, the sensor can be expressed in only the particular neurons of 
interest, and it can be modified to use other vesicular membrane proteins as an anchor, such as 
VGlut70. SpH also shows high sensitivity of vesicular fusion events due to the large change in 
fluorescence resulting from the transient pH change it measures, which allows for the study of 
presynaptic activity from single action potential measuments71–73.  
 While this technique has been very successful in cell culture, its application for intact 
mammalian systems remains limited by high background74. Therefore, the use of SpH in mice in 
vivo (and even ex vivo brain slices) has been limited, and only capable of measuring spatially 
large activations of groups of neurons, such as in the olfactory bulb75. Moreover, similar to the 
endocytic dyes, this technique still is not a direct measurement of neurotransmission. SpH can 
only measure if the lumen of a synaptic vesicle equilibrated with the extracellular space, and is 
not capable of describing how much neurotransmitter was loaded or released. 
(5) Receptor-based neurotransmitter sensors: 
 There are two main types of receptor based sensors that have been developed to monitor 
neurotransmitter concentrations. First, there are receptor binding domains that have been linked 
to fluorescent proteins that increase in fluorescence after an allosteric modulation. This allosteric 
modulation has been engineered to be induced by the neurotransmitter-bound conformational 
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change of the receptor domain. In this category are the glutamate optical sensor (EOS) and the 
intensity-based glutamate-sensing fluorescent reporter (iGluSnFR). EOS combines the ligand 
binding domain of the glutamate receptor 2 subunit with the fluorescent dye, Oregon green76. A 
drawback of this system has been number of steps involved in preparing the experimental 
system. First, a genetically encoded linker is needed to be expressed on the cell surface, which 
can serve as an anchor of the EOS complex and immobilizes it on the target membrane surface. 
The number of steps was reduced with the iGluSnFR construct, which can be directly genetically 
encoded, transcribed, and membrane-expressed in the neurons of interest. iGluSnFR uses a 
circularly permutated GFP as its fluorescent reporter, and the E. coli glutamate-binding protein 
(gltI)77. Because this sensor can be expressed right at the synapse, pre- or post-synaptically, it 
can directly measure neurotransmitter release from a single synapse. However, the fact that this 
sensor must be genetically encoded, limits its potential use in species not readily amenable to 
genetic manipulations, including humans. Additionally, as of now, this system has only been 
demonstrated to work for the glutamate neurotransmitter, and is not yet developed for 
catecholamine studies. 
The second type of sensors in this group are cell-based neurotransmitter fluorescent 
engineered reporters (CNiFERs), which utilize a signal transduction pathway to cause a whole 
cell fluorescent readout78. For this technique, whole cells must be implanted in the area of 
interest and then they only report on neurotransmitter changes that happen to escape the synaptic 
junction. Just recently, DA and NE CNiFERs were constructed and their use was demonstrated 
in vivo79. These particular catecholamine CNiFERs work by using either the D2 GPCR for DA, 
or α1A for NE, and linking their downstream G-protein cascade with an increase in intracellular 
calcium levels. The intracellular calcium levels then result in fluorescent readout by the FRET-
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based calcium sensor, TN-XXL80. This technique is quite useful since it directly measures 
neurotransmitter release, has a high signal to noise ratio, and is very specific. In this regard, this 
particular sensor is actually very similar to electrochemistry, but with the addition of better 
selectivity. However, like electrochemistry, it is measuring the neurotransmitter released from 
many release sites and is not capable of observing release from individuals of that population. 
1.4.4 Fluorescent False Neurotransmitters 
 After reflecting on all of the available tools to study catecholamine release, it was clear 
that none were ideal. There is currently no reporter capable of measuring direct catecholamine 
release from a single event at a signal release site. However, with the development of fluorescent 
false neurotransmitters (FFNs), we think that we are approaching this goal. While not directly 
measuring catecholamine concentrations, the idea behind FFNs was to create small fluorescent 
molecules that, as closely as possible, mimic native catecholamines during release. By designing 
FFNs to have common structural recognition elements of the catecholamines, such as the 
ethylamine sidechain, in combination with a fluorescent core, it was possible to generate 
fluorescent compounds that were also substrates of transporters involved in catecholamine 
neurotransmission (Figure 6). While for early generation FFNs (FFN511) this simply meant 
activity at VMAT281, newer generation FFNs (FFN102) were also selected for their activity at 
the appropriate membrane transporter (DAT or NET)82. Therefore, instead of passively diffusing 
into neurons and then getting trapped in vesicles through VMAT, newer generation FFNs were 
designed to be more polar and only cross the membrane through transporter activity. This 
resulted in FFNs, such as FFN102, that are dual VMAT2 and MAT substrates with higher 
selectivity and better signal to background ratios than earlier generation FFNs82. Our laboratory 
is continuing to advance this technology through characterization of new functionality and 
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applicability, as well as expanding the neurotransmitter systems with which they can be used. 
These advancements will be the main focus of this thesis in the following chapters, but I will 
include here a brief description of how FFNs work and some of the previously published work in 
this area. 
 
Figure 6. Modified schematic of the neurotransmitter life cycle to include FFNs (yellow stars). 1) The applied FFN 
is actively loaded into release sites through DAT activity. FFN in the cytoplasm is then loaded in vesicles through 
VMAT2 activity (inset). As described in more detail in Chapter 2, loading into the acidic vesicles can lead to a 
change in fluorescence for pH-sensitive FFNs. 3) After vesicle fusion, the FFN is released into the extracellular 
space, where the pH returns to ~7.4. 4) Through DAT uptake, the FFN is then reloaded into release sites or washed 
away. 
 
 Since FFNs are actively accumulated through transporter activity, they can be loaded into 
cells or synaptic release sites by simple bath application. Unlike some of the previously 
described genetically encoded sensors, which require time consuming viral injections or selective 
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breeding, or endocytic dyes, which require harsh loading conditions, the FFN loading concept is 
relatively quick and widely applicable to multiple experimental systems. One system that has 
been of particular importance for studying our early generation dopaminergic FFNs has been the 
dorsal striatum of ex vivo acute mouse brain slices. This is an area rich in dopaminergic 
projections primarily from the substantia nigra (SN) that can be visualized with FFNs83. When 
loaded into release sites, the FFN appears as small points (~1µm) of increased fluorescence 
intensity, which we call “puncta”. Due to the inherent benefits of fluorescence imaging, we are 
able to observe changes in these puncta with a spatial resolution applicable to a single release 
site, and temporal resolution on the millisecond timescale. By measuring these same fluorescent 
changes in the presence of compounds that cause neuromodulation or animal models of different 
disease states, it is possible to understand the role of these conditions in changing 
neurotransmitter uptake, vesicular loading, and release with single synapse resolution. The use of 
FFNs to study each of these parameters, which all affect neurotransmission, is discussed 




Figure 7. Measuring neurotransmitter release with FFNs. A) General mechanism for measuring tonic 
neurotransmitter release with FFNs. Loaded FFN can be detectably released when a significant portion of the 
vesicular stores eventually fuse with the plasma membrane after 1000s of electrical pulses (EPs), stimulation begins 
at arrow. This results in a significant decrease in the total fluorescence at the release site. B) Short bursts of EPs, 
which mimic DA phasic firing patterns, lead to only slight FFN release, and a small change in fluorescence (∆F/F) 
compared to the total fluorescence left within the release site. Compared to the fluorescence rundown pre-
stimulation present in all conditions (due to FFN102 washing away or leaking out), this change is difficult to 
measure. C) Using a pH-sensitive FFN that increases in fluorescence when released, a “FFN flash” can be created 




 For measuring neurotransmitter release, we have designed new FFNs capable of 
exhibiting changes in fluorescence that are sensitive enough for studying both phasic and tonic 
firing regimes (Figure 7). Tonic firing patterns are the relatively slow (2-10Hz for dopaminergic 
neurons84) and consistent pace-making activity that is prevalent in some neurons,  and 
particularly important in the dopaminergic85 and noradrenergic86 systems. Experimentally, the 
tonic firing behavior can be studied using long electrical trains at a slow frequency (1-10Hz, 
100s - 1000s of pulses). For these experiments, we look for a decrease in the fluorescence 
intensity of puncta over time, as the probe is consistently released from the puncta during a long 
train of activation (Figure 7A). Useful FFN probes for this purpose are excellent VMAT2 
substrates and not pH-sensitive, so there is no conflicting increase in fluorescence signal. These 
probes are used in experiments aimed at studying differences in the extended behavior of 
individual release sites, such as reserve pool activation87. For studying phasic activity, however, 
the decrease in fluorescent signal caused by only a few action potentials using this type of FFN 
would not be sufficient when compared to the overwhelming fluorescent signal that remained in 
the puncta (Figure 7B).  To overcome this challenge, and increase the signal to background 




Figure 8. A) Structure of FFN102, the first DA-selective and pH-sensitive FFN. Highlighted in red, the 7-hydroxy 
group has a pKa (6.2) between the pH of the vesicles (~5.5) and extracellular space (~7.4). B) The protonated and 
deprotonated 7-hydroxyl have different spectrophysical properties, and therefore the absorbance of FFN102 is pH-
sensitive. Based on the excitation (C) and emission (D) fluorescence profiles of FFN102, there is an observable 
increase in fluorescence when FFN is released from the vesicles, which we call the “FFN flash.” 
 
 Phasic firing is a transient burst of activity that increases extracellular neurotransmitter 
concentrations to a higher level than basal tonic firing, but only for a very short time (2-10 spikes 
at ~20Hz for dopaminergic neurons88). Phasic firing of DA is important for its role in modulating 
post-synaptic targets, and changes in phasic firing patterns have been shown to influence 
behavioral conditioning89.  Due to the relatively few vesicular fusion events that occur within a 
single burst window, newer generation FFNs were designed to harness the pH difference that 
exists between loaded vesicles and the extracellular space in order to generate a more significant 
change in fluorescence per vesicle fusion (Figure 7C)82,90. These FFNs utilize a fluorescent 
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coumarin structural core with a 7-hydroxy motif that is tuned to a pKa between the vesicular 
lumen (~5.5) and the extracellular space (~7.4, Figure 8). There is a significant change in the 
fluorescence excitation spectrum between the protonated (vesicular) form and the non-protonated 
(extracellular) form (Figure 8C). As a result, when a vesicle loaded with this type of FFN fuses 
with the membrane and releases its content, there will be an increase in fluorescence emission, or 
“FFN flash” (Figure 8D). Being pH-sensitive, these FFNs also have the ability to report on the 
changes in vesicular loading that occur intracellularly, which can lead to modulations of quantal 
size. In Chapter 2, I will discuss the use of pH-sensitive FFNs in both of these functional 
applications in more detail. 
1.5 Outlook 
 The success of a new tool in neuroscience is measured by its ability to fill a void between 
what neuroscientists want to know and how they can know it. Such research tools can prove 
something that was previously only speculated through correlation. While I described a few of 
the most common and well integrated methods of studying neurotransmission, the tools of the 
future are continually being developed. I believe that FFNs have the potential to be the next 
significant tool to make a valuable impact on how neuroscientists think about, and study, 
catecholamine neurotransmission. In this effort, this thesis will describe some examples of how 
chemical synthesis and FFN characterization has led to a novel FFN for the NE neurotransmitter 
systems, as well as how DA- and NE-FFNs can be effectively applied to build-upon, or 
complement, the short-comings of previous imaging technologies to study the regulation of 
neurotransmission in new ways.  
26 
 
1.6 Summary of Thesis Chapters 
Chapter 2: Chapter 2 will explore the use of the pH-sensitive functionality of FFN102 to study 
the mechanisms that regulate changes in pre-synaptic plasticity, a component of 
neurotransmission. This includes using the FFN flash to quantitatively trace DA release, changes 
in the release probability of individual release sites, and changes in vesicular loading that can 
affect quantal size. While, we have successfully demonstrated use of the FFN102 to measure DA 
release and changes in vesicular loading, continued work is needed to measure the release 
probability from single release sites. 
Chapter 3: Chapter 3 will summarize efforts to expand the scope of the FFN program to study 
neurotransmitter systems other than DA using fluorescent phenylpyridiniums. We identified a 
fluorescent phenylpyridinium, APP+, with excellent labeling properties for DA, NE, and 
serotonin. However, the properties of the probe were found to be ill-suited for measuring 
neurotransmitter release, and as a result, we concluded this class of compounds were not viable 
FFN leads. 
Chapter 4: Chapter 4 will highlight the thought process, synthesis, and screening required to 
generate a novel NE-FFN lead, followed by its characterization and application in acute murine 
brain slices where it loads noradrenergic cell bodies and synapses, and enables stimulated NE 
release studies. This chapter also describes the application of this compound in a series of in vivo 
experiments, following the optimization of this experimental system for successful use with 
FFNs. This work opens the possibility for many exciting future FFN experiments studying the 
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Chapter 2: FFN102: Functional Applications of the 




 A fluorescent false neurotransmitter (FFN) is designed to trace neurotransmitter release 
with a small fluorescent molecule that, using the native protein machinery, is loaded into 
neurons, packaged into synaptic vesicles, and then released. This concept for the FFN program 
was established well before I began my thesis research, and the work of my predecessors has 
contributed significantly to the development of this program. In the introduction to this chapter, I 
will briefly summarize the status of the FFN program at the time I started working on the project 
(2.1.2), and then describe how the progress made to that point led to the ambitious objectives we 
set for the next phase of the FFN program – exploring the utility of the first pH-sensitive FFN in 
a series of experiments designed to examine the mechanisms that regulate presynaptic 
neurotransmission release (2.1.3). I would like to thank all the members of the FFN team, from 
the laboratories of both Dr. Sames and Dr. Sulzer, as well as our collaborators over the years, for 
providing the intellectual groundwork on which my work was built. 
2.1.2 Identification of the First pH-sensitive and DA-selective FFN, FFN102 
 My story begins with the identification and initial characterization of FFN102, the first 
prospective FFN that had been selected as a dual substrate for the dopamine (DA) plasma 
membrane transporter (DAT) and the vesicular monoamine transporter (VMAT2), based on a 
series of screening experiments performed in transfected HEK cells1. When tested ex vivo in the 
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striatum (an area rich with dopaminergic release sites) of acute murine brain slices, this probe 
demonstrated major improvements in DA-selectivity versus previous generation probes. As a 
DAT substrate, FFN102 was actively transported across the plasma membrane of DAT-
expressing cells, in contrast to earlier generation FFNs that were substrates for only VMAT2, 
and as such, needed to be lipophilic enough to cross the plasma membrane, through non-specific 
passive diffusion2. The lower lipophilicity of FFN102 (LogD: -1.45, compared to FFN511 LogD: 
1.0) resulted in much lower non-specific staining and higher colocalization with dopaminergic 
structures1. 
Additionally, as a 7-hydroxycoumarin, the fluorescence of FFN102 is pH-sensitive. The 
differences in electronic excitation of the protonated versus deprotonated states of the 7-
hydroxycoumarin led to exploitable pH-dependent photophysical properties of FFN102. 
Designed with an electron withdrawing chlorine on the 6-position, the pKa of the 7-hydroxyl 
group on FFN102 is 6.2, between the vesicular (~5.5) and extracellular (~7.4) pHs3. The 
fluorescence excitation spectra of FFN102 is ratiometric with peaks at 340 nanometers for the 
protonated form and 370 nanometers for the deprotonated form (Chapter 1, Figure 8). When 
deprotonated, the electrons of the 7-hydroxyl group are more readily donated into the ring, 
decreasing the energy required to reach the excited state, which undergoes rapid acid-base 
equilibration and has a modified pKa around 1-24. Therefore, the shared excited form only leads 
to a single fluorescence emission wavelength at 453 nanometers that has a pH-dependent 
magnitude (Chapter 1, Figure 8). Thus, the transition of FFN102 from the acidic environment of 
the vesicular lumen into the more neutral pH environment of the extracellular space should result 
in a significant increase in fluorescence. With its dual membrane transporter selectivity and new 
pH-sensitive functionality, FFN102 appeared to be a prime candidate to take the FFN program in 
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a new direction: exploring the utility of FFNs in studying the mechanisms involved in regulating 
neurotransmission in native systems. 
 
Figure 1. A representative example of the acute murine brain slice from the dorsal striatum and the changes in 
fluorescence that occur following electrical stimulation of loaded FFN102-treated acute murine brain slices1 (Allen 
Brain Atlas).  A) Sagittal mouse brain slice highlighting the dopaminergic cell bodies in the substantia nigra and 
where the acute slice was collected in the dorsal striatum that contains the dopaminergic release sites. B) The 
collected coronal slice. C) Plot that depicts the change in total fluorescence of the entire field of view over time, 
relative to initial fluorescence. At t=0 (marked by an arrow), 10Hz local electrical stimulation started and then 
continued for the remainder of the trace. The observed rundown in fluorescence prior to stimulation results from 
some FFN102 washing away or leaking out of the puncta. Panels B and C are images of a representative field the 
FFN102 fluorescence observed (D) right before initiation of the electrical stimulation, and E) at the time of 
maximum fluorescence increase: 50sec after electrical stimulation.  This peak in fluorescence represents the 
fluorescent “flash” that occurs when FFN102 transitions from the acidic environment of the vesicle to the 
extracellular space.   
 
In the 2013 paper initially characterizing FFN102, its new functionality was briefly 
explored in acute murine brain slices1. Specifically, the dorsal striatum of acute murine brain 
slices was loaded with FFN102 and the resultant fluorescence was measured before and during 
extended electrical stimulation (1-10Hz for 1000s of pulses – a firing pattern comparable to tonic 
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neuronal firing).  Prior to the initiation of the electrical stimulation, a punctate pattern of 
fluorescence was observed within the dopaminergic projections of this brain region, as 
confirmed by pharmacological DAT inhibition, colocalization with established dopaminergic 
markers, and DAT-knockout experiments1.  Following the local electrical stimulation, known to 
trigger vesicular DA release into the extracellular space, a significant increase in fluorescence 
(approximately 20 percent) was observed throughout the whole frame1. This change in diffuse 
fluorescence was consistent with a portion of the FFN102 within vesicles (visual punctate 
fluorescence) being released into the less acidic environment of the extracellular space.  As seen 
in Figure 1, the timeline for the increase in fluorescence (the fluorescent “flash”) started 
instantly after stimulation and then peaked approximately 1 minute following 10 hertz electrical 
stimulation, before gradually decreasing. Note that the slow decrease in fluorescence observed 
pre-stimulation (“rundown” fluorescence) was thought primarily to result from nonspecific 
staining of the FFN probe washing away, or some degree of leaking from the puncta.  
The fluorescence remaining in the FFN-loaded dopaminergic release sites following 
electrical stimulation was also measured.  After subtracting the increases of the FFN flash in the 
background, similar (although slower) destaining kinetics of the release sites were observed with 
FFN102 as compared with FFNs that were not pH-sensitive5. Therefore, it was concluded that 
the electrical stimulation triggered the release of FFN102 from acidic vesicles in the 
dopaminergic projections, which led to increases in diffuse fluorescence in the extracellular 
space and the eventual depletion of all FFN102 from a sub-set (10-20%) of dopaminergic release 
sites1. These initial experiments validated the concept that a pH-sensitive FFN was capable of 
generating a detectable fluorescent flash in a functional model of neurotransmission. 
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2.1.3 Rationale for Applying Functional FFNs to Study Presynaptic Neurotransmission 
Regulation 
 Essentially, at the start of my thesis research, we had learned that the pH-sensitive 
FFN102 could generate observable changes in fluorescence in electrically stimulated acute brain 
slices ex vivo, but not much more. To put into perspective the subsequent research to be 
described later in this chapter, I will first describe the rationale for using FFN102 in the 
functional experiments we performed. Additionally, while the specific experiments described in 
this chapter relate to dopamine (DA) specific neurotransmission, due to the specificity of 
FFN102, the rational for using FFNs for these type of presynaptic regulation experiments can be 
applied to other functional, pH-sensitive FFNs, both current and those in development. This 
aligns well with the overall objective behind the FFN program, which is developing, and using, 
novel fluorescent research tools to support the study presynaptic neurotransmission regulation in 
a wide range of neurotransmission pathways, with a sensitivity and specificity not before 
possible. 
Initially, we sought to further characterize the FFN release phenomenon in murine brain 
slices following tonic stimulation, in which we observed full destaining of only a small 
percentage (10-20%) of fluorescent puncta in the dopaminergic projections loaded with FFN102, 
or FFN200 (a pH-insensitive DA-FFN), after the local electric stimuli1.  The remaining “silent 
puncta” (80-90%), which did not release all of their fluorescent tracer, did not show statistically 
significant decreases in fluorescence over the long trains of electrical stimulation (1-10Hz for 
1000s of pulses) compared to the “rundown” in fluorescence observed in non-stimulated puncta. 
We sought to determine whether it was possible to use the FFN102 pH-sensitive “flash” to 
further characterize this heterogeneity in puncta release, and explore whether heterogeneity of 
puncta was also present during physiologically relevant phasic burst firing patterns. In such an 
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experimental design, highlighted in Figure 7C of Chapter 1, we would measure the increase in 
fluorescence after only a few electrical pulses (EPs) delivered at a higher frequency (>20Hz), a 
frequency similar to the patterns commonly observed during DA phasic release6,7.  
Phasic firing patterns are a particularly important means for regulating DA presynaptic 
neurotransmission, because they provide a mechanism of modulating the target neurons of the 
dopaminergic signal. During tonic activity, the DA release sites deliver a signal more similar to 
“wired transmission” (discussed in more detail in Chapter 1), as the DAT activity near the 
synapse is capable of fully recycling extracellular DA before the following pulse8. During phasic 
firing, however, released DA saturates the available DAT and there is an increased degree of DA 
spill-over that can reach multiple postsynaptic targets9,10. Depending on frequency of the firing 
events, the spread of the released DA can be controlled. The importance of this type of “volume 
transmission” generated by phasic firing patterns is supported by evidence that shows DA 
receptor and transporter expression located extrasynaptically11,12. In living animals, DA burst 
firing is related to the response of sensory13 and conditioned14 stimuli. Therefore, animal 
behavior changes are directly related to dopaminergic firing patterns presynaptically, which not 
only affect the strength, but also the targets of a particular regulatory signal. It is our hope that 
pH-sensitive FFNs would be able to trace these changes in extracellular dopamine following a 
phasic burst firing event. 
Another potential application of functional FFNs would be to study the release 
probability from individual release sites – a second means of presynaptic neurotransmission 
regulation. Neurotransmitter-filled vesicle fusion is a stochastic event that occurs after EPs arrive 
at the release site with a certain probability. That release probability can change over time: either 
increasing (potentiation) or decreasing (depression) depending on a still growing list of identified 
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conditions. Additionally, the release probability of synapses, even along the same axon15, are 
generally heterogenous16–18. Potential explanations for this heterogeneity include the variabilities 
in the postsynaptic target19, the size and replenishment rate of the vesicular pool20, or differential 
presynaptic protein expression levels that can lead to synaptic plasticity21,22. Current optical tools 
for estimating this probability at individual release sites primarily include the use of a pH-
sensitive GFP (e.g. VGLUT-pHluorin23) or vesicular dye (e.g. FM1-4324,25). The use of vesicle-
labeling dyes is limited in its application due to poor change in fluorescence relative to total 
fluorescence (∆F/F). As such, the use of dyes, like FM1-43, for measuring release probability has 
been limited to estimations based on the release caused from a train of many EPs25. On the other 
hand, vesicular-linked pHluorins can have substantial ∆F/Fs, and have been used to image single 
vesicular fusion events in cell culture, enabling the direct determination of the probability of 
vesicular fusion23. However, application of pHluorins in more intact experimental systems, such 
as acute murine brain slice or in vivo, remains problematic.  
It is also possible with a pH-sensitive FFN to trace changes in VMAT2 activity and 
therefore measure the amount of neurotransmitter loaded and released per vesicle (quantal size). 
This is another important presynaptic mechanism for regulating plasticity26, and is a regulatory 
mechanism that cannot be studied using pHluorins and vesicular dyes. Unlike either of the two 
previous optical techniques, FFNs are substrates of VMAT2 and therefore have the potential to 
trace concentration changes in loaded vesicles at individual release sites, as well as the amount of 
final content that gets released. In addition to changes in release probability, neurons have been 
shown to regulate the amount of neurotransmitter released and strength of a particular synaptic 
connection through quantal size27. While some synaptic connections lead to neurotransmitter-
receptor saturation, there is growing evidence that other connections do not naturally have 
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saturated receptors and increases in quantal size can directly lead to changes in the strength or 
duration of postsynaptic signaling28. This is potentially even more important for dopaminergic 
release sites that can participate in volume transmission, as described above. This “synaptic 
scaling” is thought to work in combination with firing rate changes to allow for the 
multiplicative control of presynaptic regulation29,30, and to be an important controlling 
mechanism that changes during chronic perturbations of normal conditions27,29,31.  
The mechanisms behind how quantal release is controlled, however, are still poorly 
understood. It is possible to regulate release after fusion, through controlling the duration of the 
vesicle fusion pore during a “kiss and run” event, and thereby preventing full neurotransmitter 
release32. This type of neurotransmission regulation has been shown to be especially prevalent 
with DA release33,34. Other regulatory methods are thought to occur before fusion and involve 
changes in the dynamics of neurotransmitter concentrations between the plasma and vesicular 
membranes. These mechanisms, with particular emphasis on the DA system, will be explored in 
more detail in section 2.2.7. 
In summary, following the initial characterization of FFN102, a pH-sensitive fluorescent 
probe with dual DAT/VMAT2 activity, we designed a series of experiments to explore the utility 
of FFN102 in studying three potential mechanisms of dopaminergic presynaptic regulation:  
burst firing patterns, release probability, and quantal size at individual dopaminergic release 
sites. The following Results and Discussion will describe some of the interdependent steps taken 




2.2 Functional Experiments Examining DA Release - Results and Discussion 
2.2.1 Applying FFN102 to Study the Paradoxical Depression Effects of Cocaine and 
Methylphenidate on DA Release 
 The next step to validating the potential functional application of FFN102, and the 
beginning of my thesis work, was to further characterize the increase in fluorescence observed 
following an extended tonic stimulation. Our goal was to determine whether this FFN fluorescent 
flash was quantitatively related to DA release, by comparing changes in the flash to changes 
observed with established methodologies to assess DA release. Specifically, in a collaborative 
effort with Dr. Nicola Mercuri (University of Rome), we had the opportunity to explore whether 
the FFN102 flash directly correlated with DA release following the pharmacological modulation 
of dopaminergic neurotransmission in acute brain slices as measured by electrochemistry, 




Figure 2. Constant potential amperometry (CPA) recordings of DA release under varying concentrations with 3 
different DAT-inhibitors, cocaine, methylphenidate, and nomifensine. This set of experiments was conducted in 
wild-type mice (Panel A) and mice with a mutation in DAT (Panel B) that caused it to be insensitive to inhibition 
from cocaine (DAT-CI). The top panels depict the time delay for depression of DA release as measured by CPA 
following 10µM cocaine administration.  The next two figures show the effect of increasing concentrations of 
cocaine or methylphenidate on DA release.  Lower concentrations of cocaine and methylphenidate in WT mice led 
to an increase in DA by blocking DA reuptake, but at higher concentrations they led to a decrease through an 
unknown mechanism. In DAT-CI mice, all concentrations led a decrease in DA release, as these compounds can no 
longer inhibit DA reuptake in the modified DAT.  Treatment with the DA inhibitor nomifensine (final figures) led to 




Importantly, this experimental design also allowed us to use FFN102 to explore the 
paradoxical depression effects that cocaine and methylphenidate have on DA release when 
applied at high concentrations (≥10µM) in the striatum of acute murine brain slices. Both of 
these neuropharmacological agents are relatively potent inhibitors of DAT (Ki’s: cocaine 
~200nM, methylphenidate ~50nM), which typically lead to increased extracellular DA 
concentrations through inhibition of DA reuptake36. However, at high concentrations of both of 
these agents, our collaborators observed an unexpected depression in DA release. This 
depression was observed using both constant potential amperometry (CPA) (Figure 2) and 
microdialysis (see publication35). The lack of DAT-mediation of this effect was demonstrated 
when this depressive effect was still observed in mice expressing a cocaine-insensitive DAT 
mutant (Figure 2, panel B), and not when using an alternative DAT inhibitor (nomifensine) 
(Figure 2, lower panels). Additionally, our collaborators did not observe any modification of the 
field excitatory postsynaptic potentials in the striatum, suggesting that this effect was not due to 
the anesthetic-like effect of cocaine37. This was supported by the fact that methylphenidate, 




Figure 3. A) Representative images of FFN102-labeled dopaminergic projections in the dorsal striatum of acute 
murine brain slices before and after local electrical stimulation in untreated, or 30µM cocaine-treated conditions. We 
observed significantly less fluorescence increase following electrical stimulation in the presence of cocaine. B) Time 
course of change in normalized FFN102 fluorescence during a washing period, a cocaine treatment period (starting 
at arrow), and electrical stimulation period (10Hz local stimulation, starting at t=0). No change in rate of 
fluorescence decay was observed prior to electrical stimulation, with or without cocaine treatment. Following 
electrical stimulation, the maximum magnitude of the FFN flash occurred at 50sec. C) Significant reductions in the 





 In an effort to further understand the mechanism causing depressed DA release, FFN102 
was used in high-cocaine experimental conditions, and the effects on the tracer inside the neuron 
before stimulation, and on the FFN flash caused after stimulation were observed. For these 
experiments, FFN102 (10µM) was loaded into dopaminergic projections of the striatum of acute 
murine brain slices over 30 minutes. FFN102 was then imaged for 10 minutes during a washing 
period, followed by another 10 minutes in the presence or absence of 30 micromolar cocaine (or 
methylphenidate). Finally, the acute slice was locally stimulated by a bipolar electrode for 5 
minutes at 10 hertz (Figure 3). In this experiment, we observed that there was no significant 
change in the decay of FFN102 fluorescence during washing, with or without cocaine (−1.17 ± 
0.54 w/o cocaine, −0.98 ± 0.11 w cocaine change/minute; mean ± S.E.; 2-3 slices per animal, 5 
different animals/condition; non-significant, one-way ANOVA) (Figure 3B). However, we did 
observe a significant decrease in the maximal ∆F/F after electric stimulation. Treatment with 
cocaine resulted in a 70 percent reduction of the FFN flash (p < 0.0001, one-way ANOVA), 
while methylphenidate resulted in a 48 percent reduction (p < 0.0001, one-way ANOVA) 
compared to untreated conditions (Figure 3C). Therefore, it is probable that the DA loaded into 
release sites remained unaffected by the cocaine treatment, since otherwise there would have 
been an expected change in the decay rate of FFN102 fluorescence pre-stimulation due to 
leaking of FFN102 from the vesicles or due to the vesicular pH gradient being decreased. More 
likely, the reduction in FFN102 flash (correlating with the reduction in DA release) was due to a 
reduction in the number of vesicles fusing with the plasma membrane following electrical 
stimulation. 
 This experiment was exciting for the FFN program for two reasons. First, relative 
changes in the FFN flash mirrored the increases of extracellular dopamine concentrations 
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measured with established methodology. This suggested that the magnitude of the flash has a 
direct relationship with the amount of vesicular DA being released. Second, this is the first 
example of using a pH-sensitive FFN to provide insights into the mechanism behind an unknown 
biological phenomenon. There is currently no other technique applicable to acute murine brain 
slices that would have been able to generate the same data, and demonstrate that DA release was 
reduced, but the vesicular loading of individual dopaminergic release sites remained unchanged 
under these conditions. 
2.2.2 Applying FFN102 to Study DA Release under Phasic Firing Conditions 
 Satisfied that the FFN flash had a direct correlation with DA release, we next explored 
using FFN102 to trace DA release under phasic firing conditions. For dopamine, in vivo phasic 
firing patterns are usually bursts of 2-10 spikes that occur around a frequency of 20 hertz6. To 
mimic this pattern in acute slice, we chose to electrically stimulate at 25 hertz with 5 EPs. 
Previous observations of FFN102’s flash under tonic firing conditions (10Hz) showed that peak 
fluorescence was not reached until 40-50 seconds after stimulation, or 400-500 EPs. Considering 
that the maximal ∆F/F achieved during that time frame was only approximately 20 percent, there 
was concern that a hundred-fold reduction in the number of EPs might result in an insignificant 
∆F/F signal to noise ratio. Nevertheless, acute murine brain slices were loaded with FFN102 





Figure 4. Change in DA-FFN fluorescence after application of 5 electrical pulses (5EPs) at 20Hz under varying 
conditions. A) Normal conditions with FFN102 (pH-sensitive), resulting in a 5.3% maximum increase. B) The first 
derivative of the fluorescence change of FFN102 release highlighting the increased release of the first time point 
(first 2 EPs) compared to the following ones. C) Normal conditions with FFN200 (not pH-sensitive), resulting in a 
1.3% maximum increase. D) FFN102 flash during inhibition of calcium channels with cadmium ions (200µM Cd2+), 
resulting in no significant increase. E) FFN102 flash in mice that express 5% VMAT2 (VMAT-hypomorphs), 
resulting in a 0.9% maximum increase. 
 
For these experiments, the imaging rate was dramatically increased from an image 
collected every 10’s of seconds to one every 100 milliseconds (10Hz). This was achieved by 
scanning a smaller area (5x5µm) with a shorter pixel dwell time, but with the same pixel 
resolution as before. The increased imaging rate allowed for the collection of more detailed 
temporal information about the kinetics of the FFN flash. Under these imaging and stimulation 
conditions, we observed a significant increase (5.3±0.2) in fluorescence attributed to the FFN 
flash, as measured by an average ∆F/F measured over the whole 5x5 micron frame (Figure 4A) 
(2-3 slices per animal, 3 animals). Excitingly, the ∆F/F from only 5 EPs was already a third of 
the maximum ∆F/F achieved from 500 EPs. Also interestingly, compared to extracellular DA 
levels after release, this fluorescence increase was relatively long-lasting, and persisted for 
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seconds before returning to basal levels. This was most likely due to the fact that even after 
reuptake of the probe by DAT into the cell, FFN102 continued to add to the increase in total 
fluorescence until the fluorophore was reloaded into acidic vesicles. Additionally, protonated 
FFN102 from other areas of the striatum could have been diffusing into the field of view from 
other release sites. This is consistent with the relatively slow loading time of FFN102 by DAT 
compared to DA. 
In an effort to further characterize the fluorescence increase observed following phasic 
burst firing, we next repeated these experiments under a series of varied conditions:  using a DA-
FFN that is not pH-sensitive (FFN200); inhibiting calcium channels with cadmium ions; or using 
a mouse line with low expression of VMAT2 (Figure 4)38,39. First, using FFN200 under the 
same experimental conditions led to a ∆F/F increase of only 1.3±0.5 percent (Figure 4C) (2-3 
slices per animal, 3 animals). We believe this increase was due to the “inner filter effect,” which 
occurs when fluorescent dyes are highly concentrated, where the dye is not equally excited 
throughout the sample, or the emission is partially quenched internally40. Therefore, at the high 
concentrations found in loaded vesicles, the fluorescence signal was no longer directly related to 
fluorophore concentration. We believe that the 1.3 percent increase is representative of the 
degree to which the inner filer effect was decreasing the overall FFN fluorescence within the 
release sites, an effect that was observable without a pH-sensitive FFN. It is likely that the inner 
filter effect was also responsible for a small portion of the ∆F/F observed with FFN102, but the 
majority of the fluorescent signal was resulting from the pH-sensitive functionality. 
Next, we completely blocked vesicular release by inhibiting calcium channel function 
using 200 micromolar cadmium ion conditions (CdCl2). This resulted in a complete elimination 
of the FFN flash (Figure 4D). This suggests that none of the increase in ∆F/F was due to an 
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artifact of the electrical stimulation protocol, and that fluorescent changes were only occurring in 
combination with vesicular fusion.  
Lastly, we repeated the burst firing stimulation in a mouse line that expresses VMAT2 at 
5 percent the normal level in wild-type mice (VMAT2-hypomorphs)39. Note that in the VMAT2-
hypomorphs, measured DA release was unexpectedly high compared to what might have been 
expected based on only 5 percent VMAT2 expression. The DA release in this mouse line was 
approximate 30% of that compared to wild-type littermate mice. In quantifying the FFN102 
flash, we measured a similar reduction DA release as measured by the ∆F/F observed in this 
mouse line (0.9±0.2, mean ± SEM, 2-3 slices per animal, 3 animals) (Figure 4E. This represents 
an 83 percent reduction compared to the ∆F/F observed in wild-type littermate mice. This 
indicated that the FFN102 flash was dependent on FFN102 being loaded into vesicles through 
VMAT2. Additionally, the degree of correlation between VMAT2-dependent vesicular DA 
loading and observed DA release was comparable to VMAT2-dependent vesicular FFN102 
loading and the resulting magnitude of the FFN flash. By experimenting with different 
conditions during the burst firing experiments, we concluded that the FFN flash from FFN102 
was dependent primarily on increases in fluorescence due to changes in pH when FFN-loaded 
vesicles fused with the plasma membrane, and was not an artifact of electrical stimulation. 
Additionally, vesicular loading was dependent on VMAT2 active transport. 
2.2.3 Applying FFN102 to Observe Single Action Potentials 
 Even when imaging at 10 hertz, we observed that the first frame imaged after the 
initiation of the stimulation already had a significant fluorescent increase. In fact, over 50 percent 
of the total ∆F/F generated over the 5 EPs occurred within the first frame (100ms, Figure 4B), 
after only 2 EPs. This is consistent with the timeframe of DA release patterns in acute murine 
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brain slices. Dopaminergic projections in the striatum of acute coronal slices are severed from 
the cell bodies in the substantia nigra, and are therefore inactive, with no endogenous tonic firing 
in this experimental system. Therefore, using cyclic voltammetry (CV) to measure DA release, 
stimulation from one EP results in a massive release of dopamine, while subsequent EPs release 
very little41. If the dopaminergic projections were allowed to rest for over a minute, the massive 
first pulse release phenomenon is restored. It is likely that this same phenomenon could be 
observed with the FFN102 flash if it were quantitatively tracing DA release. Therefore, our next 
objective was to explore whether it was possible to image the FFN102 flash after just one EP 
using even faster imaging conditions. 
 
Figure 5. Timeframe of FFN flash in murine acute brain slices following stimulation with a single electrical pulses 
(EP). A) Representative individual trace of the fluorescence change in an ~2µm2 field of view centered on one 
FFN102-labeled release site (inset) after electrical stimulation from 1 EP (t=0). B) Average of all traces resulted in a 
significant increase (4.0%) that peaked after 60ms. 
 
 The next set of experiments were conducted using the same FFN loading conditions as 
described previously (2.2.1), but imaged using a spiral scanning image collection method of an 
even smaller area (2x2µm) centered around a single puncta. Instead of imaging in a square 
pattern similar to a printer, a spiral scan more efficiently images a circular field of view through 
spirals of decreasing size. These temporal improvements allowed us to further increase our 
imaging rate to 67 hertz (15ms per frame). An electrical stimulus of just one EP was then applied 
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locally and the change in fluorescence of the whole frame was measured. From these 
experiments we observed a significant flash with a ∆F/F of 4.0±0.7 percent from one EP (Figure 
5), only 25 percent smaller than the magnitude observed with 5 EPs. This magnitude of ∆F/F is 
consistent with our observations of DA release in the acute brain slice, however, the peak ∆F/F 
was not reached until time point 4, or 60 milliseconds following the stimulation. This suggests 
that a large portion of the flash measured could have been generated by FFN102 release 
occurring outside of the field of view and then diffusing into the area being measured. 
Nevertheless, while the average fluorescent flash appeared delayed, there was evidence that for 
certain puncta the increase in fluorescence was almost immediate. The relationship between the 
imaged puncta and the time delay will be explored in more detail in 2.2.5. 
2.2.4 Applying FFN102 to the Measurement of DA-release Paired Pulse Ratios 
 Excited by the relatively large ∆F/F of the flash achievable from one EP, we wanted to 
further use this parameter to explore the paired pulse phenomenon observed with DA release in 
the striatum. While an initial electrical pulse results in a large release of dopamine, a second 
“chase” pulse can be applied, the response magnitude of which increases logarithmically with the 
increase in the interval time41. After 60 seconds, the subsequent pulse results in an equivalent 
amount of DA release. To measure if the paired pulse effect was also observable with the FFN 
flash, acute murine slices were collected from individual animals and distributed evenly for 
electrochemical and optical measurements. I would like to thank Dr. Danny Korostyshevsky, a 




Figure 6. Ratio of the DA release between the first electrical pulse and the subsequent paired pulse depending on 
the time interval between them. Resulting paired pulse rate of DA-release recovery as measured by the FFN102 
flash or cyclic voltammetry (CV). The T1/2’s for each are similar – FFN flash: 34s, CV: 38s. 
 
 Coronal acute murine brain slices of the striatum were cut in half and equally separated 
for optical measurements with two-photon microscopy or electrochemical recordings with CV, 
which were then run in tandem. Simultaneous imaging and recording within the same slice 
would have been ideal, but was problematic due to the effects of the laser interfering with the 
recording electrode of CV. For measurements, each half was treated equally, which included 
using the same solutions, loading FFN102 in parallel (10µM for 30min), and initiating the 
stimulation at the same time for both halves. Five pairs of pulses with varying delay intervals 
were delivered to each slice, and then the order was reversed and the process repeated in the next 
slice. The resulting paired pulse ratios of DA release as measured by CV or optical fluorescence, 
were then plotted depending on the interval lengths between the pulses (Figure 6). We observed 
an almost identical trend in measured DA release between the two methods, and very similar 
kinetics for the time required to restore DA release (T1/2’s – CV: 38s, FFN Flash: 34s). This 
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further supports the conclusion that the FFN flash relates directly to DA release and can be used 
as an optical measure of this parameter. 
 Importantly, it was noted that in the optical measurements of DA release the maximum 
∆F/F of the FFN102 flash throughout the set of pulses within the same slice decreased steadily 
over time. While the paired pulse ratio of the last set of EPs still matched well with the CV data, 
the relative magnitude of the ∆F/F compared to the first set of EPs was greatly diminished. 
Unlike DA which undergoes rapid reuptake through DAT, FFN102 is less efficiently recycled, 
potentially due to the weaker binding affinity (Km-apparent: ~4.2µM), and slower uptake kinetics 
(as inferred from loading kinetics)1. Combined with the lack of internal biosynthetic protein 
machinery that can regenerate lost stores of FFN102, unlike DA, the overall amounts of vesicular 
FFN102 must steadily decrease after each pulse more rapidly than that observed with DA in 
acute brain slice. In fact, in the CV data from these experiments, it was observed that after the 
first couple of pulses the amount of DA released actually increased slightly, before slowly 
starting to decrease. We believe that this may have been due to a small competitive effect of 
FFN102 during loading, which replaced some of the vesicular DA. With each subsequent 
stimulation this effect would be diminished, as FFN102 concentrations in the slice would 
decrease more rapidly than DA. A similar effect was explored in the original FFN102 paper1, 
where DA reuptake kinetics were measured with CV in the continuous presence of FFN1021,  
but our recent data suggests that even a previous FFN102 incubation, followed by a washing 
period, still has an effect on DA release. Additionally, these observations help shaped the design 
of future FFN102 experiments. In an effort to reach a more stable FFN102 vesicular 
concentration over time, experiments described below (2.2.5) also included a low concentration 
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(1µM) of FFN102 in the artificial cerebral spinal fluid (ASCF) perfusing over the brain slice to 
replenish the FFN lost after each release event. 
 After successfully measuring comparable paired-pulse ratios, combined with previous 
observations, we concluded that the pH-sensitive FFN flash can be used to measure DA release 
analogously to electrochemical techniques, such as CV. With this type of “optical CV” it may be 
possible to measure DA release from very localized areas; however, efforts to identify “puncta-
specific” changes in fluorescence have so far been unsuccessful. Nevertheless, even being able to 
measure general DA release from a small area (few microns) is potentially important when 
considering the location-specific variability of different areas of the striatum. This is supported 
by evidence that demonstrated in vivo heterogeneity of DA release found in relatively small areas 
(~100µm) of the striatum that had different spontaneous release patterns and responses to DAT-
inhibition42.  Another example of this type of heterogeneity is found in the ventral striatum, 
where local “hotspots” of opioid receptor expression43 have been identified, which can be found 
on, and directly modulate, dopaminergic projections in that area44. 
To substantially improve on electrochemical techniques, however, we would need to 
fully realize the benefits possible with optical imaging techniques and measure neurotransmitter 
release from individual release sites. At current imaging rates, we have been unable to identify 
changes in fluorescence at a particular puncta that do not match the average change found across 
the field of view. This is why the previous quantification of these experiments has generally 
included the ∆F/F from the whole frame. Our lack of prior success with measuring changes at 
individual release site was likely due in part to the excitation volume of the microscope and the 
speed at which FFN102 is diffusing. First, due to the limitations of two-photon excitation, the z-
plane spatial resolution of the microscope (~2µm), as measured with microbeads of uniform size, 
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is much larger than the average dopaminergic release site (~0.3µm)45. While the x-y resolution 
(~0.35µm) is capable of resolving an individual release site, there will always be a fluorescence 
contribution from the background signal included from the z-plane. Therefore, if the ∆F/F of the 
background is larger than any local fluorescence changes that might occur, the individual 
contribution will be diluted by the global background change. This leads into the second issue, 
the rate at which FFN102 diffuses throughout the field has been too fast to allow identification of 
the source location of signal generation. This is problematic if the ultimate goal is to be able to 
identify when an individual release site fires. 
2.2.5 Applying FFN102 to the Measurement of Single Pulse Release Kinetics 
 Unable to change the spatial resolution properties of the microscope, we sought to tackle 
the problem of identifying individual firing events by changing the way we examine the flash 
from one EP. First, we needed to better understand our experimental system and to focus on how 
to best maximize the change in ∆F/F from an individual release site. At this point it had been 
confirmed with two different DA-FFNs (FFN102 and FFN200) that the majority of labeled 
dopaminergic release sites (80-90%) were “silent,” and did not release a significant portion of 
their loaded FFN when stimulated with long trains of electrical pulses similar to tonic firing 
conditions (1000s of EPs)1,5. Similar observations have been observed with the membrane dye, 
FM1-43, which only loads recycling vesicular pools. Stimulation of dopaminergic projections in 
the presence of this dye, leads to FM1-43 loading of only 10 percent of dopaminergic release 
sites5. Using a mouse line expressing the genetic calcium sensor GCaMP3 under control of the 
DAT promoter (DAT-GCaMP3), it was confirmed that the majority of these silent dopaminergic 
release sites were actively being stimulated (~70%) and undergoing calcium transients, but did 
not result in significant release of FFNs or loading by FM1-435. While presynaptically silent 
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puncta have been reported in the glutamatergic46–48 and GABAergic49,50 systems previously, and 
there are potential theories that vesicle priming might be the underling mechanism51,52, this has 
not yet been explored in dopaminergic neurons. 
 We also knew from electrochemical and FFN flash experiments in acute brain slices, that 
the first EP results in a massive amount of DA release, while depending on the interval, the 
subsequent EPs release relatively little. Combined with our understanding of silent puncta, we 
hypothesized that during phasic bursts of EPs (or the first EP after a period of rest) a large 
portion of dopaminergic terminals must be participating in DA release, while after continuous 
stimulation of long trains of EPs, members of this population turn off. This would leave only a 
small portion of dopaminergic release sites that have the mechanisms in place to continually 
recycle their vesicular pool and release all of the loaded FFN. Based on this assumption, we 
hypothesized that if we delivered a relatively slow tonic sequence of EPs to dopaminergic 
projections that the majority of puncta might have a high release probability during the first 
couple pulses and then only a few (10-20%) maintain a high release probability for the remainder 
of the pulses or activate their reserve pool of FFN loaded vesicles53. This portion of release sites 
would be the same ones identified to fully destain after even longer sequences of EPs (100s-
1000s). Additionally, the problems associated with significant background fluorescence 
contribution from a single EP, as discussed previously, would be greatly reduced when 
performing the imaging following a series of pulses. As seen with the paired-pulse experiments 





Figure 7. Time course of FFN102 fluorescent changes from a single time course at an individual release site in 
acute murine brain slices following single EPs separated by 2s (10 total). A) Representative individual trace from 
the fluorescence change in the field of view centered on one FFN102-labeled release site following 10 individual 
EPs (each horizontal bar indicates the duration of the individual trace analyzed in B, and the tick in the middle 
indicates the time when a single EP was delivered). B) Each individual EP from the 10 EP set was analyzed further 
individually to determine if and when a significant increase occurred. Panel B includes a representative individual 
EP trace extracted from the full trace in panel A as indicated by the red box. 
 
 To test our hypothesis, which can account for all of our FFN flash observations and our 
understanding of how dopaminergic release sites in acute brain slices behave, we designed 
imaging and stimulation conditions to attempt to measure release of FFN102 from individual 
release sites during a series of slow tonic EPs. Again, we used a spiral scanning imaging protocol 
with slightly modified parameters from section 2.2.3 to collect 2 micron2 images of one FFN102-
labeled release site at a rate of 100 hertz. For the stimulation protocol, we delivered 1 electrical 
pulse locally every 2 seconds, for 10 total pulses over 20 seconds (Figure 7A). At our imaging 
rate, this would allow for enough images to generate a pre- and post-EP fluorescence time course 
for each pulse of the set individually (Figure 7B). As discussed in 2.2.4, for these experiments, 
FFN102 at a low concentration (1µM) was included in the perfusion ACSF and present 
throughout the experiment to replenish FFN102 vesicular stores. To further allow for FFN102 
reloading, after each set of stimulations, we included a 5 minute wait period before the total 
process was repeated multiple times at multiple release sites from each acute slice. As a negative 
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control, these experiments were also repeated without electrical stimulation. Using this 
experimental design we collected a large amount of FFN flash data from the area around 
individual release sites following 1 EP, which resulted in the massive release of DA, followed by 
9 subsequent EPs that resulted in minimal DA release, as confirmed by CV. 
 
Figure 8. MATLAB analysis of the normalized changes in FFN102 fluorescence from the trace of a single EP at an 
individual release site in acute murine brain slice. A) Representative plot of p-values generated from a moving 
cluster of time points (5) over the course of an individual trace before and after 1 EP (arrow, t=0) from a t-test. B) 
Setting a p-value threshold of p<0.05, the periods when significant increase occurred were collected. In this 
example, a significant increase was observed 50ms after the initiation of the EP. Also highlighted are examples of 
false positive periods that were selected during pre-stimulation due to the noise of the data collection. 
 
 To analyze these data we developed a MATLAB script that separated the 10 EPs from a 
single set into 10 equally spaced traces centered on each of the electrical pulses (exemplified in 
Figure 7B). The fluorescence baseline signal pre-pulse for each individual trace was used to 
generate a line of best-fit, which was then used to normalize the post-pulse fluorescence for each. 
From this baseline-corrected trace, we next looked at a moving group of 5 time points and, using 
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a t-test, determined the probability that this particular cluster of points was statistically greater 
than the baseline. The p-values generated from the moving set of groups from each trace were 
then collected and plotted (exemplified in Figure 8A). Using a significance threshold, set as any 
p-value less than 0.05, the time periods with a statistically significant fluorescence increase were 
determined. This data was slightly smoothed to remove any time periods that only lasted two 
time points or less (Figure 8B). This process was repeated for each of the 10 EPs from a single 
set, and then from each set between all acute slices and animals. In total, we were able to analyze 
over a thousand fluorescent traces before and after individual EPs. 
 
Figure 9. Analysis of combined MATLAB data for changes in FFN102 fluorescence observed following the initial 
EP (EP1), subsequent EPs (EP2-10), or no stimulus. This plot details what percentage of electrical pulses (EPs) 
generated a significant fluorescence increase over time (EP occurred at t=0). After the first EP in the set (EP1) a 
significant fluorescence increase was observed in 96.7% of the fields of view after 80ms. The average probability of 
observing significant increases in fluorescence of the following EPs (EP2-9), was much lower and slightly delayed 
(38.1% after 150ms) than after EP1, but still significantly higher than the control (EP10 was not included here due to 




 While collecting these data was a time consuming process, understanding the data 
collected proved to be the challenging part. The initial goals were to determine if we could 
observe significant increases in fluorescence from the weak DA-releasing signal that occurred 
after individual EPs (EP2-10) that followed the initial EP stimulus (EP1), and to understand the 
temporal relationship as to when significance was reached relative to when the EPs occurred. As 
expected, EP1 from each set virtually always resulted in a significant fluorescent increase, but 
surprisingly, we were also able to observe significant fluorescent increases in the FFN flash after 
subsequent individual EPs as well. We also observed that the percentage of EPs resulting in 
significant increases appeared to depend on the time interval after stimulation. Grouping only 
EP1s together from all sets collected, a significant increase was observed in 96.7 ± 2.3 percent of 
measured frames after 80 milliseconds (Figure 9) (mean ± SEM for 60 EP1s from 2-3 slices per 
animal, 6 animals). After this time point, the percentage of frames with a significant increase 
slowly started to decrease, presumably as FFN102 started to wash away or get recycled into 
acidic compartments. Importantly, using the diffusion coefficient for dopamine in acute brain 
slice (2.7*10-6 cm2/s), after 80 milliseconds the FFN could have traveled up to 6.5 microns, an 
area much larger than the field of view54. If the signal increase was generated from FFN102 
being released from the individual release site in view, we would expect an increase after just the 
first time point (10ms). Therefore, we suspect that the delayed increases must have been due to 
diffusion of FFN102 released from other release sites, out of the field of view or a delayed circuit 




Figure 10. The data from representative individual EPs from the group of subsequent EPs (2-10) plotted as 
described in Figure 9. There was no statistical difference in any of the remaining EPs, except for EP10, which had a 
slower rise time and lower overall magnitude, highlighted by brackets. 
 
 A similar general delayed effect was observed with the subsequent EPs as well. EPs 2-9 
all exhibited similar behavior with no significant differences when averaged together. EP10 did 
have a maximum release that was measurably slower and of lower overall magnitude than the 
others, and this difference is highlighted in Figure 10, which includes representative examples 
from individual EPs from the 2-10 group. When EPs 2-9 were grouped together, the maximum 
percent chance to observe significant release is 38.1±2.3 percent, occurring at 150 milliseconds 
post-stimulation (Figure 9). This is almost twice the amount of time observed after EP1, and 
could correspond to diffusion from release sites up to 9.2 microns away. We believe this timing 




Figure 11. Some possible explanations based on diffusion for the variability observed in the temporal delay between 
when electrical stimulation occurred and when a significant fluorescence increase was observed. A) If the 
fluorescence change from an individual release is significant on its own, then the release from the puncta in the field 
of view (FOV) should cause an instantaneous increase in fluorescence (1-2 time points post-stimulation). B) If the 
imaged puncta did not fire, but a neighbor did, there would be a delayed increase based on the distance between the 
releasing puncta and the FOV. C) If the FFN released from one puncta was not sufficient to measure above the 
noise, then a significant increase would only be achieved when the additional fluorescence from neighboring release 
sites diffused into the FOV. This increase would also be delayed, as determined by the distances from the FOV, and 
density of neighboring release sites. 
 
 If we consider the current threshold of significance in the MATLAB analysis as 
involving some amount of new deprotonated FFN102 within the frame, relative to the 
fluorescence of the individual release site in the field of view, then there are multiple possibilities 
they may explain how that amount of FFN was reached based on diffusion (Figure 11). First, the 
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release site in the frame could release enough protonated FFN from its vesicular stores to 
generate a sufficient change in fluorescence relative to its remaining FFN fluorescence (∆F/F) 
with a duration long enough to pass the threshold. We expect that for this type of event, 
statistical significance should be reached almost instantly after stimulation (Figure 11A). 
Encouragingly, for some EPs we were able to detect significant increases in fluorescence after 
just one or two time points. Second, we can continue to assume that the flash from one release 
site can generate a significant enough ∆F/F to be detected, however, this release site is now 
located out of the field of view. Therefore, depending on the distance from the imaging area, the 
significant signal caused by this release site would be delayed (Figure 11B). Lastly, it is possible 
that the amount of FFN102 released from a single site is not sufficient on its own to be detected 
by this method, especially if it is a distant neighbor to the release site being imaged. In this case, 
the number and location of nearby release sites relative to the imaging site would be the most 
important factor in determining whether significance is reached (Figure 11C). The more 
numerous the neighbors, the higher the probability that significance would be reached if a 
subpopulation of them were firing, as well as, the closer the neighbors, the shorter the time 
interval between stimulation and significance increases. 
 It is likely that there are examples of each within the current collection of data, but strict 
classification at this time is premature. To further determine the importance of the individual 
release sites within the imaging frame, these experiments need to be repeated with some FOVs 
focusing on only background (an area with no release site) or an area of fluorescence expected 
not to release (blood vessels). This would help us understand the role of the release site in 
producing the flash, versus the contribution of diffusion, and if the release from the puncta in the 
FOV is measurably significant on its own. These experiments have started, but are not yet ready 
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to allow us to draw conclusions. As described later, in future directions (4.2.2), there are also 
other ideas to help delineate signal from the release site in the field of view from signal 
generated from the neighboring area. For example, implementing microscope scanning upgrades 
that improve the imaging rate, or performing our imaging experiments in areas with less dense 
projections that may decreases the background signal.  However, to complete this section, I will 
continue by analyzing the traces from individual EPs where increases in fluorescent signaling 
significance were reached within the first couple images following stimulation, because these 
fluorescent increases were most likely to result from release occurring at the release site within 
the field of view.  
 
Figure 12. The probability of observing significant FFN102 fluorescent increases, “firing event” (FEs) when 
comparing different temporal cutoffs for when that increase must have occurred by. After setting the temporal 
cutoffs as a number of imaging frames (every 10ms, between 1 and 8 frames), each imaging set (10 EPs) was plotted 
based on how many FEs were detected out of the possible 10. A significant increase in FEs was observed for all 
temporal windows (even at 10ms) when comparing stimulated (A) and unstimulated conditions (B), with the 
average number of FEs detected increasing with the amount of time included post-stimulation. We also observed an 
apparent bi-modality in the number of FEs detected in the stimulated conditions (highlighted by arrows) that became 
more pronounced the longer the temporal windows. 
 
 While there is more work to complete, analyzing the current data set has already led to 
some potentially interesting findings. By setting a series of increasing temporal windows after an 
EP stimulation to asses when a significant increase in fluorescence was detected (FFN102 firing 
66 
 
event, or “FE”), indicating that DA release occurred, we were able to compare the timing of each 
FE detected, at each of the individual release sites, in each of the temporal windows. 
Specifically, for each of the 10 EPs within an imaging set, we assessed whether or not a 
significant fluorescent increase (or detectable FE) occurred within a designated time frame, and 
then the total number of FEs that occurred within each imaging set centered on an individual 
release site. The probabilities of detecting a certain number of FEs (out of 10) that occurred 
within each imaging set were then plotted for each of the temporal windows assessed (Figure 
12). When assessing the 10ms temporal window (1 imaging frame after stimulation, 
corresponding to a potential FFN102 diffusion of 2.3 microns), we observed only a slight 
increase in the number of FEs after stimulation compared to the false positive rate observed in 
the non-stimulated control. However, as the duration of temporal window in the analyses 
increased, the increase in the number of FEs observed between the stimulated and non-stimulated 







Figure 13. Normalization of the number of firing events (FEs) detected at individual release sites within specific 
temporal windows following EP stimulation. Using the data from Figure 12, the average number of false positive 
FEs detected in the control conditions (unstimulated) were subtracted from the stimulated condition and replotted. 
After subtraction, we observed a significant percentage of imaging sets that did not have any measurable 
fluorescence increases (FEs) within these temporal windows. However, we also observed a significant percentage of 
release sites with an increase in FEs, and which retained the bi-modality observed previously (highlighted by 
arrows). Depending on the duration temporal window, a large portion of the imaging sets demonstrated 1 FE or 3 
FEs. If the average density and firing probabilities of dopaminergic projections were all the same, then it is likely 
this increase in FEs and bi-modality is not due solely to diffusion 
 
After the false-positives, which had a good fit to a Poisson distribution (p-value <0.05 for 
all temporal intervals), in the non-stimulated condition (Figure 12B) were subtracted from the 
data derived from stimulated conditions, a significant increase in FEs were still observed from 
the first time temporal window onward (10ms, 20ms, 30ms, etc.) (Figure 13). When the 
temporal window exceeded 30 milliseconds, we observe a deviation in FEs from a Poisson 
distribution that became more pronounced as later time points were included (p-value increases 
from ~0.1 to ~0.7). There was a peak in the percentage of imaging sets that demonstrated few 
significant increases in fluorescence above control (0-1), and an observed second peak in the 
percentage of imaging sets that had multiple (~3 FEs). Assuming that all of the sets had a 
random distribution of neighbors, with equally random release probabilities, and the detection of 
FEs was primarily the result of diffusion of FFN102 from neighboring release sites, then we 
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would expect a normal distribution of the FE percentage for stimulated sets, similar to the control 
sets, but shifted to the right. The sets with many close neighbors to the field of view would likely 
have a higher percentage of FEs than sets with more sparse neighbors, leading to a normal 
distribution that would be centered based on the average density of release sites. Because the 
distribution in Figure 13 appears to be bi-modal, it is possible that the existence of this second 
“hump” of imaging sets, which have a high percentage of multiple FEs (~3), suggest that 
diffusion of FFN102 fluorescence is not the only factor contributing to the flash detected at 
single release sites after EP stimulation. This is supported by recent evidence that suggested that 
DA release in the striatum from a single EP has two temporally distinct release events. First, an 
immediate release from direct stimulation of the dopaminergic release site, and then a delayed 
release (~100ms) due to an acetylcholine mediated circuit component55. We will confirm if this 
is related to the delayed FFN flash with nicotinic receptor antagonists. 
In summary, we are optimistic about the observations we have generated so far. We have 
determined that it is possible to observe significant increases in FFN102 fluorescence after 
electrical stimulation on the millisecond timescale, potentially from individual release sites. 
Additionally, significant increases in florescence could be detected for each EP, including EPs 
other than just EP1 that release much less DA than the first stimulus. 
2.3 Measuring Intracellular Vesicular Changes with FFNs - Results and Discussion 
2.3.1 The Regulatory pathways Involved in the Loading of DA Vesicles 
 In addition to generating a flash upon release, a pH-sensitive FFN also has the potential 
to measure changes that occur within the release site before vesicular fusion occurs. An example 
of this behavior was explored in the experiment involving high concentrations of cocaine 
described in section 2.2.1, but under this condition, no apparent changes in vesicular pH were 
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responsible for the depression in DA release. However, through a collaborative effort with Dr. 
Zachary Freyberg (Columbia University), dopaminergic intracellular trafficking and quantal size 
was again explored using FFN102 in the context of glutamatergic co-transmission in the 
dopaminergic projections of the striatum.  
 How changes in quantal size can affect postsynaptic targets (and vice versa) was 
discussed in 2.1.3, but the presynaptic mechanisms in place for regulating how much 
neurotransmitter is loaded into vesicles will be further elaborated here. Within release sites there 
is a delicate balance between the concentration of the neurotransmitter in the cytoplasm and 
vesicular lumen. The equilibrium of neurotransmitter concentrations between the extracellular 
space, cytosol, and vesicles is maintained by biosynthesis, biodegradation/metabolism, 
membrane transport, and vesicular transport mechanisms. Changes in any of these mechanisms 
can ultimately affect the amount of neurotransmitter that is loaded per vesicle, and subsequently 
released per fusion event. As substrates for transporters on both the cell surface and vesicular 
membranes, FFNs have the potential to track changes in the mechanisms controlling both of 
these transport processes. While changes in the rate of neurotransmitter biosynthesis can impact 
quantal size, they will not be discussed here due to the fact that FFN loading and fluorescence is 
not directly related to these pathways. 
 In the design of our experiments, we considered the fact that neurons within the brain are 
highly resource efficient when it comes to their neurotransmitters. The vast majority of released 
neurotransmitter is recycled back into neurons through reuptake by plasma membrane 
transporters (such as DAT for DA). For dopaminergic neurons, loss of DAT in knockout mice 
led to an overall 95 percent reduction in total DA levels, as DA biosynthesis simply cannot keep 
up with the amount of DA released56,57. The critical importance of DAT has also been observed 
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in our own laboratory. The dopamine projections of the striatum in acute brain slice experiments 
were able to continue to release dopamine after hours of stimulation, as opposed to only a few 
EPs in DAT-KO mice. DAT functions by transporting one molecule of DA into the cytoplasm 
through the inward co-transport of two sodium and one chloride ion, thereby using the sodium 
concentration gradient and membrane potential found at the plasma membrane to power DA 
transport58. Through controlling the intracellular stores of DA available for vesicular loading, 
changes in DAT activity can affect DA quantal size. As a substrate for DAT, FFN102 has the 
potential to measure these changes in DAT activity by measuring initial rates of loading or 
clearance following a stimulus. Combined with the fluorescence flash after exocytosis that traces 
changes in relative DA release, FFN102 has the potential to assess whether changes in DA 
release are related to varying DAT or VMAT2 activity at an individual release site. 
 The second neurotransmitter equilibrium that is important for determining quantal size 
resides at the synaptic vesicular membrane. For monoamines, VMAT2 is the transporter 
responsible for loading DA into the vesicle. VMAT2 uses an antiport mechanism that transports 
one protonated DA molecule in for two protons out. The proton electrochemical gradient that 
powers VMAT2 activity is generated by the vacuolar H+-ATPase (vATPase). Through ATP 
hydrolysis, protons are actively pumped into the vesicle generating a pH and electrical gradient. 
In monoamine synaptic vesicles, chloride ion antiport channels are also expressed on the 
vesicular membrane, which transport two chloride ions in for one proton out59. This transport 
helps dissipate the electrical component of the proton gradient by equilibrating more charge (net 
3) than protons (1), allowing for a larger build-up of the pH gradient60. This pH gradient is then 
the primary driving force of monoamine loading, and changes within the vesicle that affect this 
pH gradient can have a drastic effect on neurotransmitter loading61. Other than transporters, the 
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degree of loading is also influenced by the rate at which neurotransmitters leak out of the vesicle, 
and the rate of neuronal firing. If vesicle fusion is occurring too fast for full equilibration by 
VMAT2, the quantal release of those vesicles is potentially diminished. The following work in 
this section describes a potential novel role of VGLUT in regulating vesicular loading in some 
dopaminergic neurons. Contrary to VMAT2, VGLUT activity is primarily driven by the 
electrical potential at the vesicular membrane, and transporting in negatively charged glutamate 
could be acting in a function similar to the chloride channels28. 
 
Figure 14. Uptake of FFN206 into dopaminergic projections of the fly brain after application of KCl as measured 
through change in fluorescence relative to initial fluorescence (F/Fi). With FFN206 in the perfusion, there was 
increased loading of FFN206 after application of 40mM KCl (highlighted by green arrow), but before exocytosis 
occurred. This increase in loading was not present with treatment of the lipophilic weak base, chloroquine (CQ, 
50µM). Data obtained via two-photon microscopy of whole drosophila brains provided by Dr. Zachary Freyberg. 
 
2.3.2 Exploring the Role of VGLUT in Vesicular Loading 
 The idea for these experiments was built upon an observation in fly brain experiments, 
with the identification of a strange phenomenon that occurred before exocytosis induced by high 
potassium concentrations. Here, I will include just the relevant observations from our 
collaborator’s work that led to our own experimentation. First, using the pH-insensitive DA-FFN 
best suited for experiments in the fly, FFN20662, they observed that in the presence of 
extracellular FFN, there was increased uptake of FFN206 into dopaminergic projections when 
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high potassium concentrations are added (Figure 14). This resulted in a 40% percent increase in 
fluorescence that occurred just prior to complete FFN release when exocytosis occurs. Using the 
genetically-encoded vesicular pH-sensor, dVMAT-pHluorin, they identified that during this 
period of increased uptake there was an acidification that occurred within the vesicles (Figure 
15B). Through colocalization experiments, VGLUT was determined to be present in the 
dopaminergic neurons exhibiting this acidification phenomenon (Figure 15A). Suspecting that 
the negatively charged glutamate could be acting in a similar mechanism as chloride, to dissipate 
the electrical vesicular membrane potential and increase the pH gradient, these experiments were 
repeated using flies with VGLUT-RNAi. Reduction of VGLUT led to an approximately 50 
percent decrease in the magnitude and duration of the acidification, indicating the potential 
importance of this transporter in this phenomenon (Figure 15B). 
 
Figure 15. VGLUT involvement in the uptake of FFN206 in dopaminergic projection of the fly brain after treatment 
with KCl. A) Colocalization of the dopaminergic marker, tyrosine hydroxylase (TH-Gal4), with VGLUT (LexA-
VGlut). Circled in red is a magnification of the area being studied, which has a high concentration of dopaminergic 
projections. B) The pH-sensitive dVMAT-pHluorin fluorescence decreased during the application of 40mM KCl, 
corresponding with an increase in acidity. The average duration and magnitude of the acidification were reduced by 




2.3.3 Using FFN102 to Study the Role of VGLUT in Vesicular Loading in Acute Murine Brain 
Slices 
 The next goal of the project was to evaluate the role of VGLUT in the loading of 
dopaminergic vesicles in mice. However, before building upon the observations derived from a 
fly experimental system, it was necessary to first determine if a similar acidification occurred in 
a mammalian system. Because the pHluorin system is not yet applicable for use in acute murine 
brain slices, the FFN program was utilized to repeat the fly VGLUT experiments in a 
mammalian system, using FFN102 as the intracellular/vesicular pH-sensor. These experiments 
were conducted by loading the dopaminergic projections in the striatum of acute murine brain 
slices with FFN102 (10µM for 30min) and then imaging them during washing, and throughout a 
KCl depolarization treatment (40mM). Typically, imaging of dopaminergic projections in the 
striatum is conducted in the dorsal lateral part, an area dense with dopaminergic innervation, but 
these experiments were conducted in the ventral medial area, an area with greater dopaminergic 
VGLUT expression63. Prior to the drastic increase of fluorescence caused by FFN102 release, we 
observed a shift in the rate of fluorescence decay that temporally aligned with the arrival of 
increased K+ concentrations (Figure 16). The rate of fluorescence decay increased compared to 
the rate observed during washing, possibly indicative of increased transport of cytoplasmic 




Figure 16. Changes to the fluorescence of FFN102-labeled dopaminergic projections in the ventral striatum of acute 
murine brain slice following a 40mM KCl treatment (started at arrow, ~150sec). After normalizing the exponential 
rate of decay from the trace pre-KCl treatment, there was an increase in the decay rate of FFN102 fluorescence, 
after-KCl treatment and before exocytosis (large increase in total fluorescence), as highlighted by the bracketed 
region. 
 
Further exploration of this “dip” was made possible through the interlaced scanning of 
the same field of view with two lasers set as close to the excitation maxima of the protonated and 
deprotonated forms of FFN102. By simultaneously measuring the ratio of the two forms of the 
probe it was possible to determine if the observed dip was an artifact or indicative of a shift in 
the equilibrium of the two forms inside the release site. Using buffers of varying pH, the 
wavelengths of each laser were optimized to provide the greatest difference in fluorescent signal 
between the high and low pH conditions. Upon identifying optimal imaging conditions, the 
FFN102 high potassium experiment was repeated using interlaced scanning from two different 
lasers, and then the ratios between the fluorescence collected from each laser plotted over time 
(Figure 17). Due to a combination of the variability introduced when imaging an acute brain 
slice, lack of a pH control inside the release sites, and unknown distribution of FFN102 between 
the cytosol and vesicles, the following results are representative of only relative changes in pH. 
For analysis of the data, the rate of the ratio change during washing pre-KCl was used to create 
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an exponential best-fit to normalize the data between slices. Additionally, the average flash that 
occurred after release was used to normalize the magnitude of the ratios between different 
animals. We noticed that during the observed dip in fluorescence, there was a significant 
protonation of FFN102 within the frame. The magnitude of this acidification was 24.2% 
compared to the total alkalization that occurred when KCl depolarization led to complete 
emptying of the vesicles (2-3 slices per animal, 5 different animals). We initially had hoped to be 
able to analyze individual puncta to identify release sites that did or did not exhibit this 
acidification (potentially indicating release sites with or without VGLUT), but at the current 
imaging rate and resolution, the ratio data from this analysis were extremely noisy. I am 
confident that future optimization of this experimental setup could lead to less noise and 
improved quantification of individual release sites. 
 
Figure 17. Plot of the normalized fluorescence ratio of the protonated versus deprotonated forms of FFN102 in 
ventral striatum of acute slice, before and after treatment with 40mM KCl. This was measured using interlaced two-
photon imaging with two lasers set at either 690nm (protonated) or 740nm (deprotonated). There was a decrease in 
this ratio (acidification, magnitude: 24.2%) observed after KCl was applied (black arrow), but before exocytosis 




To further assess whether VGLUT2 was responsible for the acidification observation, 
these experiments were repeated in mice with a viral knockdown of the transporter. A mouse line 
with VGLUT2 flanked by LoxP genetic sequences (floxed) were injected in the ventral 
tegmental area (VTA, the source of dopaminergic neurons that project to the ventral striatum) 
with a virus that either led to the expression of cre recombinase or mCherry. Cre recombinase 
identifies LoxP sites and can lead to site-specific recombination. In this case, expression of cre 
recombinase in the dopaminergic neurons of the floxed VGLUT2 mouse line resulted in specific 
reduction in the expression of the VGLUT2 gene in those neurons. Additionally, mCherry 
expression was used in this experiment as a viral and genetic background control for this mouse 
line. Cre recombinase and mCherry expression levels in dopaminergic neurons (VTA) and 
projections (striatum) were confirmed through immunohistochemistry on each acute brain slice 




Figure 18. Confirmation of virally injected protein expression in the dopaminergic projections in the ventral 
striatum of acute murine brain slices. Mice with a floxed-VGLUT2 gene were either injected in the ventral 
tegmental area (VTA, location of dopaminergic cell bodies) with a mCherry or Cre recombinase virus 2 weeks prior 
to imaging with FFN102. After imaging with FFN102, acute slices from the striatum were collected and 
immunostained for either mCherry (A) or Cre (D), and the dopaminergic marker, tyrosine hydroxylase (TH, B and 
E). A strong colocalization of mCherry (panels A-C) or Cre recombinase (panels D-F) expression and dopaminergic 
projections is observed. 
 
When imaging the FFN102-loaded brain slices from these mice, we were able to detect 
pH changes in the mCherry injected control mice with a similar acidification magnitude (41.2%) 
as in wild-type (WT) conditions (Figure 19A). In VGLUT2-knockdown conditions, however, 
there was a significant reduction in the magnitude and duration of the acidification dip. The local 
acidification maximum in the knockdown condition was 13.6%, only slightly larger than the 
standard deviation of the baseline signal (2-3 slices per animal, 3 different animals) (Figure 
19A). We further quantified each of these conditions (WT, WT+KCl, Cre+KCl, and 
mCherry+KCl) to incorporate the duration factor into the quantification of the dip in 
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fluorescence ratio. This was done by measuring the total area under the curve (AUC) between 
the time KCl reached the brain slice and the time exocytosis started to occur (Figure 19B). We 
observed an 83% reduction in the acidification AUC between WT mice and mice without 
VGLUT, indicating a potentially important role of VGLUT in the observed acidification 
phenomenon. 
 
Figure 19. A) Comparison of the FFN102 fluorescence ratios over the 40mM KCl treatment in mice of the same 
genetic background that had either a mCherry control viral injection, or a Cre recombinase viral injection into the 
VTA. The acidification dip pre-exocytosis was almost completely abolished in the Cre injected condition. B) 
Quantification of all 4 total conditions (WT mice with KCl, WT mice without KCl, floxed-VGLUT2 mice with Cre 
and KCl, and floxed-VGLUT2 mice with mCherry and KCl). There was an 83% reduction in the pre-exocytosis 
acidification when Cre was expressed in the floxed-VGLUT2 mouse line. 
 
In summary, using the pH-sensitive FFN102, we were able to identify KCl-dependent 
changes in dopaminergic vesicular loading and further develop the speculated role of 
glutamatergic co-transmission in regulating DA quantal size64. Further work is needed to fully 
understand this mechanism, and to determine whether this phenomenon occurs under 
physiologically relevant release conditions. In general, these results are an exciting step forward 
for the FFN program, as we were able to successfully demonstrate the use of a pH-sensitive FFN 
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to measure intracellular vesicular loading changes, another example of a novel functional 
application of FFNs, and one that would not be possible currently with other tools in the field. 
2.4 Conclusions 
2.4.1 Summary 
 This chapter explored the potential of the pH-sensitive DA-specific FFN, FFN102, in 
fulfilling two important goals of the FFN program. These goals were to develop a fluorescent 
tool that could measure changes in presynaptic plasticity through quantifying both the release 
probability and changes in vesicular content of individual release sites. In order to quantify 
changes in release probability, we measured the fluorescence increase (FFN flash) created when 
FFN102 was released from an acidic vesicle into the neutral extracellular space. We also 
demonstrated that this FFN flash correlated well with DA release, as measured by well-
established electrochemical and microdialysis techniques in the field. Subsequently, we 
demonstrated that the FFN flash was also observable under phasic firing conditions and could be 
modulated as expected with pharmacological agents or genetic modification. Further, we 
observed that in the acute brain slice, the FFN flash was measurable from just a single EP; 
however, identifying the relationship between the flash and an individual release site remains to 
be established.  
Ongoing efforts to measure the FFN flash from a particular DA release site focused on 
using imaging parameters with the fastest temporal resolution that were still able to produce 
significant signal changes. However, due to the nature of how the FFN flash works, and the 
speed at which FFN102 diffuses, it may not be possible to demonstrate definitely whether a 
particular release site fired, but with enough data we may start to draw conclusions based on 
probability. Although we have not definitively demonstrated a measurable release from a single 
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DA release site, the experiments performed towards this goal have already started to elucidate 
potential mechanisms behind silent puncta, as observed with a bi-modality of release detected 
near individual puncta after only individual EPs. Additionally, the much higher probability of 
detecting release after the first EP, could be used to provide insight behind the massive striatal 
DA release observed following the first EP in the acute brain slice. 
 The second major FFN102 result described in this chapter was the demonstration of the 
utility of FFNs to measure another method of presynaptic neurotransmitter regulation, changes in 
vesicular loading. By simultaneously measuring changes in the relative concentrations of 
protonated and deprotonated FFN102, we were able to demonstrate a change of the intracellular 
vesicular equilibrium of dopaminergic release sites loaded with the FFN102 tracer in acute 
murine brain slice. This data, supported by evidence generated in fly brain experiments, 
demonstrated the hypothesized role of glutamatergic co-transmission in regulating quantal size in 
ex vivo experimental systems64. These experiments represent the first demonstration of the ability 
of FFN to measure intracellular vesicular pH changes within acute murine brain slices by 
leveraging the pH-sensitivity and functionality of FFN102. Combined with the ability to also 
quantify neurotransmitter release, FFN102 represents the first FFN with distinct improvements in 
functionality over currently availed technologies capable of only measuring pH. It is our hope 
that the demonstration of the FFN102 functionality described throughout Chapter 2 will serve as 
the proof of concept for the value that FFNs will provide to studying the presynaptic changes that 
contribute to the regulation of neurotransmission in the brain. 
2.4.2 FFN102 - Future Directions 
 As described above, we have demonstrated that the flash of FFN102 fluorescence 
occurring after vesicular release is directly correlated to DA release. However, identifying the 
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exact individual release sites responsible for that change in fluorescence has been problematic. 
To tackle this challenge we have planned two future experimental improvements. First, the two-
photon microscope will be upgraded with a Resonant Galvanometer. Controlling the scanning 
mirrors of the microscope using a resonant galvanometer can result in up to a six-fold 
improvement in the rate of imaging an x-y plane compared to standard galvo imaging65. 
Resonant scanning decreases the amount of time wasted focusing the mirrors on each pixel in the 
field of view, while leaving the quality of the image unaffected. As discussed previously, due to 
the constant problem of FFN102 diffusion, any temporal improvements in image acquisition will 
allow for better separation between the individual release site signal and neighboring background 
signal contributing to the flash. Second, as will be discussed in more detail in Chapter 4, we now 
have access to a pH-sensitive FFN that labels the sparse noradrenergic release sites in the cortex. 
In addition to the imaging rate, the magnitude of the background signal when trying to measure 
changes from an individual release sites in this system will be equally important. Also, repeating 
these experiments in an area with sparse innervation may lower the background signal due to 
release from neighboring puncta, which may lead to an improved quantification of the individual 
release site signal. 
 Lastly, as will be discussed further in Chapter 4, it is our goal to move from the acute 
brain slice experimental system to measurements that take place in vivo in the intact brain. As 
such, we hope to be able to further test FFN functionality in an in vivo experimental system 
without the artifacts present in acute brain slices. It would be interesting to see if the magnitude 
of the flash is still significant when working with living, intact brain tissue. It would also be 
important for the FFN program to evaluate whether some of the conclusions drawn with FFNs in 
acute brain slice, such as silent puncta, will still hold true when tested in vivo. In conclusion, the 
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extensive joint laboratory effort that established the foundation for the FFN program has 
generated some truly unique research opportunities. In this chapter I describe the functional 
experiments I performed using the first DA-specific and pH-sensitive FFN, FFN102; hopefully 
laying the foundation for use in future presynaptic regulation studies. 
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Chapter 3: APP+ is a Marker of Catecholamine 




3.1.1 More than just Dopamine 
While the Fluorescent False Neurotransmitter (FFN) project is already being used to 
study dopamine (DA) neurotransmission in a way previously impossible, if this tool concept is 
going to provide a broader and more lasting impact on the field of neuroscience, then it needs to 
be applicable to more than just the DA system. Studying the direct effect of only one type of pre-
synaptic neuron on its target cannot provide a comprehensive understanding of neuronal 
regulation.  Instead, this type of understanding will require systematic studies that explore a wide 
range of potential neurotransmission inputs. The interconnections that comprise and control the 
circuits of the brain are exceptionally difficult to study because of the number of signaling 
pathways that are involved.  This is exactly why, to be most impactful, FFNs must also be 
developed that can support the study of other, non-DA, neurotransmitter signaling systems. 
Although several examples of potential FFN functional uses were highlighted in Chapter 2, 
FFN102 is limited to studying the role of DA. Thus, our ultimate goal is to establish a multi-
functional platform of selective FFN probes for all different types of neurotransmitters.  Ideally, 
this would expand the possible application of FFNs to a much broader group of research 
questions across multiple brain regions, and allow a more complete elucidation of the role of 
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each type of neurotransmitter input in each of these systems. Due to the success of our DA-
FFNs, we embarked on this new project by first exploring highly related members in the 
monoamine family; norepinephrine (NE) and serotonin (5-HT). 
At the origin of the FFN project, our group screened a series of potential small 
fluorescent cores that could be potential FFNs. While this screen identified the coumarin core, 
which led to many successful DA-FFN probes2–4, reviews of the literature highlighted the 
potential for fluorescent phenylpyridiniums as substrates for monoamine transporters (MATs) 
other than just the dopamine transporter (DAT). Particular examples of this group that were 
absent from our initial screening libraries appeared to be highly promising (discussed in 3.1.3). 
Therefore, combined with the resources and previous laboratory experience in developing and 
testing DA-FFNs, we sought to evaluate this additional fluorescent core as a potential FFN 
candidate for the NE and 5-HT systems. 
3.1.2 Origins of MPP+ and the MAT link 
 The link between phenylpyridiniums and monoamines originates from the non-
fluorescent 1-methyl-4-phenylpyridium (MPP+), which stems from medical observations 
collected from a group of recreational drug users5,6. An impure synthesis of the µ-opioid receptor 
agonist, 1-Methyl-4-phenyl-4-propionoxypiperidine (MPPP), led to the significant generation of 
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as an undesired side product. The 23-
year-old patient who inadvertently took MPTP developed severe Parkinsonism symptoms within 
days, which lasted for 18 months6. This degeneration was ultimately attributed to the metabolite 
of MPTP, 1-methyl-4-phenylpyridinium (MPP+). First, MPTP crosses the blood brain barrier, 
after which it metabolizes to MPP+ through monoamine oxidase-B (MAO-B)7. MPP+ is then 
taken up in monoaminergic neurons specifically, as it is a substrate of the MATs: the dopamine 
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transporter (DAT)8,9, the norepinephrine transporter (NET)10, and the serotonin transporter 
(SERT)11. After entering the cell, MPP+ is then concentrated in the matrix of the mitochondria, 
driven by the electrical gradient of the mitochondrial membrane and the positive charge on the 
pyridinium7. Once inside, MPP+ inhibits the electron transport chain through the binding of 
Complex I12, which leads to ATP depletion and cell death. 
 Our group was further drawn to this molecule as a potential structural scaffold due to the 
discovered protective nature of the vesicular monoamine transporter (VMAT) in cells exposed to 
MPP+13. Increased VMAT2 expression can help rescue cells from MPP+ neurotoxicity, while 
inhibition of VMAT2 leads to increased neurotoxicity of the compound14. It is believed that by 
sequestering the compound into vesicles, VMAT2 limits the available MPP+ in the cytosol 
capable of entering the mitochondria and harming ATP production. For the FFN project, this 
compound posed an interesting potential lead, as it is a substrate for three monoamine 
transporters, it is sequestered into vesicles, and through slight chemical modifications, could be 
highly fluorescent. 
3.1.3 Selection of APP+, a Fluorescent MPP+ Analogue 
 One of the first and most widely characterized fluorescent MPP+ analogues is 4-(4-
(dimethylamino)styryl)-1-methylpyridinium (ASP+). ASP+ was first identified as a substrate for 
the low affinity and polyspecific transporter, organic cation transporter (OCT)15. In the brain, 
OCT-3 can transport monoamines, but with much less specificity and higher concentrations 
required compared to the respective MATs16.  More recently, however, it was discovered that 
ASP+ is also a weak substrate of the three MATs (DAT, NET, and SERT), similar to MPP+17. In 
fact, ASP+ was one of the first successful examples of a fluorescent reporter of MAT activity. 
ASP+ has been used in this capacity to label cells expressing DAT, NET, or SERT, as well as to 
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study MAT binding and transport kinetics18. Although, the widespread use of ASP+ has been 
limited by the high binding constant and very slow catalytic turnover observed for MAT activity. 
A screen of ASP+ analogues led to the identification of (E)-4-[2-(6-hydroxy-2-
naphthalenyl)ethenyl]-1-methyl-pyridinium iodide (HNEP+), which showed a promising 
increase in MAT activity19. However, like ASP+, HNEP+ is also highly lipophilic and had high 
non-specific uptake when used at concentrations required for studying MAT activity18. 
 
Figure 1. A) Elimination of the propanoyloxy group from the opioid agonist, MPPP, leads to formation of the 
undesirable compound, MPTP. In the brain, MPTP is oxidized by monoamine oxidase (MAO) to MPP+, which is a 
potent DAT, NET, and SERT substrate. B) Fluorescent MPP+ analogues, APP+ and ASP+, are potential FFNs for 
monoamine-systems other than DA. 
 
 The previous generation of fluorescent MPP+ analogues were improved upon by using 
the smaller and less lipophilic compound 4-(4-dimethylamino)phenyl-1-methylpyridium (APP+) 
(Figure 1). This compound is much closer in size and structure to MPP+, only deviating by a 
single dimethylamine electron donating group. While this fluorescent molecule had previously 
been used in photophysical chemistry, it was not until recently that its potential utility in 
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neuroscience become realized20. In tandem with our own research interests with this potential 
molecule, APP+ was shown to be a substrate for DAT, NET, and SERT, and identified as the 
fluorescent reporter in the commercial Neurotransmitter Transporter Uptake Assay Kit21,22. As a 
result, we decided to explore APP+ as a potential FFN lead, and a potential scaffold that could 
generate NE or 5HT selective FFNs. This chapter describes the characterization of this 
compound’s utility as a labeling tool in both cell culture and ex vivo acute mouse brain slices, as 
well as the functional characterization of this probe as a potential reporter of monoaminergic 
neurotransmission. 
3.2 Results and Discussion 
3.2.1 APP+ is a DAT, NET, and SERT Substrate in Cell Culture 
 After identifying the most promising fluorescent analogue lead, APP+, we first wanted to 
confirm the observations that it was in fact a substrate of the three primary MATs: DAT, NET, 
and SERT. For these experiments, we used transfected cell cultures (either EM4 or HEK cell 
lines) overexpressing one of the MATs. APP+ (2µM) was bath applied to the cells (10min) and 
then cell fluorescence was measured. I would like to thank Dr. Rich Karpowicz, a former 





Figure 2. A) Representative fluorescent images of APP+ uptake (2µM for 10min) in hDAT-EM4 cells, compared to 
nomifensine (2µM) inhibited (B), or null-transfected EM4 cells (C). D) Representative fluorescent images of APP+ 
uptake (2µM for 10min) in hNET-HEK cells, compared to nomifensine inhibited (E), or null-transfected HEK cells 
(F). Scale bar: 15µm. 
 
 In hDAT-EM4 cells, treatment with APP+ resulted in significant punctated accumulation 
that was not present in null-transfected or DAT-inhibited (nomifensine, 2µM) EM4 cells (Figure 
2A-C). Based on the charged nature of the APP+ dye and the previous MPP+ literature, we 
suspected that these intracellular puncta were most likely mitochondria. We confirmed this by 
the high degree of colocalization of APP+ fluorescence with that of Mitotracker Deep Red 
(Figure 3). These experiments were repeated with similar results in both hNET-HEK (Figure 
2D-F) and hSERT-HEK23. During these experiments we also observed very low extracellular 
background fluorescence signal.  This is consistent with the poor spectroscopic properties of the 
dye in aqueous environments, due to the twisted intramolecular change transfer (TICT) that 
occurs in polar environments (Figure 4)24,25. If the dihedral angle between the two ring systems 
is too great, the excited electron will decay in a nonradiative manner. Nonpolar environments or 
geometric restriction, such as when bound to a protein binding pocket, limit this rotation, which 




Figure 3. A) Higher magnification representative image of the APP+ fluorescence pattern in hDAT-EM4 cells. B) A 
comparable image in null-transfected EM4 cells. C) Mitotracker Deep Red (20nM for 10min) fluorescence pattern 




Figure 4. A) APP+ absorbance spectra in solvents of variable polarity. Highest absorbance was observed in 
chloroform, the least polar solvent out of the group. B) APP+ fluorescence excitation and emission spectra in either 
chloroform or phosphate buffered saline (PBS). Very little fluorescence was observed in PBS, a polar solvent, 




3.2.2 APP+ is a VMAT2 Substrate in Cell Culture 
 After confirming the broad MAT substrate scope, we next tested APP+ for VMAT2 
activity. These experiments were performed in HEK cells overexpressing rodent VMAT2 
(VMAT2-HEK)27. Unlike the previous lines, VMAT2-HEK cells do not overexpress a 
monoamine transporter. As a result, for these experiments we used much longer incubation times 
(2µM for 60min) to allow APP+ to cross the membrane through other slower or less selective 
means. Interestingly, we observed that there was significantly less fluorescence accumulation in 
VMAT2-HEK cells than that of their null-transfected HEK cell counterpart (Figure 5). Similar 
to the DAT-EM4 cells, null-transfected HEK cells showed a strong punctated staining pattern, 
while VMAT2-HEK cells had much dimmer puncta. Using Mitotracker Deep Red we saw no 
apparent difference in the mitochondrial labeling between the two cell lines, ruling out potential 
differences in the number, or membrane potential, of the mitochondria between the two cell lines 
(Figure 5). Similar to what is known about MPP+ and VMAT2, we believe that this result is due 
to a second potential APP+ concentration sink in acidic compartments generated by VMAT2 that 
competes with APP+ accumulation in mitochondria. Due to the previously discussed 
photophysical properties of this fluorophore, APP+ is potentially only weakly fluorescent in 




Figure 5. A) In TetR-HEK control cells, APP+ (2µM) fluorescence signal strength and pattern was comparable to 
observations in hDAT-EM4, and hNET-HEK cells. The incubation time required to reach comparable fluorescence 
was considerably longer without expression of a MAT (60min). Mitotracker Deep Red (B) still had a high degree of 
colocalization (C) in TetR-HEK cells. D) APP+ fluorescence signal, under the same loading conditions, in VMAT2-
HEK cells was significantly reduced. Using Mitotracker Deep Red (E), we confirmed that the decrease in 
fluorescence signal was not due to an absence of mitochondria or degradation of the mitochondrial membrane 
potential. 
 
 We explored this hypothesis further using two different VMAT2 inhibitors, 
dihydrotetrabenazine (dTBZ, 2µM) and reserpine (1µM). Surprisingly, these inhibitors did not 
consistently rescue the bright punctated mitochondrial labeling as observed in the controls 
(Figure 6). Results from this experiment were quite variable, but inevitably did not lead to a 
quantifiably significant change between uninhibited and inhibited VMAT2-HEK cells. In trying 
to explain this result, we had to look more closely at the VMAT2-HEK system and the properties 
of APP+. First, unlike our potential neuronal targets, the VMAT2-HEK cells have no surface 
MAT activity and there may have been only a very low concentration of APP+ that crossed the 
membrane. This intracellular concentration could still be sequestered into acidic compartments if 
a small percentage of VMAT2 were still active, or it could be pumped out of the cytosol through 
96 
 
an efflux transporter. Since MPP+ was used as a method of selective pressure in generating this 
VMAT2-HEK cell line, an efflux transporter capable of transporting APP+ might even be 
upregulated in this cell line27.  
 
Figure 6. APP+ uptake (2µM for 60min) in TetR-HEK cells (A) resulted in a strong fluorescence signal and 
mitochondrial punctated pattern, compared to APP+ fluorescence in VMAT2-HEK cells (B), as observed in Figure 
5. C) Inhibition of VMAT2 with reserpine (1µM) did not significantly restore APP+ fluorescence. 
 
During our experimentation, however, it was independently reported in Dr. Miller’s 
laboratory that APP+ could be used as a reporter to assay VMAT2 activity28. While this report 
was promising for confirming that APP+ was a VMAT2 substrate, the problems faced during our 
experimentation with APP+ and VMAT2-HEK cells highlighted potential problems of using this 
dye as an FFN. Although the system is far removed from that of an actual neuronal synapse, 
potential sequestering of APP+ into the vesicular lumen of neuronal synapses would need to 
result in a measurable amount of fluorescence if we hoped to observe activity-dependent changes 
as with other FFNs. Some of this concern was again dissuaded by follow-up results published by 
Dr. Miller’s laboratory, where they were able to show fluorescence overlap between VMAT2-
mCherry and APP+, which could be reduced with TBZ (20µM) inhibition29. Therefore, we 
thought the probe was interesting enough to pursue for further experimentation in brain tissue.  
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3.2.3 APP+ Labels Catecholamine Neurons in Brain Tissue 
 The next set of experiments describe the first use of APP+ dye in ex vivo acute murine 
brain slices. At the time, use of this dye had only been previously characterized in cell culture 
and the peripheral nervous system30. Based on our previous familiarity with the DA system, and 
available genetic markers within the laboratory, we first looked at APP+ uptake in DA cells and 
projections. Using mice that express GFP under the catecholamine specific tyrosine hydroxylase 
promoter (TH-GFP),  APP+ cellular uptake was colocalized with GFP signal in the substantia 
nigra (SN) and ventral tegmental area (VTA), areas rich with DA neurons (Figure 7). For these 
experiments, the brain slice was perfused with 500 nanomolar APP+ for 30 minutes, followed by 
a 10 minute wash period. This resulted in a significant number of cell bodies that had fluorescent 
signal from each fluorophore, as well as a large degree of nonspecific punctated structures (~2-
3µm) only observed in the channel collecting APP+ fluorescence. When counting the number of 
cells with GFP that were also APP+ positive, as determined by a fluorescence intensity two fold 
greater than the background, we observed a 76 percent colocalization (84/110 cells from 6 
different mice). Importantly, when comparing colocalization in the other direction, I was unable 
to find any APP+ positive cells that did not also have TH-GFP, suggesting that APP+ cellular 
uptake was specific to dopaminergic neurons, but uptake by all dopaminergic neurons was not 
complete. It is possible that some of the TH-GFP positive neurons may not have accumulated 
detectable levels of APP+ due to poor overall health or lower DAT expression compared with 
their neighbors. To confirm that this uptake was DAT dependent, the experiment was repeated 
using a pretreatment (15min) with the DAT-inhibitor nomifensine (2µM). This resulted in a 
significant reduction in the number of colocalized cells, from 76 percent to 7 percent (3/43 cells 
from 3 different mice) (Figure 7). However, the use of this DAT-inhibitor did not affect the 
punctated APP+ staining surrounding the cells, and while the APP+ cellular labeling in this area 
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seemed to be strongly dopaminergic and DAT-dependent, the scattered puncta staining seemed 
non-specific. Discussed later in this chapter will be our hypothesis on the cause for this scattered 
punctated background labeling. As for the cell bodies, a higher magnification revealed that 
unlike what we had observed with our coumarin-based FFNs, the labeling was perinuclear with 
puncta in the soma. This is consistent with our observations in cell culture, and it is likely that a 
significant portion of the fluorescence in neuronal cell bodies was from mitochondrial bound 
APP+. 
 
Figure 7. Colocalization of APP+ and dopaminergic neurons of the ventral tegmental area (VTA) and substantia 
nigra (SN) that express GFP under the catecholamine-specific tyrosine hydroxylase promoter (TH-GFP). A) APP+ 
(500nM) loaded cell bodies in this area after 30min. B) TH-GFP from the dopaminergic neurons in the same field of 
view. C) Overlay of the two fluorophores resulted in a 76% colocalization between APP+ and dopaminergic cell 
bodies. We observed significant background signal, although labeled cell bodies were visible, as highlighted with 
yellow arrows. D-F) This experiment was repeated in the presence of the DAT-inhibitor, nomifensine (2µM), which 
significantly decreased APP+ uptake in cell bodies, but not the background. The resulting colocalization of cell 




 In addition to DA cells, TH-GFP also labels NE cells. Therefore, with this genetic marker 
we also measured APP+ uptake in the locus coeruleus (LC), which is the primary location of NE 
cell bodies in the brain. Initial results of this colocalization experiment performed in adult mice 
showed very little APP+ uptake. Further literature research into the LC showed that NET 
expression drastically changes with age, with dramatic decreases observed in the LC upon 
reaching adulthood31,32. Repeating colocalization in young mice (21-30d postnatal) yielded much 
more promising results (Figure 8). Similar to what was observed in the SN/VTA, all APP+ 
positive cells also had TH-GFP, and 59% of TH-GFP positive cells also had APP+ (74/126 cells 
from 3 different mice). We believe that this increase in the amount of colocalization when using 
young animals was due to the greater NET expression responsible for actively transporting 
APP+. The colocalization percentage might have been higher if the animals used were at peak 
NET expression (10d postnatal), but collecting slices from animals younger than 3 weeks would 
have been much more challenging. Lastly, we briefly looked for serotonergic labeling in the 
dorsal raphe (DR), but at the time we did not have a genetic marker for serotonergic neurons. 
Also, measuring SERT-specific APP+ labeling in this area was made more difficult by 






Figure 8. Colocalization of APP+ and noradrenergic neurons of the locus coeruleus (LC) that express GFP under 
the catecholamine-specific tyrosine hydroxylase promoter (TH-GFP). A) APP+ (500nM) loaded cell bodies in this 
area after 30min. B) TH-GFP from the dopaminergic neurons in the same field of view. C) Overlay of the two 
fluorophores resulted in a 76% colocalization between APP+ and dopaminergic cell bodies, as labeled by yellow 
arrows. Scale bar: 20µm. 
 
3.2.4 APP+ Labels Dopaminergic Projections 
 In addition to labeling cell bodies, we were also interested in examining the projections 
of those neurons, and, in particular, potential release sites. We chose to perform these 
experiments in the dorsal striatum (DS) and study the same dopaminergic projections as 
described in Chapter 2, due to the familiarity with the area and the availability of colocalization 
markers. When loading the projections in this area with the APP+ dye, a lower concentration 
(100nM) and shorter incubation time (15min) were sufficient to observe bright APP+ puncta 
(Figure 9B). Additionally, because of the low concentrations used, and the low background 
signal present due to the aqueous photophysical properties of the dye, very little washing was 
required to achieve a strong signal/background ratio. Colocalization of APP+ puncta with TH-
GFP resulted in a high degree of overlap, with a quantification of 83.4 ± 6.9% of APP+ puncta 
that colocalized with TH-GFP (mean ± SD, 2-3 slices per animal, 3 different animals) (Figure 
9). Unlike what was observed in cell bodies, 10.1 ± 5.7% of APP+ puncta were actually bright 
enough to cause significant florescent bleedthrough and be detected in the GFP channel when 
using WT animals without GFP as a control (mean ± SD, 2-3 slices per animal, 3 different 
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animals) (Figure 10). While the two-photon excitation spectra are fairly well separated, the 
similar emission wavelengths of GFP and APP+ resulted in this small percentage of 
bleedthrough. 
 
Figure 9. A) Representative image of GFP signal in the dorsal striatum of acute murine brain slices driven by the 
catecholamine-specific promoter tyrosine hydroxylase (TH-GFP) B) APP+ (100nM for 15min) fluorescence in the 
same area. C) There was a strong colocalization between the two fluorophores, and an 83.4% colocalization of 
APP+ puncta with TH-GFP. Scale bar: 5µm. 
 
 
Figure 10. Overlap of APP+ and GFP fluorescence emission resulted in small amount of APP+ fluorescence 
entering the GFP imaging channel (B). This fluorescence bleedthrough led to a potential increase in falsely 




 In light of this bleedthrough issue with GFP, we used a second independent confirmation 
of dopaminergic labeling, FFN102. We have already demonstrated that FFN102 has greater than 
a 90% colocalization with TH-GFP, and has photophysical properties that can be well separated 
from APP+ (FFN102 is described and characterized in Chapter 2)2. Colocalization between these 
two fluorescent probes was performed in wild type animals, and resulted in a 74.1 ± 6.9% of 
APP+ puncta colocalizing with FFN102 puncta (mean ± SD, 2-3 slices per animal, 3 different 
animals) (Figure 11). These results are consistent with the TH-GFP and bleedthrough control 
experiments, and highlight that >70% of APP+ puncta in the dorsal striatum are dopaminergic.  
 
Figure 11. A) Representative image of FFN102 (10µM for 30min) signal in the dorsal striatum of acute murine 
brain slices. B) APP+ (100nM for 15min) fluorescence in the same area. C) There was strong colocalization between 
the two fluorophores, and 74.1% colocalization of APP+ puncta with FFN102. Scale bar: 5µm. 
 
To further confirm dopaminergic projection labeling by APP+, inhibiting DAT with a 
nomifensine (1µM) pretreatment led to a 2.3-fold reduction in the number of APP+ puncta 
(Figure 12). While the reduction was statistically significant, we noticed that the majority of the 
remaining puncta were very large (>1µm). While these puncta were still within the maximum 
observed size range, typical dopaminergic release sites are usually less than 0.5µm, suggesting 
that these structures were most likely not dopaminergic synapses34. It is possible that when the 
high-affinity DAT activity was blocked, weaker and competing transport mechanisms on non-
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dopaminergic structures contributed more to the staining pattern. We thought it was possible that 
APP+, like MPP+ and ASP+, might also be transported by low-affinity and high-capacity 
transporters, such as OCT-3. This theory was confirmed in our laboratory with hOCT3-
transfected HEK cells and corticosterone inhibition35. These results could also explain the high 
non-specific background observed in the cellular-uptake experiments in the VTA/SN and LC, 
where the amount of DAT expression relative to the field area was much lower36,37. In 
conclusion, however, APP+ fluorescence in the dorsal striatum seemed to be fairly specific for 
dopaminergic projections under normal experimental conditions, and could lead to a potential 
FFN if that staining pattern changed upon neuronal activity. 
 
Figure 12. A) Quantification of the number of APP+ puncta in the dorsal striatum of acute brain slices with and 
without the DAT-inhibitor, nomifensine (1µM). Nomifensine resulted in a 2.3 fold reduction in the number of 
puncta. B) Representative image of APP+ fluorescence in this area under normal conditions. C) Representative 
image of APP+ fluorescence in the presence of nomifensine. We noted an increase in very large puncta that are most 
likely not dopaminergic in the presence of nomifensine (red arrows). Scale bar: 5µm. 
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3.2.5 APP+ is not an FFN 
 One of the defining characteristics of an FFN is that it can be used as a measure of 
neurotransmission. This means that the probe must be packaged into vesicles and show a 
quantifiable change upon vesicular exocytosis. While APP+ seemed to be relatively selective at 
entering dopaminergic synapses, and it is suspected to be a VMAT2 substrate, we next needed to 
assess potential changes to the APP+ puncta fluorescence using two different neuronal 
stimulation protocols in acute slices. The first protocol involved perfusing the slice with an 
increased K+ concentration (40mM KCl) to chemically depolarize the membranes. This is a very 
harsh method of inducing exocytosis that for our previous FFNs caused almost complete 
destaining of all labeled puncta within ~3 minutes, as well as significant movement of the slice 
due to global neuronal activation. It was first noticed that continual imaging of a small area of 
APP+ puncta over time led to rapid destaining that was not dependent on the arrival of the 
change in K+ concentration. The same imaging protocols and similar laser power used for 
measuring release over time of FFN102 and other probes in our lab, led to rapid photobleaching 
of the APP+ probe2. This was confirmed by imaging APP+ washing/bleaching kinetics over time 
at different imaging frequencies. The probe fluorescence was very stable over 15 minutes when 
imaged every 1 minute, but showed a 73% decrease when imaged every 15 seconds. When 
40mM KCl stimulation experiments were repeated at this slower imaging rate there was a 15.3 ± 
2.5% decrease in the APP+ puncta fluorescence after 8 minutes (mean ± SD, 2-3 slices per 
animal, 3 different animals). Although the 40mM KCl perfused slices showed a significant 
reduction in APP+ staining versus untreated slices just 1 minute after increased K+ 
concentrations reached the slice (t-test, p < 0.05), the extent of the total destaining observed did 
not mimic the almost complete FFN102 depletion observed after ~3 minutes under similar 




Figure 13. A) Change in average puncta intensity over time in the presence or absence of 40mM KCl depolarization 
conditions. We observed a significant decrease in fluorescence intensity of APP+ puncta, but only to a very small 
degree (15.3%). Representative images of APP+ fluorescence before (B) and 8min after (C) KCl depolarization. We 
observed a large number of puncta still present after KCl, compared to the complete elimination observed with 
FFN102 puncta after a KCl treatment2. Scale bar: 5µm. 
 
One limitation of using 40mM KCl is that there are drastic spatial deformations of the 
acute slice that occur when every single neuron is triggered to fire. This leads to slice shifts that 
change the microscope field of view and make tracking individual puncta over a long time 
course problematic. As a result, it is impossible to definitively identify the source of that 15% 
reduction in APP+ fluorescence using this method. We hypothesized that there were two likely 
possibilities based on our previous experiments with this probe. First, the APP+ signal from 
different dopaminergic projections was primarily from APP+ in hydrophobic environments, such 
as mitochondrial membranes, and not from the probe that is sequestered into vesicles. This type 
of staining pattern would then be relatively uniform across the whole population of APP+ 
positive dopaminergic terminals, and would result in a small and equal change in fluorescence 
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from every puncta. The second possibility is that there is some heterogeneity between the puncta 
and that some might have a much higher proportion of fluorescence that is contributed by the 
vesicular population. These puncta might not have a nearby mitochondria or other favorable 
hydrophobic environment that overwhelms the fluorescent signal. As a result, these puncta, 
which are a small portion of the total population (~15%), might completely destain, while the 
others would show a very weak change in fluorescence. 
 
Figure 14. Quantification of the percent change in puncta number (A) and relative intensity (B) during the course of 
tonic electrical stimulation (local 10Hz stimulation for 600pulses). We observed no significant change in either 
parameter by the end of the stimulation, as well as no individual puncta that were identified to fully destain. 
Representative images of APP+ fluorescence in the same field of view before (C) and 6min after (D) electrical 




To test these hypotheses we switched to an electrical stimulation protocol similar to the 
protocol described in Chapter 2 (2.2.1), which is known with other FFNs to result in significant 
fluorescent changes in some release sites. Local electrical stimulation is a milder and more 
physiologically relevant way to activate neurons than 40mM KCl perfusion, and therefore does 
not cause drastic changes in the field of view. Again, imaging every 15 seconds, 3600 pulses 
(10Hz) were delivered locally to the striatum and the specific fluorescence of individual puncta 
was measured over time (Figure 14). This stimulation protocol led to no significant change in 
the number of puncta, 94.6 ± 11.8% for unstimulated vs. 86.7 ± 9.7% for stimulated, or average 
fluorescence of a puncta, 89.6 ± 9.2% for unstimulated vs. 91.6 ± 3.1% for stimulated (mean ± 
SD, 2-3 slices per animal, 3 different animals, ANOVA: p > .05). Additionally, no puncta were 
identified by our selection criteria similar as described in Chapter 2 (2.1.3) to have decreased in 
intensity sufficiently to be considered destained. 
 
Figure 15. Representative images of FFN102 (A) and APP+ (B) fluorescence from loaded dopaminergic neurons in 
the ventral tegmental area. To determine if APP+ was acutely toxic, APP+ was loaded into these neurons first 
(500nM for 45min), then FFN (10µM) was added to the APP+ solution for the following 30min. We did not observe 
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any qualitative changes in FFN102 loading, or morphological changes to the cell bodies, over this time period. Scale 
bar: 20µm. 
 
These results suggest that the releasable vesicular APP+ only accounted for a small 
percentage of the total fluorescence from each puncta. Therefore, APP+ might not be the next 
broad spectrum FFN that we originally were seeking, but its interesting properties could be 
useful for other experiments, such as in vivo changes in mitochondrial density or membrane 
potential of monoaminergic neurons. As a result, we wanted to test for acute toxicity of this 
probe for relatively short exposures similar to the experiments described above, a potentially 
important parameter when considering the future applications of APP+. This was tested by 
conducting a 45 minute pretreatment of APP+ (500nM) in SN/VTA neurons in acute brain slice, 
followed by standard FFN102 loading over 30 minutes2. Imaging at the end of the 75 minute 
time course showed the typical APP+ labeling as previously described, as well as, typical 
FFN102 labeling as previously observed in our group (2-3 slices per animal, 2 different animals) 
(Figure 15). On this time scale, APP+ did not seem to have a detrimental effect on DAT activity, 
although this evidence is simply supportive and not conclusive. If APP+ was negatively 
impacting mitochondria and ATP production on this time scale, it is expected that DAT activity 
would be impaired after the sodium potassium pump lost its energy source38. This also suggests 
that the small changes in simulated release we observed with 40mM KCl and electricity were not 
due to APP+ toxicity. Additionally, this supports the conclusion that APP+ could be used as a 
monoaminergic neuronal marker for functional assays within a time window before MPP+-like 
toxicity starts to occur (estimated 18h for MPP+)39. 
3.3 Conclusion 
 In this chapter, the monoamine specific application of APP+, a fluorescent analogue of 
the MPP+ toxin, was explored in the search for new FFNs. We confirmed reports that APP+ was 
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a substrate of the three monoamine transporters, DAT, NET and SERT, a first for a fluorescent 
probe in our assays. Testing for VMAT2 activity suggested that APP+ was also a substrate, 
which was independently confirmed during our experimentation28. Based on the results obtained 
in these preliminary cell culture assays, we then tested this compound in ex vivo acute mouse 
brain slices to determine its behavior in neurons. 
 These ex vivo experiments showed that there was selective accumulation of the APP+ 
probe in both dopaminergic and noradrenergic cell bodies through monoamine transporter 
function, but that there was also surrounding puncta staining through a DAT/NET-independent 
uptake mechanism. Additionally, as observed in cell culture, staining in these cell bodies was 
punctated and perinuclear, which is likely to be mitochondrial. This highlights a potential use of 
APP+ as a monoaminergic cellular marker similar to GFP, but without requiring genetic 
manipulation. Further, due to its accumulation in mitochondria, this probe could also be used as a 
monoamine selective mitochondrial reporter, or in assays elucidating the connection between 
MPP+ toxicity and Parkinsonism. 
 APP+ was also tested in dopaminergic projections to further access its potential viability 
as an FFN. The APP+ punctated staining pattern observed in the dorsal striatum showed high 
colocalization with both TH-GFP and FFN102 dopaminergic markers (~75%). However, this 
staining remained largely stable after both 40mM KCl and electrical stimulation conditions 
(<15% fluorescence change). This was thought to be due to the relatively small percentage of 
fluorescence signal that came from APP+ inside the vesicular lumen relative to the total synapse. 
This was in part due to the poor photophysical properties of the probe in hydrophilic compared to 
hydrophobic environments, and the competing sequestering of this charged molecule in 
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mitochondrial membranes. We therefore concluded that APP+ was suitable for labeling studies, 
but it was not applicable for further pursuit as a new, functional NE or 5HT-FFN lead. 
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Chapter 4: FFN270: A New pH-sensitive Optical 
Tracer of Norepinephrine that Resolves Individual 
Noradrenergic Synapses and Their Activity in vivo 
 
4.1 Introduction 
4.1.1 Studying Norepinephrine Neurotransmission 
 In the initial search for a norepinephrine (NE) specific fluorescent false neurotransmitter 
(FFN), the phenylpyridinium core appeared promising initially (Chapter 3), but did not meet all 
the criteria of a true FFN. To trace neurotransmission, a FFN must load into specific release 
sites, get packaged into vesicles, and most importantly, be released upon vesicle fusion. 
Undaunted, we continued to search for fluorescent compounds that could accumulate in 
noradrenergic neurons and be used to trace NE release, in other words, a NE-FFN. The critical 
need to develop new methods for studying NE neurotransmission in particular is due to the 
severe limitations of the currently available tools combined with existing evidence highlighting 
the importance of NE as a global modulator of neuronal activity across many brain area. 
Additionally, because the exogenous substrate scope of NET is sufficiently promiscuous (Figure 
1, see also discussion in Chapter 3.1), we believed further pursuit of a NET-driven NE-FFN 




Figure 1. Representative NET substrates. Highlighted in blue are a series of phenethylamines with varying degrees 
of oxidation that are all NET substrates (EC50 < 500nM, except for (1R,2R)-2-methylamino-1-phenylpropan-1-ol). 
Aminorex is a similarly structured NET substrate (~50nM). Highlighted in red are the series of compounds 
discussed in Chapter 3 that have all been shown to be NET substrates. 
 
 As briefly covered in Chapter 1, the current tools to study catecholamine 
neurotransmission have room for improvement, but the deficiency of the toolkit is greater for NE 
transmission in comparison to dopamine (DA) transmission. This lack of adequate tools has 
made studying the role of NE in the brain particularly challenging and highlights a rationale for 
the development of a NE-FFN. It is only recently that advancements in electrochemical 
techniques and electrodes have enabled the functional distinguish between NE from DA or other 
analytes, but many of these techniques have yet to be usefully applied beyond an in vitro 
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setting4–6. Traditionally, electrochemical NE detection has only been correlative to extracellular 
NE concentrations when applied to specific brain areas with low DA levels, when combined with 
microdialysis7, or when relative changes in metabolite concentrations are measured8. Recent 
adaptations of cell-based neurotransmitter fluorescent engineered reporters (CNiFERs) to the NE 
system has improved the ability to specifically detect extracellular NE concentrations in relevant 
time scales9. However, both CNiFER and electrochemical methods still lack sufficient spatial 
resolution to resolve individual synapses. 
 
Figure 2. The aldehyde of NeuroSensor 521 reacts with the primary amine of NE to form an iminium ion. This 
dehydration reaction is driven forward by the high concentrations of NE found within the vesicles. The maximum 
excitation wavelength of the product is significantly red shifted, and can result in fluorescence increases of 5.3 fold 
when saturated with NE. As highlighted with a blue circle, this chemosensor is not specific for NE and can react 
with any concentrated primary amine10. 
 
 Development of fluorogenic chemosensors, such as the coumarin-based NeuroSensor 521 
(Figure 2), have enabled high-spatial resolution imaging of norepinephrine containing large 
dense core vesicles (LDCV) in chromaffin cells10. NeuroSensor 521 reacts with the primary 
amine of NE, forming an iminium ion, which results in a significant red shift in the excitation 
wavelength of the fluorophore.  Unlike previous norepinephrine imaging techniques that require 
fixation, it is possible to use NeuroSensor 521 in living systems. However, its application has 
been limited to cell culture. Furthermore, although this sensor demonstrates selectivity for the 
primary amine of norepinephrine over the secondary amine of epinephrine, it is also highly 
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reactive with many other important neurotransmitters with primary amines, including dopamine, 
glutamate, and glycine10. As a result of this lack of specificity, the potential utility for this sensor 
in dissecting the role of individual neurotransmission pathways in brain tissue is limited.  
Overall, due to the limitations of the techniques recently developed for measuring NE 
release, they have not yet played an important role in elucidating the function of NE in the brain. 
The vast majority of research in this area has been performed by measuring large scale changes 
in bulk NE release. This includes, but is not limited to, measuring with microdialysis11, 
electroencephalogram (EEG)12, or recording the collective firing of the main nucleus of 
noradrenergic cell bodies13, the locus coeruleus (LC). While these methods are well-established 
and have led to many advancements in understanding the role of NE, they have extremely poor 
spatial or temporal resolution. One of the most popular methods, recording from noradrenergic 
neurons in the LC, has excellent temporal resolution, but is correlated with global extracellular 
NE levels. Spatial resolution can be improved to levels approaching electrochemistry when using 
microdialysis, but the poor temporal resolution remains a large are problem (seconds 
timescale)11. A more complete and detailed understanding of the roles and regulation of NE in 
the brain can only be realized by introducing robust new methods for studying NE 
neurotransmission that have improved spatial and temporal resolution. 
4.1.2. Norepinephrine Functions in the Brain 
 NE produces its effect on target neurons via activation of G-protein coupled receptors 
(GPCRs). This specific group of GPCRs, called adrenergic receptors, has 3 sub-families, α-1, α-
2, and β adrenergic receptors. Each subtype has been shown to have variations in substrate 
binding or particular G-protein coupled signal transmission14. Depending on the adrenergic 
receptor subtype, NE binding can lead to activation of either the Gs (stimulation of adenylate 
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cyclase), Gi (inhibition of adenylate cyclase), or Gq (activation of phospholipase-C) proteins15. 
Modulation of adenylate cyclase leads to changes in cyclic-AMP production, which has an 
extensive range of intracellular downstream effects depending on neuronal type. Activation of 
phospholipase-C leads to increased intracellular calcium levels, which can increase the 
probability of neuronal firing, discussed in more detail in 4.3.8. The varying, and sometimes 
competing, effects of these adrenergic receptors means that NE modulation does not always have 
the same pre- or post-synaptic effect, making studying the role of the NE system in 
neuromodulation even more complex. 
 Despite drawbacks with current methods of studying NE neurotransmission, and the 
complicated nature of adrenergic receptors, a large body of evidence supports the connections 
between NE regulation and numerous cognitive functions and psychiatric disorders. Primarily 
originating from the locus coeruleus (LC), noradrenergic neurons widely project to many areas 
of the brain and central nervous system, including the cortex, hippocampus, hypothalamus, 
amygdala, spinal cord, and others16. Having a regulatory impact on such diverse group of brain 
regions has led to implicating NE dysregulation in an equally diverse group of disorders, 
including depression17,18, attention deficit hyperactivity disorder19, post-traumatic stress 
disorder20, drug addiction/withdrawal21–23, and autism24,25. Additionally, in Parkinson’s disease, 
degeneration of NE neurons is observed prior to DA depletion and is thought to be responsible 
for the cognitive disorders that are present in the prodromal stage before the onset of motor 
disturbances26. However, the exact mechanism by which NE dysregulation plays a role in each of 
these diseases and disorders has not yet been clearly established, because the normal function of 
NE in the brain is still poorly understood. This is in part due to the lack of adequate research 
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tools (as discussed above) to assess how each NE-synaptic connection contributes to the 
functioning of this important neurotransmission pathway. 
 Traditionally, NE was believed to be a global regulator of tonic brain activity. Because 
the neuronal projections of the LC innervate more brain regions than any other described 
nucleus, it was believed that NE must be having a general regulatory effect on brain activity27. 
Experiments using iontophoretically applied NE to specific neurons or brain areas generally 
demonstrated a decrease in spontaneous neuronal activity, while either enhancing or suppressing 
evoked activity of targeted neurons28,29. Combined with data that showed drastic changes in NE 
brain levels from sleep to awake30 and from normal to stressed31 behaviors, NE was thought to 
globally modulate brain activity for heightened sensory responsiveness. Particular increases in 
LC neuronal firing were observed when a stimulus interrupted the animal’s ongoing activity, 
suggesting that NE plays an important role in attention and arousal, helping to determine the 
importance of a stimulus and coordinate the brain’s appropriate functional response32. However, 
recent evidence suggests that the role of NE is more complicated. First, the neurons of the LC are 
not all phenotypically equal, nor are they distributed homogenously within this nucleus. The LC 
has its own sub-regional organization, with four phenotypically distinguishable groups of 
noradrenergic cell types that project to specific brain regions33. The LC neurons that project into 
different brain regions can also have different firing rates and different morphological axonal 
arborization patterns, presumably due to the differences in NE-driven neuromodulation occurring 




Figure 3. A) Visual representation of the “adaptive-gain” theory. NE neuronal targets can be differentially 
modulated by NE input. An increase in gain caused by NE neuromodulation leads to an increase in contrast of the 
excitatory or inhibitory response of the target neuron, leading to a more binary behavior. B) Animal behavioral 
performance follows an inverted-U pattern with levels of LC activity. Low LC activity leads to inattentiveness, 
while periods of burst firing lead to active engagement with the task. However, consistently high activity leads to 
poor task performance and an easily distracted behavior35. 
 
 From this evidence, a current hypothesis in the field states that NE modulates its neuronal 
targets by either increasing the activity of units receiving excitatory input or decreasing activity 
of those receiving inhibitory inputs36. This “adaptive-gain” hypothesis helps explain why 
increased levels of NE can have conflicting modulating effects on the firing rates of different 
neurons within the same population (Figure 3). This increased modulating function of NE during 
arousal actually has an inverted-U-shaped relationship to functional behavior. Low tonic LC 
activity results in a careless and inattentive behavior. Low tonic firing with periods of increased 
LC phasic firing facilitates the evaluation and exploration of a particular new task as important 
or rewarding. However, continuously high LC activity leads to a distractible behavior where the 
ongoing activity is no longer novel or engaging37. Therefore, it is hypothesized that NE-driven 
“arousal” plays an important role in decision making, and acts as a filter to determine which task 
is worth exploring and engaging further, while simultaneously allowing for a currently engaged 
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and ongoing task to be modified with the addition of new information35. This role in behavior is 
believed to be accomplished by the LC exerting regulating control over multiple brain areas 
simultaneously, and modulating the firing of particular regions in-sequence. 
 Related to input processing, there is also a link between the NE-system and cognition. 
The normal quiescent behavior of LC neurons during slow-wave sleep is interrupted by transient 
increases that are observed only if there was a recent intensive learning experience38. It is 
believed this NE release plays a role in memory consolidation by modulating long-term 
potentiation or depression (LTP or LTD) through activation of β-noradrenergic receptors and the 
downstream cyclic-AMP cascade39. Additionally, the NE-system has been deemed to be 
important in memory retrieval. Animals that had forgotten a previously learned memory task 
would show drastic memory improvements when the LC was remotely stimulated40 or when 
extracellularly NE levels were increased pharmacologically41. Mice lacking the noradrenergic-
specific protein used to synthesize NE (and epinephrine), dopamine β-hydroxylase (DBH), 
showed the ability to remember tasks up to 48 hours later, but showed poor retrieval of long-term 
memories42. Furthermore, in humans, fMRI has been used to show that increased LC activity 
strongly correlates with memory retrieval, especially during the retrieval of memories linked to a 
strong emotional response43. 
 In summary, the NE-system appears to play critical roles in regulating arousal of the 
brain and in coordinating the firing patterns of different brain regions to appropriately evaluate 
particular sensory information, consolidate memories, or retrieve memories. The majority of the 
research in this area, especially behavioral, has relied on global LC firing patterns or artificial 
NE increases to connect the NE-system to a particular response. However, the various regions of 
the LC and its projections are not uniform, and the particular firing patterns and axonal 
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arborization vary for individual noradrenergic neurons. As will be discussed in more detail later 
in this chapter, FFNs would provide a unique opportunity to study native NE neurotransmission 
on the micro-anatomical scale. The ability to determine how individual noradrenergic release 
sites affect neighboring neurons or postsynaptic targets may provide insights into how the 
macroscopic NE-driven neuromodulation leads to the associated functional behaviors. 
4.2 Results and Discussion 
4.2.1 Initial NET Substrate Leads 
 The story of developing our first NE-FFN is one that comes full circle. It begins in vivo 
with preliminary observations from two of our DA-FFNs (FFN102 and FFN202)44,45, rapidly 
progressing to chemical optimization of related core molecules using NET-transfected cell 
culture screens, followed by characterization of the optimized fluorescent probes in acute murine 
brain slices, and finally, returning in vivo to demonstrate the utility of the resultant NE-FFN 




Figure 4. A) Structure of FFN202, the first FFN to be tested in vivo. B) Two-photon fluorescence image of FFN202 
taken in Layer 1 of the somatosensory cortex. Red arrow: cell body, Blue arrow: axonal structure. C) 3-D 
reconstruction of FFN202 labeling in the outer 100µm of somatosensory cortex. More axonal structures are 
observed traveling in the z-plane. Scale Bar: 10µm. 
 
Thanks to the collaborative help of Dr. Wenbiao Gan (New York University), we had the 
opportunity to explore the uptake of FFN102 and FFN202 into the outer layers of the 
somatosensory and motor cortex in vivo (Figure 4). With FFN102, we did not observe any 
specific uptake into axons or release sites in this preliminary in vivo experiment. Although, with 
the 3-ethylamine structural isomer, FFN202, we observed a few fluorescent strings that looked 
axonal. Due to the comparative lack of FFN102 uptake, we suspected that the FFN202 uptake 
was most likely not into dopaminergic structures, but may represent the sparse, structurally 
similar, noradrenergic projections that are present throughout the cortex. As a result, we decided 
to screen our coumarin library for any NET-specific uptake using the same hNET-transfected 
HEK cells described in Chapter 3 (3.2.1). I would like to thank Dr. Adam Henke, a former post-
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doctoral member of Dr. Sames’ laboratory, for his collaborative help with these initial cell-based 
screens, as well as the chemical synthesis of new leads described below. 
 
Figure 5. A) Total cellular fluorescence after loading of 3- and 4-series 7-hydroxycoumarins (5µM) in hNET-HEK 
cells. Signal to Basal ratio (S/B) was determined by comparing FFN fluorescence in the presence and absence of 
2µM nomifensine after a 30min incubation period. Included are the structures of each FFN used in the experiment 
and the structural numbering for the coumarin core. Representative images of FFN201 without inhibitor (B) and 
with inhibitor (C). In panel B, loaded-FFN201 exhibits diffuse distribution throughout hNET-HEK cells, but this 
loading was blocked with nomifensine in panel C. 
 
 When FFN102 and FFN202 were initially applied to hNET-HEK cells (5µM for 30min), 
with and without NET-inhibition (nomifensine, 2µM), FFN102 showed no NET-specific uptake 
and FFN202 showed slight NET-specific uptake. Intrigued by these results, we also screened the 
structural core molecules of each of these FFNs: the 3-aminoethyl-7-hydroxycoumarin (FFN201) 
for FFN202 and the 4-aminoethyl-7-hydroxycoumarin (FFN101) for FFN102. This was in hope 
of better understanding what structural features may be driving the difference in NET-specific 
uptake. Similar to FFN102, the 4-series core showed no NET-specific uptake, suggesting that the 
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ethylamine side chain in the 4-position prevents NET transport. In contrast, we observed a very 
strong NET-specific uptake with the 3-series core, FFN201 (S/B Ratio: 9.9±0.2, mean ± SEM, n 
= 3). The signal-to-basal ratio of FFN201 was over five-fold greater than that of FFN202 (Figure 
5). This suggested that the 3-position for the ethylamine side chain is tolerated by NET, but that 
the chlorine on the 6-position for FFN202 was limiting NET activity. The electron withdrawing 
group (EWG) chlorine was originally added to this position to modulate the pKa of the 7-
hydroxy group45. In the absence of the EWG that pulls electron density from the ring, the pKa of 
the 7-hydroxyl on FFN201 is 8.0, well outside of the range required for measuring a change in 
fluorescence when transported between the vesicular lumen (pH: 5.5) and the extracellular space 
(pH: 7.4). Addition of the chlorine to the 6-position, as seen in FFN202, lowered the pKa to 6.4, 
making possible its use in functional release studies, similar to those described in Chapter 2. 
With FFN201 now identified as our new lead NE-FFN core, a series of pH-sensitive analogues 
were synthesized and tested for hNET activity. 
4.2.2 Identification of FFN270 in hNET-HEK Cell Culture Screens 
 Based on the observations from the initial transfected cell-based screens above, a second-
generation set of 3-aminoethyl-7-hydroxycoumarin compounds were synthesized and tested in 
hNET-HEK cells (5µM for 30min). These compounds, depicted in Figure 6A, either include the 
smaller (than chlorine) EWG, fluorine, on the 6-position, or an EWG (Cl or F) on the 8-position. 
7-hydroxycoumarins were also synthesized with the aminoethyl group in 6- and 8-positions 
around the coumarin core, but none of these were active at hNET (not shown). The results from 
screening these compounds in hNET-HEK cells are included in Figure 6B, which showed that 
increased bulk at either the 6- (FFN202) or 8-position (FFN269) drastically reduced hNET 
activity. However, unlike what was observed at the 6-position, a fluorine was well tolerated at 
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the 8-postion (FFN270), and retained 86 percent of the activity observed with FFN201 (S/B 
FFN270: 8.5±0.5, FFN201: 9.9±0.2, mean ± SEM, n = 3). The spectroscopic properties of the 8-
fluoro analogue, FFN270, were then measured to confirm a pH-dependent ratiometric 
fluorescence with a pKa in the desired range (5.5-7.4). Consistent with other 7-
hydroxycoumarins, FFN270 showed a stronger fluorescence at higher pH values, with an 
isosbestic point at pH 6.1, which is suitable for future functional pH-sensitive experiments. 
 
Figure 6. A) Chemical structures of selected 7-hydroxycoumarins tested for hNET activity with hNET-HEK cells. 
B) S/B ratios for each fluorophore collected as described in Figure 5. Highlighted with red arrows are the newly 
synthesized compounds to complete the series. C) Representative images of FFN270 without inhibitor (C) and with 
inhibitor (D). 
 
4.2.3 Assessing FFN270 Transport in VMAT2-HEK Cell Culture Assays 
 Encouraged by the NET-specific uptake and spectrophysical properties of FFN270, we 
next determined whether FFN270 was actively transported by the vesicular monoamine 
transporter (VMAT2), using the same transfected VMAT2-HEK cells described in Chapter 3 
(3.2.2). These cells were incubated with FFN270 (20µM) for two hours (Figure 7). Longer 
incubation times were required for this assay compared to the hNET-HEK screen due to the lack 
of a transfected plasma membrane transporter (NET) and the poor lipophilicity of the compound 
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(LogD: -1.5). Following the 2 hour incubation, a bright punctated staining pattern was observed, 
similar to that previously observed with older generation FFNs, such as FFN102 and FFN20245.  
 
Figure 7. A) VMAT2-dependent loading of FFN102 and FFN270 were compared using the normalized intensity of 
puncta (number of puncta multiplied by average fluorescence intensity) in VMAT2-HEK cells after a 2h incubation 
(20µM) under different conditions. B) Representative schematic depicting the rationale for intracellular punctate 
fluorescence with active VMAT2, and general cytosolic labeling in null-transfected or inhibited conditions. The 
fluorescent probes passively diffuse through the plasma membrane were they are then actively concentrated in acidic 
compartments by VMAT2 activity. Without active VMAT2 (inhibition or null-transfected) intracellular fluorescence 
is only resultant from equilibrative passive diffusion. Representative images of FFN270 in (C) VMAT2-HEK cells, 
(D) dTBZ (2µM) inhibited or (E) reserpine (2µM) inhibited VMAT2-HEK cells, and (F) null-transfected HEK293 
cells. Each image set includes a bright field image and a fluorescence image. 
 
Using FFN102 as a benchmark VMAT2 substrate, which is known to produce robust 
exocytosis-dependent fluorescent changes in acute murine brain slices44, we compared VMAT2-
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dependent loading of FFN270 with that of FFN102. Loaded acidic compartments appeared as 
fluorescent puncta within the cells. The puncta were then selected for quantification based on 
their size and fluorescence intensity as compared to the background. The normalized intensity 
(number of puncta multiplied by average fluorescence intensity) of these puncta in FFN270- and 
FFN102-treated VMAT2-HEK cells were then compared with the number in null-transfected 
HEK cells (without VMAT2) or with cells treated with VMAT2-inhibitors: reserpine (2µM) or 
dihydrotetrabenazine (dTBZ, 2µM). Under any of the conditions in which VMAT2 activity was 
absent or inhibited, the normalized intensity of FFN270 was drastically reduced (between 88 and 
90%). These results suggest that, unlike APP+ as described in Chapter 3 (3.2.2), the 
accumulation of FFN270 into acidic compartments due to VMAT2 activity comprised the 
predominant portion of total FFN270 fluorescence. Thus, FFN270 appeared to meet the cell-
based screening criteria for a NE-FFN:  NET-dependent uptake and VMAT2-dependent 
accumulation into acidic compartments.  Additionally, the FFN270 VMAT2-HEK cell-culture 
results matched closely with those of FFN102 (FFN270: 945±173 and FFN102 733±60, mean ± 
SEM, not significant, n = 4), indicating that FFN270 may also have significant vesicular 
accumulation in the VMAT2-expressing neurons present in acute murine brain slices, as did 
FFN102. 
4.2.4 Labeling of Noradrenergic Neurons in Acute Murine Brain Slices 
 After passing the transfected cell-based screening criteria for a new NE-FFN, we then 
sought to determine whether FFN270 would prove useful in studying NE neurotransmission in 
living brain tissue, by performing a series of studies in acute murine brain slices.  The first step 
in this process necessitated that we determine whether FFN270 is a substrate for murine NET by 
testing the uptake of this compound by the noradrenergic cell bodies of the mouse LC. As 
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discussed in Chapter 3 (3.2.3), the mice used for these experiments were younger (21-30d 
postnatal) than the typical adolescent mice (49-70d) used in all other experimentation requiring 
mice, due to the decreased NET expression in adult animals46,47. Using the tyrosine hydroxylase 
(TH) promoter driven GFP as a positive label of catecholaminergic neurons, acute brain slices 
containing LC neurons were incubated with FFN270 (10µM) for 30 minutes, followed by a wash 
for 10 minutes before imaging. A significant accumulation of FFN270 fluorescence, as measured 
by two-photon excitation, was observed in neuronal cell bodies also containing the TH-GFP 
signal, as well as in the lining of blood vessels (Figure 8). FFN270 positive cell bodies were 
selected for quantification if their fluorescence was two standard deviations above the 
background signal. Similar to the results observed with APP+, 72 percent of the noradrenergic 
cell bodies in the LC labeled with GFP actively accumulated FFN270 (62/86 cells from 6 
different mice). While there was also FFN270 uptake in what appeared to be the endothelial 
lining of the blood vessels, no uptake in other neurons or glial cells was observed in this region. 
As a negative control, uptake of FFN102 was also tested in this area. As expected, no significant 
uptake of this DA-FFN was observed in any TH-GFP positive cells of the LC.  This result is 
consistent with the findings from our hNET-HEK cell culture experiments, and our hypothesis-
generating preliminary in vivo experiment, in which no uptake of FFN102 was observed in the 




Figure 8. FFN270, but not FFN102, labels noradrenergic neurons in the locus coeruleus (LC). A) Atlas image 
highlighting the location of the LC in the mouse brain (Bregma: -5.5mm, Allen Brain Atlas). B-D) FFN270 (D) 
strongly colocalized with the noradrenergic label TH-GFP (C), resulting in a 72% colocalization of noradrenergic 
cell bodies (labeled by red arrows, as determined by fluorescence > 2xSD of background, 62/86 cells, 6 animals). 
Cells that did not colocalize are highlighted with a blue arrow, and blood vessels are highlighted with a yellow 
arrow. E-G) When repeated with FFN102 (E), no colocalization was observed with TH-GFP (F). Scale Bar: 10µm. 
 
 Our next steps were to confirm that the uptake of FFN202 into axons in the outer layers 
of the somatosensory and motor cortex, observed in our initial hypothesis-generating in vivo 
experiment (Figure 4), represented uptake into noradrenergic projections, and to demonstrate 
that FFN270 can also be actively accumulated into these noradrenergic projections. For these 
experiments we chose to image the noradrenergic projections in the outer layers (Layers 1 and 
2/3) of the barrel cortex for 3 main reasons; 1) accessibility for future in vivo functional 
experiments, 2) the demonstrated importance of NE in this area of the brain, and 3) the potential 
for observable changes in fluorescence to be shown by FFNs. First, two-photon imaging in the 
outer 200 microns of the intact cortical layers of the barrel cortex in vivo is already a well-
established method that has been used to image individual spine turnover48, calcium transients49, 
and changes in membrane potential50. Using multiphoton microscopy, it is possible to collect 
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images at this depth with single synapse spatial resolution and observe changes in fluorescence 
of only a few percentage points.  
Second, NE-driven neuromodulation in the barrel cortex is linked to major changes in the 
sensory information processing function of the cortical networks in this area. Specifically, 
changes in NE release affect the strength and temporal patterns of spontaneous synaptic inputs of 
the barrel cortical networks13,51, while differentially augmenting sensory induced cortical neuron 
firing rates during whisker deflection52. Depending on the firing frequency of the LC, a subset of 
barrel cortical neurons are maximally facilitated or suppressed, and the members of this network 
change as the frequency of LC input changes13. As discussed earlier, recent evidence no longer 
supports the belief of homogenous global noradrenergic activity. On a large scale, LC neurons 
that project to different brain regions demonstrate different firing rates, however, a more directed 
study of the firing patterns of specific NE synaptic connections has not been possible34. The 
intent for this experiment is to determine whether FFN270 can be used in the barrel cortex to 
further elucidate the role of NE inputs on specific cortical neurons by locally measuring NE 
neurotransmission from individual release sites, potentially during live sensory input behavior. 
The differences in the effects of NE on postsynaptic targets could be due to differential 
postsynaptic adrenergic receptor expression or a presynaptic regulatory mechanism made visible 
by FFNs. It is possible that with a NE-FFN we could observe presynaptic heterogeneity of 
noradrenergic synapses, similar to the properties of dopaminergic synapse discussed in Chapter 
2. As a whole, the noradrenergic projections of the barrel cortex pose an exciting new territory 




Figure 9. Representative images of different FFNs (10µM) loaded into layer 1 of the barrel cortex (A, Bregma: -
1.0mm, Allen Brain Atlas) of acute murine brain slices (30min, 10min wash). A) FFN270, B) FFN093, C) FFN202, 
D) FFN102. For structure and expected loading based on hNET-HEK data of each FFN refer to Figure 6. Expected 
noradrenergic axons appeared as long strings with punctated release sites, while blood vessels appeared as large 
tubular structures. Scale Bar: 10µm. 
 
 Imaging FFN270 in the barrel cortex was performed using the same loading conditions 
used in the LC experiments (10µM for 30min, followed by a 10min wash). These conditions 
resulted in sparse FFN270 staining that resembled beads on a string, similar to what was 
observed in the preliminary in vivo experiment. For these images, 20 micron thick z-stacks were 
collected and then maximally z-projected into a single plane image due to the relatively sparse 
density of these structures. This experiment was then repeated with the second best compounds 
tested in the hNET-HEK screen, FFN093, as well as FFN202 and FFN102 as controls. 
Representative images are included in Figure 9 and the results are consistent with the cell 
culture data. FFN270 had the highest density of labeled structures with the greatest signal-to-
background ratio, followed closely by FFN093. Similar to what was observed initially in vivo, 
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FFN202 did have a few labeled structures, but they were less dense and had smaller signal-to-
background ratios. It is possible that not all of these structures had the same level of NET 
expression leading to only some capable of loading enough FFN202 to be visible above 
background, while others were unable to transport enough of the poor substrate to be visible. 
Lastly, FFN102 incubation resulted in virtually no punctated structures, and less fluorescence 
than any of the three other FFNs tested. Like the FFN270, however, blood vessel staining was 
still present. It is possible that some of the limited FFN102 signal observed might be due to 
dopaminergic projections potentially present in the barrel cortex, but potential dopaminergic 
projections are primarily thought to be in the deeper layers (IV),53 and dopaminergic projections 
in the cortex typically have poor DAT expression54. Additional experiments would be required to 
determine if the FFN102 fluorescence signal is sparse DAT expression or non-specific 
background. 
 
Figure 10. A) FFN270 axonal labeling in Layer 1 of the barrel cortex was inhibited with nomifensine (2µM, Nom.) 
or reboxetine (500nM, Rebox.). The average number of puncta along strings was significantly higher in control 
conditions (68.5±22) compared to Nom. (7.7±0.7) and Rebox. (17.5±3.5) conditions (n=3).   Representative images 
of FFN270 labeling under normal loading conditions (B) or inhibited with Nom. (C) or Rebox. (D). Blood vessel 




 To confirm that the punctate fluorescence observed with FFN270 was due to NET uptake 
into noradrenergic projections, loading of FFN270 into the brain slices was performed in the 
presence of the NET inhibitors, either nomifensine (2µM) or reboxetine (500nM) (Figure 10). 
Quantification of the number of puncta along strings showed a 89.1 percent decrease of these 
structures when inhibited with nomifensine, and a 74.5 percent decrease when inhibited with 
reboxetine (Control: 68.5±16 Nom.: 7.7±0.5 Rebox.: 17.5±2.5, mean ± SEM, 2-3 slices per 
animal, 3 different animals per condition). As expected, nomifensine almost completely 
eliminated FFN uptake in these structures, but the decrease resulting from reboxetine inhibition 
was incomplete. It is possible that since nomifensine is both a DAT (Ki ~ 50nM) and NET (Ki ~ 
25nM) inhibitor, and reboxetine is only a NET (Ki ~ 10nM) inhibitor (DAT Ki > 10µM), that 
some of the FFN270 labeled structures were dopaminergic55. Alternatively, it may be that the 
reboxetine concentration and pre-incubation times used (15min) were insufficient to completely 
block NET activity, so that some structures were still bright enough to be selected for counting. 
 
Figure 11. Representative images of noradrenergic projections in Layer 1 of the barrel cortex in TH-GFP, labeled 
with FFN270 (A) and TH-GFP (B). C) We observed a high level of colocalization (>80%) between the two 
fluorophores indicating that FFN270 labels noradrenergic projections. Scale Bar: 10µm. 
 
 To further characterize the nature of these structures, TH-GFP mice were again used for 
NE-neuron colocalization studies. In general, the strength of the GFP signal in the noradrenergic 
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projections in the cortex are much weaker than the GFP signal in the noradrenergic cell bodies in 
the LC, due to the axonal separation between the brain stem and these sparse distal projections. 
However, we were able to image TH-GFP positive structures in the barrel cortex when using 
longer imaging dwell times and higher laser power (see Experimental 5.3). When comparing the 
percent colocalization of FFN270 puncta and GFP signal found along the strings, there was 
greater than 80% overlap between the two channels (2-3 slices per animal, 3 different animals) 
(Figure 11). Consistent with the inhibition data, this result further supports the conclusion that 
FFN270 labels catecholaminergic projections in the barrel cortex, but due to the tyrosine 
hydroxylase promoter being active in both dopaminergic and noradrenergic neurons, this 
experiment alone cannot distinguish between these two neuronal types. Dopamine β-hydroxylase 
(DBH) is the enzyme that converts dopamine to norepinephrine through the copper cofactor 
catalyzed oxidation of the beta position of the aminoethyl group on DA56,57. Importantly, the 
promoter of this protein in the brain is specifically active in noradrenergic neurons and could be 
useful in distinguishing between dopaminergic and noradrenergic neurons in the brain. A DBH 
driven cre recombinase mouse line is available from the Mutant Mouse Resource and Research 
Center, but this line is cryopreserved58. It would be possible to obtain this line in the future and 
crossbreed with a floxed mCherry mouse line already in the laboratory, which would then 
activate fluorescent mCherry expression in only neurons that expressed the cre recombinase. 
However, the time to unfreeze the line, obtain a breeding pair, and then generate double mutants 




Figure 12. Representative image of staining pattern of dopamine β-hydroxylase (DBH) antibodies in Layer 1 of the 
barrel cortex. Note that fixation/staining was performed after imaging with FFN270 in healthy tissue, resulting in 
non-ideal DBH staining conditions. Colocalization with FFN270 was problematic, because a) FFN270 did not 
remain in the tissue after fixation and antibody conjugation steps, and b) FFN270 images collected pre-fixation were 
difficult to register with DBH images due to tissue deformation caused during the fixation process. However, we did 
observe some strings of puncta (marked by arrows) that corresponded to noradrenergic projections with a density 
that was similar to FFN270 puncta. Scale Bar: 10µm. 
 
 In a further attempt to confirm that noradrenergic projections were present in the exact 
areas where we were observing FFN270 fluorescent structures in our acute brain slice 
experiments, the slices were fixed after imaging and then re-imaged after immunostaining for 
DBH. Unfortunately, after the 4% paraformaldehyde fixation and antibody conjugation steps, 
none of the FFN staining remained in the slice. We attempted to use the vasculature to locate the 
same area after fixation, which worked reasonably well, but we were unable to re-locate the 
exact same axons again, possibly due to deformations of the slice that occurred during the 
fixation process. However, we did observe noradrenergic axons with a similar density pattern as 
generated with FFN270 (Figure 12). This is consistent with noradrenergic staining patterns 
collected from other researchers in similar brain regions33. While the collection of data in this 
section highly suggested that the majority of the monoaminergic projections visible in this area 
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with FFN270 were noradrenergic, these experiments were unable to demonstrate this 
definitively. Of note, in section 4.3.8, another piece of evidence is described using an in vivo 
system that would further support this conclusion and eliminate any remaining uncertainty. 
4.2.5 Stimulated FFN270 Release in Acute Murine Brain Slices 
 
 
Figure 13. Representative images of FFN270 loaded noradrenergic projections in Layer 1 of the barrel cortex in 
acute brain slice, before (A) and 5min after (B) 40mM KCl depolarization. C) Preliminary quantification of the ∆F/F 
of certain FFN270 labeled objects in the field of view. Red: noradrenergic axon, Blue: blood vessel, Green: non-
specific spot. Scale Bar: 10µm. 
 
 An important requirement for any NE-FFN is that it also must be able to measure the 
synaptic vesicle content release from noradrenergic release sites. FFN270 has been shown to 
label noradrenergic axons, so the next step was to examine whether this probe can be used to 
trace NE release. As outlined in Chapter 3, this process involved measuring fluorescence 
changes under both electrical and chemical release conditions. For FFN270, we first measured 
fluorescence changes using 40mM KCl to induce membrane depolarization. Figure 13 includes 
representative images before and after (5 minutes) K+ induced depolarization. There was visually 
more change in the fluorescence of the axonal strings compared to the blood vessels, but finding 
the same field of view before and after the treatment was problematic. The slice deformations 
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caused from this treatment, as discussed in more detail in Chapter 3 (3.2.5), were more 
pronounced when imaging the outer layers of the barrel cortex near the edge of the slice. 
Combined with the sparse density of these projections, we were unable to quantify the degree of 
release associated with this technique. 
 
Figure 14. A) Change in FFN270 puncta fluorescence that destain over time in the barrel cortex in acute brain slice, 
during the course of a locally applied electrical stimulation (10Hz, 3000pulses, starts at t: 0min). B) Representative 
noradrenergic axon labeled with FFN270 over the course of stimulation. Scale Bar: 10µm. 
 
 Switching to electrically stimulated NE-release, the same stimulation protocol was used 
as described in Chapter 3 (10Hz local stimulation, 3.2.5). The sparse nature of these projections, 
however, made finding a good imaging area difficult. Imaging fast enough to measure release 
kinetics only allowed for imaging 5 z-planes, and as a result, some image sets only include a few 
puncta. Combined with the previous observation of “silent puncta” described in Chapter 2 
(2.2.5), this led to only a very limited number of destained puncta per experiment. Destained 
puncta were selected from all puncta using a MATLAB script that identified fluorescent changes 
after initiation of electrical stimulation that were significantly different from changes that 
139 
 
occurred during baseline washing (see Experimental 5.3). This included both the degree of 
exponentiality of the detaining curve compared with the baseline curve and the magnitude of 
destaining relative to the standard deviation of the baseline signal. The results are included in 
Figure 14 and the kinetics from the collection of all destained puncta demonstrated a destaining 
half-life (t1/2) of 30.3 seconds (2-3 slices per animal, 3 different animals). This t1/2 is comparable 
to the kinetics observed in dopaminergic neurons with FFN200 (~25sec at 10Hz), and 
glutamatergic hippocampal release sites with FM1-43 (~25sec at 10 Hz)59.  
Interestingly, due to the sparse nature of the axons in this area, it was easier to identify 
which puncta were along the same axons than in the striatum, and subsequently, we noticed that 
many of the destained puncta from a single field of view were found along the same axon. 
Although, we have not yet devised a quantifiable parameter to explore this preliminary 
observation further. As a negative control, these electrical experiments were repeated in the 
presence of CdCl2 (200µM) to block calcium channels, which resulted in a 88.3 percent 
reduction in the number of FFN270 puncta that destained (2-3 slices per animal, 3 different 
animals)60. We believe that the remaining 10 percent of destained puncta are the false positives 
selected by the program that are primarily due to movement within the field of view. Lastly, a 
small “FFN flash” could be observed in these experiments, but this was much smaller than the 
flash observed with FFN102 in the striatum, presumably due to the differences in puncta density. 
As discussed in Chapter 2 (2.4.2), there is interest in exploring individually the release of sparse 
puncta at much higher imaging rates with individual electrical pulses to get fluorescent changes 
with minimal background signal contamination, but this work is not ready at this time. 
 In conclusion, the acute brain slice experiments demonstrated that treatment with 
FFN270 generated fluorescent puncta in the outer layers of the barrel cortex, and that these 
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puncta appeared to be in catecholaminergic projections, with the majority being noradrenergic. 
Thus, FFN270 appears to have potential to be a useful probe for identifying noradrenergic 
projections in acute mouse brain tissue.  The pattern of staining generated was distinct from that 
of FFN102, which is DA-selective, without any detectable NET activity. Additionally, we 
demonstrated that FFN270 can be released from these projections by either chemical or electrical 
exocytosis inducing conditions, critical for a probe to be considered a functional FFN. Based on 
these characteristics, combined with the accessibility of imaging the outer layers of the cortex in 
vivo, we determined that FFN270 would be a prime candidate for further experimentation in 
vivo. To confirm previous ex vivo observations in native and undamaged neuronal networks in 
vivo, will be an important step forwards for the whole FFN program. As well, being able to 
demonstrate the in vivo utility of this new NE-FFN will support the pursuit of valuable research 
opportunities is the growing field of NE research. 
4.2.6 Characterization of FFN270 in vivo 
 I would like to thank Samuel Clark, a MD/PhD student in Dr. Sulzer’s laboratory, for his 
collaborative help with these in vivo experiments. His general knowledge and experience 





Figure 15. First in vivo images with FFNs acquired in our own laboratory. A) 3-D reconstruction of FFN270 
labeling (50µM bath applied) in Layer 1 of the barrel cortex in vivo. B) Representative single x-y plane from the 
volume in A). Scale Bar: 10µm. 
 
 For this section, I will first discuss some of the parameters that we explored to establish 
an in vivo experimental protocol that would enable us to pursue our primary FFN270 
experimental objectives, as well as allow for relatively consistent FFN experimentation over 
time. Initially, we set out to repeat the preliminary in vivo results collected with FFN202 (Figure 
4). For this, we evaluated a method for accessing and treating the surface of the murine brain in 
vivo.  This was accomplished by removing an approximately two millimeter diameter circle of 
skull and dura mater over the barrel cortex (stereotaxic coordinates from bregma: AP: -1.0-
2.0mm, ML: 2.0-3.0mm) from an anesthetized mouse, and then surrounding this hole with a 
plastic well that held artificial cerebral spinal fluid (ACSF). For experimentation, the ACSF was 
exchanged with an ACSF solution containing FFN270 (50µM) and allowed to sit directly on the 
brain tissue for one hour. We used higher concentrations and longer incubation times of the FFN 
in the intact brain compared to the conditions used in acute brain slices, due to slice conditions 
resulting in suboptimal staining with a poor penetration depth. This type of “bath application” 
resulted in the staining pattern included in Figure 15. Fluorescence was highest near the surface 
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of the brain, and decreased as the concentration of the probe and tissue depth went down. 
Excitingly, there were many bright puncta along numerous axons, much more than previously 
observed in vivo with FFN202 (Figure 4). Depending on the wash time, the signal to background 
ratio of these puncta changed dramatically. Initially, there were almost no visible puncta due to 
the overwhelming background signal, but after a 30 minute wash, we were able to image puncta 
with high fluorescence compared to the background. We also observed that the puncta 
fluorescence decreased relatively rapidly over time when compared to the rate of similar 
intensity puncta in the acute brain slice. It is possible that this is due to the slow tonic firing of 
noradrenergic neurons even in an anesthetized state30. Using this FFN loading protocol, we were 
able to image bright puncta up to two hours post-bath application. However, while this method 
worked well for initial imaging of the probe, this technique would not have been suitable for 
much of the planned future experimentation. 
 The ultimate goal of FFN use in vivo centers around the ability to image changes in NE 
release over time, or under different conditions. Thus, due to the mechanism of how FFNs work, 
the probe would need to be reapplied for each experiment. Therefore, being able to look at the 
release kinetics of individual puncta before and after behavioral conditioning or disease 
progression would not be possible with the bath application process, as it requires exposed brain 
tissue. To enhance our ability to perform in vivo FFN experiments, we sought to establish an 
experimental model in which the mouse would have a long-lasting cranial window over the 
imaging area that would also allow for repeated FFN loading. As a result, we devised a glass 
window that had a small injection port in the middle. The port was sealed with a silicon sealant 
when not in use, and this plug was removable and sealable before and after each experiment. 
This is similar to plastic windows with a comparable design used to apply drugs locally to the 
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imaging area61, but we have perfected this technique by making the windows out of glass with 
diamond drill bits. Next, we optimized the injection loading protocol for use with our fluorescent 
probes and the new port. 
 
Figure 16. A) Cartoon highlighting how the mice were held for imaging. B) Diagram of the in vivo injection port 
setup. The skin was pealed back and the surface of the skull was covered in hardened dental acrylic which held the 
glass window in place and forms a small well to hold liquid for the water emersion objective. The glass window is 
the smoother circle which has a small injection port that provides direct access to the surface of the brain. The glass 
injection needle can then inject FFN through the port. After imaging, the port can be resealed with a silicon sealant. 
C) Representative image of a single x-y plane in Layer 1 of the barrel cortex from injection-loaded FFN270 (1mM) 
in vivo. Highlighted by arrows are FFN270-lebeled noradrenergic projections in a living mouse. Scale Bar: 10µm. 
 
 Small volumes of FFN270 were loaded into the brain (~100nL) through a pulled-glass 
injection needle and a Nanoject II injector. Injecting the same concentration that worked well for 
bath application (50µM) gave very little fluorescence signal, and almost no fluorescent puncta 
were observed. We established that loading was optimal when the FFN concentration was much 
higher (1mM), and spread out over 2 different injection depths (100µm and 50µm from the 
surface). At this injection concentration we noticed strong fluorescence background at the needle 
track, but greater than 50 microns from this track, the puncta were comparable to those achieved 
using the bath application, with similar signal to background ratios (Figure 16). However, the 
nature of using a single point source-like loading compared to continual diffusion led to an even 
smaller temporal window for imaging (as described in 4.2.6). We found that one hour after 
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injection some puncta were no longer bright enough to be identified with our puncta selection 
methods. However, this temporal window was sufficiently long to measure release site activity, 
and as such, was used as our primary method of FFN loading for the following in vivo 
experiments. 
4.2.7 Amphetamine-induced Release of FFN270 in vivo 
 
 Similar to studies in acute brain slice, our interest with FFNs goes beyond neuronal 
labeling; we wanted to be able to use these tools to study neurotransmission and neurotransmitter 
concentration changes at an individual release site. This first included monitoring changes in 
FFN270 concentrations in noradrenergic projections after an intraperitoneal (I.P.) injection of a 
physiologically relevant dose of amphetamine. It is expected that amphetamine will cause 
neurotransmitter and FFN270 release from catecholamine release sites through redistribution of 
vesicle contents to the cytoplasm, reverse MAT activity, and upregulated exocytosis activity62. 
For this experiment, the FFN270 puncta in a small volume of layer 1 of the barrel cortex were 
monitored over the course of low (1mg/kg), high (10mg/kg), or null (PBS only) amphetamine 
(AMPH) doses. We observed a rapid decrease of the fluorescence intensity and number of 
FFN270 puncta after both the high and low AMPH doses. After a low dose of AMPH, only 
31.5±9.3 percent of FFN270 puncta remained after 5 minutes post-injection, a significant 
difference compared to the 78.9±4.9 percent remaining in the PBS control (6 control mice, 4 
mice per AMPH condition) (Figure 17). The approximately 21.1±5.4 percent decrease in the 
control was thought to be due to the slow tonic firing of noradrenergic neurons, as well as the 
higher degree of field of view shift that occurs when performing imaging experiments in vivo, as 
compared with acute slices. When using the higher dose, the number of puncta remaining was 
only 12 percent, similar to the percentage of selected structures that previously did not 
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colocalized with TH-GFP or were not inhibited with nomifensine in acute brain slice 
experiments. 
 
Figure 17. Representative before and 5min after injection of amphetamine (AMPH) images of FFN270 in Layer 1 
of the barrel cortex. Top row includes images acquired before I.P. administration of a high dose of AMPH 
(10mg/kg, A), low dose of AMPH (1mg/kg, B), or control (PBS, C). D-F) Representative corresponding images 
acquired 5min after each injection. G) Quantification of the number of puncta before and 5min after each AMPH 




4.3.8 Preliminary FFN270 Release with DREADDs and Optogenetics 
 The next step in characterizing FFN270 in vivo was to measure the kinetics of exocytosis 
of individual terminals when specifically stimulating only the noradrenergic neurons. Since 
AMPH causes release from multiple types of neurotransmitter systems in mechanisms that 
potentially include, but are not limited to exocytosis, we moved to more recent technologies that 
stimulate firing and thus vesicular release in specific neurons of interest. Briefly we explored 
using electrical stimulation of the medium forebrain bundle (MFB), which contains the LC to 
cortex noradrenergic axons, but there were a couple issues associated with this technique. First, 
the MFB contains a massively diverse fiber network with inputs from approximately 50 different 
brain regions. Stimulation of this bundle would be non-specific for noradrenergic neurons and 
potentially activate all of these networks and their downstream targets. Second, we observed 
shifts of the imaging plane immediately upon initiation of the electrical stimulation. It is possible 
that this brain movement was a result of the widespread activation caused by stimulating this 
neuronal bundle. Due to these technical issues and non-specificity of using electrical stimulation, 
we next explored optogenic63 and designer receptors exclusively activated by designer drugs 
(DREADDs)64 techniques. I will describe both of these techniques and our preliminary work 
toward our goals here, but note that these experiments are still on going. 
 One of the many advantages of using a living system is that we can genetically target 
neurons of the LC, and then image the distal projections of those neurons in a network that is still 
intact. Through the collaboration with Dr. Gary Aston-Jones (Rutgers University), we obtained a 
viral construct (AAV9 PRSx8-hM3DQ DREADD) that specifically expresses the excitatory 
DREADDs receptor system (Gq-coupled) only in infected noradrenergic neurons by utilizing the 
DBH promoter (PRSx8)12. The Gq DREADDs works through a specially designed receptor 
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(hM3DQ) which binds the non-native clozapine-N-oxide (CNO) molecule. hM3DQ is a 
modified muscarinic G-protein-coupled receptor that is normally inactive until it binds to CNO. 
After binding CNO, hM3DQ, like the native muscarinic-M3 GPCR binding acetylcholine, then 
specifically activates the Gq-coupled G-protein pathway64. This then leads to phospholipase C-β 
activation, increasing inositol triphosphate and diacylglycerol concentration, which ultimately 
leads to protein kinase C activation and increased calcium release from intracellular 
compartments65. In neurons, the increased calcium caused by DREADDs activation leads to 
depolarization, enhanced excitability, and burst firing66. 
 
Figure 18. Preliminary FFN270 destaining from noradrenergic projection in Layer 1 of the barrel cortex, induced by 
a clozapine-N-oxide (CNO) injection (10mg/kg, I.P.) that leads to DREADDs activation in these neurons. The 
noradrenergic-specific DREADDs Gq virus (AAV9 PRSx8-hM3DQ DREADD) was injected in the LC 2 weeks 
prior to this experiment. Highlighted in red is the ~10min time delay between CNO injection (t=0min) and a change 
in the decay rate of FFN270 fluorescence. 
 
 This system was particularly appealing for our purposes due to the simplicity of the 
experimental design and the similarity of the protocol to the AMPH experiments, which has been 
demonstrated to be very robust. The CNO can be administered through I.P. injection, which does 
not cause changes in the imaging field of view, and the timescale of the effect is well within the 
hour window when the puncta are bright enough for imaging. We collected preliminary results 
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using the same FFN270 loading and imaging protocol as described for AMPH, but using a 
mouse that had been injected two weeks prior with the noradrenergic-specific DREADDs virus 
in the LC. Following the injection of FFN270, a time course of FFN270 puncta number and 
fluorescence was collected before and after the I.P. CNO injection (0.5mg/kg), and is depicted in 
Figure 18. A change in the rate of FFN270 fluorescence over time was observed at the 15 
minute point, fairly consistent with the delay observed with CNO and I.P. injections by other 
groups66. These experiments will be repeated with appropriate controls, but are suggestive that 
FFN270 is loaded into noradrenergic neurons, and can be released through vesicular exocytosis. 
 In tandem with our experiments using DREADDs, we are also exploring the use of 
optogenetics to more precisely control LC firing. Like DREADDs, optogenetics is a technique to 
control intracellular calcium concentrations and cause vesicular exocytosis in neurons. 
Channelrhodopsin-2 (ChR2), one of the most commonly used members of the optogenetic 
family, is a seven-transmembrane helix channel discovered in green algae that only opens when 
stimulated by blue light. Inside the ChR2 is an all-trans retinol bound to the core that isomerizes 
when exposed to 470 nanometer light. This isomerization leads to a conformational change of 
ChR2 that opens a pore for cation flow. Expression of this protein in excitable cells is 
particularly interesting due to its ability to allow calcium to flow into the cell, mimicking the 
normal function of voltage-gated calcium channels on neurons67. Using this system with neurons, 
it is possible to turn flashes of blue light into a sequence of firing spikes of up to 50 hertz68. 
Optogenetics has an advantage over the DREADDs system in the precision with which neuronal 
firing can be controlled. Using a fiber optic cable implanted into the LC it is possible to locally 
deliver discrete durations of blue light and control noradrenergic firing in vivo with millisecond 
temporal control69.  
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In preparation for these experiments, we injected the AAV9-CAG-ChR2-mCherry virus 
into the LC, but have not yet begun the imaging portion of the experiment. In addition to using 
this virus to elicit ChR2 expression, the vector also contains GFP, which would allow for in vivo 
colocalization of noradrenergic projections over dopaminergic ones. Communication with 
members of the Dr. Aston-Jones laboratory determined that it is necessary to wait at least two to 
three months after injection before viral protein expression from the cell bodies reaches the long 
range projections in the cortex, however, we are in the process of confirming this. Waiting for 
expression to reach the cortex would also allow for local activation of the ChR2 if activation 
with a fiber optic cable in the LC is problematic. A cohort of these mice have been injected, and 
we are currently waiting until expression of ChR2 and GFP in the cortex is sufficient.  
4.3 Conclusions 
4.3.1 Summary 
 Inspired by preliminary evidence of FFN activity in vivo, our laboratories pursued the use 
of the coumarin core as a potential NE-FFN in tandem with other fluorescent motifs described in 
Chapter 3. Through the use of hNET-HEK cell culture screens we identified the most promising 
lead for noradrenergic labeling, FFN201. However, FFN201 was not pH-sensitive in the range 
appropriate for allowing the measurement of fluorescent changes associated with pH differences 
between the synaptic vesicles and extracellular space. As a result, a series of analogues with pKa 
modifying groups were synthesized, and FFN270 was found to be a sufficient hNET substrate 
while having a desirable pKa. Further, FFN270 was identified as a VMAT2 substrate, fulfilling 
the stringent FFN design requirements (fluorescent dual substrate for both NET and VMAT2).  
Evaluation of this compound in acute murine brain slices confirmed that it is actively transported 
into both noradrenergic cell bodies in the LC and axonal projections in the barrel cortex. 
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Additionally, this loading can be inhibited by both of the NET-inhibitors, nomifensine and 
reboxetine.  
After confirming that FFN270 is a NET substrate and a noradrenergic neuronal label in 
brain tissue, we further demonstrated that this probe could also be used as a tracer for NE. 
FFN270 release from noradrenergic terminals was observed through depolarization induced by 
high potassium concentrations as well as local electrical stimulation. Release due to electrical 
stimulation could be quantified and subsequently inhibited using the calcium channel blocker, 
cadmium ions (Cd2+). Due to the accessible nature of the labeled projections in the outer layers 
of the barrel cortex, and satisfied that FFN270 met all the required characteristics of a successful 
FFN, we decided to move on to in vivo experimentation. 
For in vivo experimentation in intact murine brains, the FFN loading protocol was first 
optimized to allow repeated and consistent use of the FFN in the same mouse over an extended 
study. This was possible through the design of a novel glass cranial window with a sealable 
injection pore, allowing for repeated local FFN injections. This method resulted in consistent 
imaging of FFN270 labeled noradrenergic projections in vivo, and using this protocol we 
demonstrated for the first time optical imaging of monoamine release from individual release 
sites in vivo (using an amphetamine injection trigger). Additionally, we are currently developing 
protocols for eliciting specific noradrenergic release with the DREADDs and optogenetics 
systems. Initial results with the DREADDs system are promising, but need to be repeated and 
with appropriate controls, and the foundation for optogenetics has been established. 
4.3.2 Future Directions 
 After the full in vivo characterization of FFN270, our future goal, and the culminating 
pinnacle of years of work spread over multiple researchers, is to apply this FFN probe to 
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elucidating the role of presynaptic neurotransmitter release regulation in the normal and 
abnormal functioning of the brain and associated behaviors. By combining this new NE-FFN 
probe with the knowledge gained about the functional uses of other pH-sensitive FFNs (Chapter 
2), we want to use FFN270 to explore the regulation of localized NE release in vivo. Critically, 
we want to assess whether the heterogeneity in catecholamine neurotransmitter release observed 
in acute brain slice (the “silent” puncta that remain after tonic electrical stimulation, or the bi-
modality of release observed from single electrical pulses) is reproduced in vivo. Further, we 
want to understand any potential links between the observed heterogeneity and biological 
significance in the form of animal behavior in vivo, something never before possible within the 
FFN program. FFN270 could be particularly important in understanding how the roles of 
individual NE release sites in the barrel cortex and the adaptive-gain theory relate to specific 
behavioral changes. For example, when the animal is introduced to a new engaging task, do all 
noradrenergic release sites react harmoniously, or is there more localized control of NE release? 
During memory formation, are there lasting changes that can be observed in particular NE 
release sites? If we observe silent puncta in vivo, we can use FFNs to determine, using intact 
circuitry, whether or not they can be switched to active releasers after certain types of 
conditioning. In ultimate conclusion, I hope this work has helped establish a new and exciting 
research approach that will have a lasting impact on how the field comes to understand the 
interconnected roles between presynaptic regulation of neurotransmission and functional 
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Chapter 5: Experimental 
 
5.1 Experimental A (Chapter 2) 
5.1.1 General Acute Murine Brain Slice Preparation and Imaging Parameters 
 This section includes a general description of the acute murine brain slice preparation that 
is applicable to all acute brain slice experiments unless otherwise noted. All wild-type animals 
used for slice striatal experiments were 2–4 month old male C57BL/6 mice obtained from the 
Jackson Laboratory (Bar Harbor, ME). All animal protocols were approved by the IACUC of 
Columbia University. For striatal slice preparation, mice were decapitated and acute 300μm thick 
coronal slices were cut on a vibratome at 4°C artificial cerebrospinal fluid (ACSF) containing (in 
mM): 125 NaCl, 2.5 KCl, 26 NaHCO3, 0.3 KH2PO4, 2.4 CaCl2, 1.3 MgSO4, 0.8 NaH2PO4, 10 
glucose (pH 7.2–7.4, 292–296 mOsm/L). After cutting, acute slices were allowed to recover for 
1h before use at room temperature in oxygenated (95% O2, 5% CO2) ACSF. 
 Slices were then transferred to an imaging chamber (QE-1, Warner Instruments, Hamden, 
CT), held in place with a platinum wire and nylon custom-made holder1, and superfused (1–2 
mL/min) with oxygenated ACSF. After appropriate loading conditions described in each section, 
fluorescent structures were visualized at >20μm depth in the slice using a Prairie Ultima 
Multiphoton Microscopy System (Prairie Technologies, Middleton, WI) with a titanium-sapphire 
MaiTai laser (Spectra-Physics) equipped with a 60 × 0.9 NA water immersion objective. Images 
were captured in 16-bit 512×512 pixel resolution with a dwell time of 10 μs/pixel using Prairie 
View software. Sections with modified imaging parameters will further describe any deviations 




5.1.2 Using FFN102 to study DA Release Depression with Cocaine and Methylphenidate (2.2.1) 
 For data collection and analysis parameters from constant potential amperometry (CPA) 
experiments, refer to the corresponding author, Dr. Nicola Mercuri (University of Rome) and the 
methods section of our published paper2. 
 For FFN experiments, the DA-selective and pH-sensitive FFN102 was used. FFN102 was 
incubated with the acute slice for 30min at 10µM. After a 5min washing period, FFN102 was 
imaged with two-photon laser excitation set to a wavelength of 760nm (near the protonated 
excitation maximum), and emitted light of wavelengths between 440-500nm were collected. 
FFN102 puncta in a 37x37µm field of view (FOV) in the dorsal striatum were imaged (512x512 
pixels) for 10min of more washing, and 10min following application of 30µM cocaine (or 30µM 
methylphenidate) that was added to the perfusion ACSF. Each time point also includes the 
images from 5 z-stacks (1µm each step) to account for any shifts in the z-plane, resulting in a 
final imaging rate of 12sec per image. Tonic electrical stimulation of 6000 pulses (200µs x 
200µA) at 10Hz was applied using a local bipolar stainless-steel electrode controlled by a 
Master-8 pulse generator. For all local stimulation experiments, the AMPA inhibitor, NBQX 
(10µM), and the NMDA inhibitor, AP-5 (50µM), were included in the perfusion ACSF. This 
was repeated in 2-3 slices per animal for 5 different animals for the 30µM cocaine condition and 
3 different animals for the 30µM methylphenidate condition. 
 To analyze the rate of washing, the stack of images in the z of t dimension were 
registered using the 3-D colocalization registration macro included with the FIJI version of 
ImageJ. Next, the Multiple Thresholds plug-in (created by Damon Poburko, Simon Fraser 
University, Burnaby, BC, Canada) was used for fluorescent puncta identification at each time 
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point. Upon visual inspection, objects that did not conform to defined properties (appropriate 
size, rounded shape, and well delimited boundaries) were discarded, as well as puncta that 
moved significantly out of the object mask during the time frame. After puncta selection, the 
average fluorescence of the puncta were collected for each time point and the rate of change pre-
cocaine treatment was compared to the rate post-treatment. The rate post-cocaine treatment was 
also compared to the rate from untreated acute slices. For measuring the magnitude of the FFN 
flash, the total fluorescence of the each trace was normalized with an exponential fit generated 
from the images pre-treatment. The maximum fluorescence relative to initial fluorescence was 
then compared between each condition. 
5.1.3 Using FFN102 to Study DA Release under Phasic Firing Conditions (2.2.2) 
 Acute slices were incubated with FFN102 at 10µM for 30min. The slices were then 
allowed to wash for 10min prior to imaging. Compared to protocol described in 5.1.1, imaging 
parameters were modified for a faster imaging rate. A small 5x5µm region of interest for only 1 
z-plane was scanned, but at the same resolution used in 5.1.1, resulting in an imaging rate of 
10Hz. For electrical stimulation, the same setup described in 5.1.2 was used, except the 
stimulation sequence was set for 5 pulses at 20Hz. The fluorescence from the whole FOV was 
collected and then compared over time. Changes in fluorescence from the whole FOV pre-
stimulation were fit with an exponential and used to normalized fluorescence over the whole 
trace. This condition was compared to conditions in which no electrical stimulus was applied or 
200µM CdCl2 was included in the perfusing ACSF. For the VMAT2-hypomorph experiments, 
mice of this genotype were sacrificed and used in parallel with wild-type mice from the same 
litter. To compare to FFN200, the optimized FFN200 loading conditions were used instead of 
FFN102. This included a 30min incubation with FFN200 (10µM), followed by a 45min wash 
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period3. All other steps were identical. This was repeated for 2-3 slices per animal for 3 different 
animals for each condition. FFN102 was repeated more as it was used as a positive control in 1 
slice from each animal. 
5.1.4 Using FFN102 to Study DA Release from Single Pulses and Paired Pulses (2.2.3/2.2.4) 
 For this set of experiments, the protocol in 5.1.3 was modified to only deliver 1 electrical 
pulse, and also acquire images at a faster rate. An increase in imaging rate was obtained by 
switching to a spiral scanning protocol of a 2x2µm region of interest at the same dwell time and 
resolution. This resulted in an imaging rate of 67Hz. Again, the total fluorescence change over 
the whole FOV was compared to the initial fluorescence from the whole FOV. 
 This experiment was then repeated using a pair of individual pulses separated at different 
temporal intervals. To compare with cyclic voltammetry (CV) measured DA release, half the 
slices from each brain were used for CV, and half for FFN imaging. In both conditions FFN102 
was loaded, and the stimulation sequence was the same. The stimulation sequence was described 
as follows: a pair of pulses spaced 5sec, 5min wait, pair spaced 10sec, 5min wait, pair spaced 
30sec, 5min wait, pair spaced 45sec, 5min wait, and then finally a pair spaced 60sec. After each 
slice the order of spacing was reversed and then repeated (60, 45, 30, 10, and then 5). The ratio 
between the fluorescence maximum after each pulse was then compared to the ratio of DA 
release as measured by CV. This was repeated in 2-3 slices per animal for 2 different animals. 
5.1.5 Using FFN to Study Single Pulse Release Kinetics (2.2.5) 
 A similar protocol as described in 5.1.4 was repeated, but using a lower resolution image, 
as determined by the Nyquist sampling calculation for two-photon images taken at 760nm (10.48 
zoom, at 128x128µm FOV). From this FOV, a smaller 20x20pixel region of interest surrounding 
1 puncta was selected and used for imaging. For these experiments, longer dwell times (30µs) 
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were used. This resulted in an improvement of the imaging rate to 100ms per frame, but still 
comparable signal to noise ratio. For these experiments, 1µM of FFN102 was also included in 
the perfusion ACSF to refill lost vesicular stores during each 5min wait period. Additionally, 
instead of delivering just 1 pulse, individual electrical pulses (EPs) were delivered 10 times and 
spaced 2sec apart. This was repeated ~10 times per slice before moving to the next one. This also 
was repeated without any stimulation as a negative control. This sequence was collected in 2-3 
slices per animal, from 6 different animals. 
 For data analysis a MATLAB script was created, that automated the following described 
steps. The fluorescence trace from the whole FOV was divided into 10 smaller traces of 150 time 
points (1.5sec) surrounding each individual pulse. The 50 time points prior to stimulation of each 
trace were used to generate an exponential best fit that was used to normalize the rest of the 
individual trace. After normalizing, a moving group of 5 time points were run through a t-test to 
determine the probability that this group was above 0. This t-test was conducted on the moving 
group of points for the whole trace, and the p-values for each test were collected. Sections of the 
p-value set that were below 0.05 for 3 or more groups of points in a row were considered 
significant increases in fluorescence. This was repeated for each of the 10 EPs, within a set and 
then for every set. 
 The periods of increase for each pulse (all EP1s, all EP2s, etc.) were then averaged 
together to see when relative to the stimulation each EP was resulting in an increase. This data is 
plotted in Chapter 2 Figure 9 and 10. These plots compare each of the EPs to one another, such 
as the change in release probability between EP1 and EP2. To compare the different release sites 
imaged in each set with one another. For this, we analyzed the data by setting a temporal window 
post stimulation and then determined whether or not a significant increase occurred within that 
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time frame. This was repeated for each EP of the 10 EPs for each imaging set, to determine how 
many times an increase was observed in that FOV (out of 10 possible). This data is plotted in 
Chapter 2 Figure 12 and 13. 
5.1.6 Using FFNs to Measure Changes in Vesicular Loading (2.3.3) 
 For all experiments performed in fly brain and details about murine viral injections, 
contact the corresponding author of our paper in preparation, Dr. Zachary Freyberg (Columbia 
University). 
 For experiments in acute murine brain slice, FFN loading was prepared as described in 
5.1.2. For using FFN102 to measure intracellular pH changes, a second laser was also used 
(Coherent Ultra II) for interlaced scanning. The maximum change in fluorescence ratio of 
FFN102 at pH 5 and 8 using two-photon imaging was observed when imaging at 680nm 
(protonated form, and laser wavelength minimum) and 740nm (deprotonated). However, when 
either of the lasers were tuned to the minimum of 680nm, there were periods where the laser 
stopped pulsing and all black imaged were collected. Therefore, all the data included in 2.3.3 
used laser wavelengths of 740nm and 690nm, which gave much more reliable results. Using 
interlaced scanning, fluorescence from FFN102 at both wavelengths was alternatingly collected 
in one channel (440-500nm). Imaging was performed on a z-stack of 5 1µm z-planes, with a 
FOV of 12x12µm (80x80 pixels) for each plane. The dwell time for these experiments was 
increased slightly (20µs) to compensate for the extra noise introduced when looking at ratios, 
resulting in an image collected every 1.7sec. 
 After loading with FFN102, the slice was washed for 10min prior to imaging. Then 
imaging was started, and 10mM KCl in ACSF (prepared by isotonic replacement of NaCl), was 
perfused over the slice after ~1min. The exact time that it takes the solution to reach the slice 
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through the perfusion tubing was measured previously using a fluorophore in the same setup. 
The change in fluorescence of the whole FOV generated from each laser was then measured and 
used to generate a ratio between the two excitation conditions. This ratio was fitted with an 
exponential best fit, which was used to normalize the whole trace. Each trace was then 
temporally aligned to when exocytosis started to occur (drastic basification shift), and the 
average magnitude collected from the slices of a particular animal were averaged and used to 
normalize the traces between each animal. The alkalization peak was set to 100%, and the 
acidification dips are all relative to that increase. This was repeated in 1-2 slices per animal for 6 
different WT animals with and without KCl. This was next repeated in 3 different animals for 
each injection condition. 
5.2 Experimental B (Chapter 3) 
5.2.1 Photophysical and Cell Culture Characterization 
 For data collection and analysis parameters from photophysical characterization and cell 
culture experiments with APP+, refer to the methods section of our published paper4 or the 
graduate thesis of Dr. Richard J. Karpowicz5. 
5.2.2 Imaging Catecholamine Neuronal Cell Bodies with APP+ in Acute Brain Slices (3.2.3) 
All acute slices were prepared as described in 5.1.1, except that midbrain coronal slices 
were collected from TH-GFP mice 20 – 25 days old due to a reported downregulation of NET on 
the surface of noradrenergic cell bodies in the LC after 30 days postnatal6,7. Dopaminergic cell 
bodies in the midbrain, from both the substantia nigra and ventral tegmental areas, and 
noradrenergic cell bodies from the locus coeruleus were identified by GFP fluorescence. Slices 
that included the appropriate brain regions were incubated using 500nM APP+ for 30min. The 
midbrain slice was then washed with ACSF for 10min prior to imaging. In order to minimize 
crosstalk between fluorophores, APP+ was detected using an excitation of 800nm and an 
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emission range of 435–485nm, and GFP was detected using an excitation of 950nm and an 
emission range of 500–550nm. To ensure that no shift in the z-plane occurs while the laser 
switches between wavelengths, a second APP+ image was collected at the end and compared to 
the first. Cell body images were captured in a larger 112 × 112μm FOV at 1024 × 1024 pixel 
resolution and a dwell time of 10μs. 
For quantification of colocalization in coronal midbrain slices, cells were considered 
positive for either fluorophore if their mean fluorescence intensity was above 2 times the SD of 
the mean background fluorescence intensity, which was determined in an area devoid of 
fluorescent puncta/cells. The number of cells was manually counted in images from at least three 
different positions per slice, 2-3 slices per animal, from 3 different animals. 
5.2.3 Imaging APP+ and TH-GFP or FFN102 Labeled Dopaminergic Axonal Processes in the 
Dorsal Striatum of Acute Brain Slices (3.2.4) 
All acute slices were prepared as described in 5.1.1. For experiments in the dorsal 
striatum, 100nM of APP+ was perfused over this area for 15min, followed by a 10min wash. 
Colocalization experiments in striatal slices of TH-GFP animals were imaged with the same 
acquisition protocol as midbrain experiments described above (5.2.2), in order to minimize 
signal crosstalk between fluorophores. To ensure that no shift in the z-plane occurs while tuning 
the laser between wavelengths, a second APP+ image was collected after GFP acquisition and 
compared to the first. Control experiments showed a lack of GFP signal using APP+ acquisition 
parameters, however, unlike in cell bodies, approximately 10% of APP+ puncta signal were 
apparent in the 500–550nm channel when using GFP acquisition parameters (Chapter 3 Figure 
10). To further assess whether APP+ signal was localized to dopaminergic neurons, we also 
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measured colocalization of APP+ with the previously established dopaminergic marker FFN102, 
which has an excitation/emission spectrum that is more readily separated from APP+.  
For colocalization with FFN102, striatal slices were pre-incubated with 10μM FFN102 
for 30min and then added to the imaging chamber where 100nM APP+ was perfused over the 
slices for 15min. After a 5min wash, APP+ was imaged with an excitation of 810nm and an 
emission of 570–640nm. FFN102 was imaged with an excitation of 740nm and an emission of 
430–500nm. To ensure that no shift in z occurs during laser tuning between wavelengths, a 
second APP+ image was collected at the end and compared to the first. We confirmed a lack of 
signal in the APP+ and FFN102 channels by their alternative fluorophore using control slices 
incubated in either only APP+ or FFN102. 
Quantification of colocalization of fluorophores was determined using Volocity image 
analysis software version 4.4 (Improvision, PerkinElmer). Fluorescent puncta were identified by 
defining a threshold of intensity as well as size and shape parameters (see Volocity user guide for 
a more detailed description of the object identification tasks). After an automatic selection of the 
objects by the program, a manual inspection was performed, where each object was visually 
inspected to confirm its validity. Selected objects that did not conform to a certain number of 
properties (appropriate size, rounded shape, and well-delimited boundaries) were discarded. 
We then determined object colocalization between APP+ and either FFN102 or GFP 
channels using Volocity’s “Measure Object Colocalization” task that calculates a colocalization 
coefficient for each individual object, which indicates the fraction of the signal above threshold 
in one channel that exists as colocalized with a second channel. Colocalization coefficients 
ranging from 0 (none of the signal above threshold in that channel exists as colocalized with the 
other channel) to 1 (all of the signal above threshold in that channel exists as colocalized with the 
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other channel) for each of the selected objects were then obtained. A colocalization coefficient of 
0.5 or higher was considered to be indicative of colocalization. Results are expressed as 
percentage of APP+ objects that colocalize with FFN102 or GFP ± SD, and were calculated from 
2-3 slices per animal, 3 different animals (~150 puncta per slice). 
5.2.4 Inhibition of APP+ Loading in the Striatum with Nomifensine (3.2.4) 
 DAT-dependent loading of APP+ in the dorsal striatum was determined through 
inhibition of DAT through a 15min pre-incubation of acute slices with 2µM nomifensine. 
Following this pre-incubation, nomifensine was then also added to the perfusion ACSF that 
contained APP+ (100nM) used for loading. After 15min of APP+ loading, the perfusion ACSF 
was switched to ASCF without APP+, but still with nomifensine. Images were collected in the 
typical 512x512 pixels and 37x37µm FOV with a dwell time of 10µs, and excitation/emission 
parameters as described in 5.2.2. The resulting staining was then quantified using the same 
puncta picking protocol described in 5.2.3 using Volocity software and compared to repeated 
conditions without nomifensine. This was repeated for 2-3 slices per animal for 3 different 
animals per condition. The final changes of puncta number were then compared using an 
unpaired two-tailed t test to determine statistical significance. 
5.2.5 APP+ Destaining with KCl in Acute Brain Slice (3.2.5) 
For experiments with KCl induced depolarization, APP+ was loaded as described in 
5.2.3. There was significant slice distortion when 40mM KCl was used, which made tracking the 
same objects over time difficult. For these experiments, 50μm z-stacks comprising 10 images, 
each image taken at 5μm intervals, were collected every 1 min. The start of the z-stack would 
begin above the surface of the slice and continue down past the 20μm depth required to avoid 
damage. From this data, it was possible to determine which z-plane contained the surface of the 
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slice, and then the slice that was ∼25μm from the surface was used for quantification. Only 
slices from the same approximate depth were compared over time. Images collected were 
512x512 pixels and 37x37µm FOV with a dwell time of 10µs. Image collection started 5min 
before treatment, and then 40mM KCl in ACSF (prepared by isotonic replacement of NaCl) was 
perfused over the slice and imaged for another 10min. 
Volocity was used to identify puncta from slices at each time point during incubation 
with and without KCl. For KCl experiments, mean intensity values of selected objects at each 
time point were normalized to the time point just before KCl stimulation and then plotted as a 
function of time. The final changes of puncta fluorescence and puncta number at each time point 
were then compared to an untreated control using an unpaired two-tailed t test to determine 
statistical significance. Data presented as averages ± SD from 2-3 slices per animal, from 3 
different animals. 
5.2.6 APP+ Destaining with Electrical Stimulation in Acute Brain Slice (3.2.5) 
For electrical destaining experiments in the dorsal striatum, the same stimulation setup 
described in 5.1.2 was used (local 10Hz stimulation of 3600 pulses). For imaging parameters, to 
compensate for shifts in the z-plane during the time course, z-stacks were acquired. To reduce 
photobleaching and more readily facilitate the tracking of puncta throughout the experiment, 
10μm z-stacks comprising 10 images separated by 1μm were collected every 1 min over a total 
of 9 min (3 min with no stimulation to monitor baseline, followed by 6 min of electrical 
stimulation). Images collected were 512x512 pixels and 37x37µm FOV with a dwell time of 
10µs. 
For electrical destaining experiments, ImageJ was used for analysis, as Volocity cannot 
correct for shifts in the z-plane. Images were registered using the 3-D colocalization registration 
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macro included with the FIJI version of ImageJ. The Multiple Thresholds plug-in (created by 
Damon Poburko, Simon Fraser University, Burnaby, BC, Canada) was then used for fluorescent 
puncta identification at each time point. Upon visual inspection, objects that did not conform to 
defined properties (appropriate size, rounded shape, and well delimited boundaries) were 
discarded, as well as puncta that moved significantly out of the object mask during the time 
frame analyzed. The mean intensity and number of puncta at each time point were then 
normalized to the time point before stimulation and plotted as a function of time. The final 
changes of puncta fluorescence and puncta number after stimulation were then compared using 
an unpaired two-tailed t test for statistical significance. Data presented as averages ± SD from 2-
3 slices per animal, from 3 different animals. 
5.2.7 APP+ Toxicity Does not Affect FFN102 Loading for Acute Experiments in Dopaminergic 
Neurons (3.2.5) 
 To determine whether APP+ was acutely toxic (~1-2hours) to loaded neurons, the APP+ 
dopaminergic cell body loading experiments were repeated as described in 5.2.2. Following 
loading of APP+ for 45min, 10μM FFN102 was then added to the perfusion ACSF and loaded in 
the same dopaminergic cell bodies over 30min. Imaging of both APP+ and FFN102 was 
performed as described in 5.2.3 and the relative FFN102 was qualitatively compared to FFN102 
dopaminergic cell body loading without APP+, as published8. This was repeated in 2-3 slices per 
animal for 2 different animals. 
5.3 Experimental C (Chapter 4) 
5.3.1 hNET-HEK Cells (4.2.2) 
For hNET experiments, HEK293 cells stably transfected with hNET were maintained in 
Dulbecco’s Minimal Essential Medium (DMEM) with GlutaMAX (Invitrogen) supplemented 
with 10% (v/v) fetal bovine serum (FBS, Atlantis Biologicals), 500µg/mL G418 (Calbiochem) to 
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maintain the transgene, 100g/mL Penicillin, and 100 U/mL Streptomycin (Invitrogen). HEK293 
cells to serve as a negative control were maintained in the same culture medium without G418, 
and otherwise treated identically. All cells were routinely cultured in 10cm polystyrene culture 
plates (Falcon), were subcultured before reaching confluence (every 3-4 days), and were 
maintained in a humidified atmosphere at 37 ˚C containing 5% CO2.  On the day of experiments, 
the growth medium was replaced by experimental medium (DMEM minus phenol red with 4mM 
L-glutamine (Invitrogen), 1% (v/v) FBS (Atlanta Biologicals), 100 U/ml penicillin (Invitrogen) 
and 100μg/ml streptomycin (Invitrogen)) with and without inhibitors as described below. 
5.3.2 Fluorometric Assay for Evaluation of hNET Substrate Activity in Cell Culture (4.2.2) 
Stably hNET-transfected HEK cells were seeded at a density of 0.08-0.09 x 106 cells/well 
in white solid-bottom 96-well plates and allowed to proliferate in growth medium for ~2 days at 
37ºC to reach confluence. On the day of the experiment, the complete growth medium was 
aspirated, wells were washed with 200μL PBS, and treated with 100μL experimental medium 
with DMSO (vehicle, 0.02% v/v) or nomifensine (2μM). The cells were incubated for 60min at 
37°C, and experimental FFNs (100μL/well of 10μM solution in experimental medium with 
DMSO (vehicle) or nomifensine 2μM) were added for a final concentration of 5μM FFN 
concentration in wells. Cells were then incubated for 30min at 37ºC. The experiment was 
terminated by two rapid PBS washes (200μL/well) followed by addition of fresh PBS buffer 
(120μL/well). The fluorescence uptake in cells was immediately recorded using a BioTek H1MF 
plate reader (3x3 area scan, bottom read mode) with excitation and emission wavelengths set at 
370nm and 460nm respectively.  Substrate activity was determined using signal to basal ratio 
(S/B): mean fluorescence uptake (with DMSO vehicle) divided by that in the presence of 
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nomifensine. Data presented as normalized uptake ± SD from three independent experiments 
(eight separate measurements per condition per experiment). 
For cell culture imaging, hNET-HEK cells or their respective controls, HEK293, were 
plated onto poly-D-lysine (conc. = 0.1mg/mL) coated clear bottom six-well plates at a density of 
0.15-0.20 x 106 cells per well and grown at 37°C in 5% CO2. Following ~4 days of growth, the 
cells had reached 80-90% confluence. The culture medium was removed by aspiration, and the 
cells were washed with PBS (Invitrogen, 1.0mL/well). To investigate the inhibitory effects of 
nomifensine and cocaine on experimental FFN uptake, cells were incubated in 0.9mL of 
experimental media containing the inhibitor (2μM) or DMSO vehicle as a control at 37°C in 5% 
CO2 for 1h. The FFN uptake was initiated by adding 0.1mL of experimental media containing 
probe (200μM, with a final probe concentration of 20μM in the uptake assay) with and without 
nomifensine (2μM) or cocaine (1μM). Following incubation at 37° C in 5% CO2 for 30 min, the 
media was removed by aspiration and the cells were washed with PBS (1mL/well) and 
maintained in fresh experimental media (1mL/well). Fluorescence images (at least 3 images/well 
in duplicate wells) were acquired with a Leica FW 4000 imaging system (Leica Microsysytems) 
equipped with a Chroma custom filter cube (ex = 350±25nm, em =460±25nm; Chroma 
Technology Corporation) and a Leica DFC-360FX camera. Fluorescence and bright field images 
were acquired with exposure time set at 600ms and 37ms respectively. All images were adjusted 
using the same contrast and brightness level using ImageJ software. 
5.3.2 Fluorescence Microscopy Imaging of Probes in VMAT-HEK cells (4.2.3) 
 VMAT-HEK (described here9) and TetR-HEK cells were plated at a density of 0.15-0.20 
x 106 cells per well on poly-D-lysine coated 6-well optical plates and grown at 37° C in 5% CO2. 
Following ~4 days of growth, the cells had reached 80-90% confluence. The culture medium was 
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removed by aspiration, the cells were washed with PBS (1.0 mL/well), and the wells were 
pretreated with experimental medium with or without the VMAT2 inhibitors reserpine (1µM) or 
dihydrotetrabenazine (dTBZ, 2µM) for approximately 60min.  To initiate uptake, solutions of 
experimental probe with or without inhibitor were added to the appropriate wells for a final 
concentration of 20µM probe with or without reserpine (1µM) or dTBZ (2µM). Cells were 
incubated at 37˚C for 2h, at which point the probe solutions were removed by aspiration and 
wells were gently washed with PBS (2mL). Wells were maintained in fresh experimental 
medium and were imaged as described above (5.3.2). 
 As described in 5.1.2, the Multiple Thresholds ImageJ plug-in (created by Damon 
Poburko, Simon Fraser University, Burnaby, BC, Canada) was used for quantification of 
fluorescent puncta in images of VMAT2-HEK cells obtained from fluorescence microscopy. 
Puncta were identified as objects conforming to defined parameters: appropriate size, rounded 
shape, and well delimited boundaries. The mean intensity and number of these puncta structures 
per image were collected and compared to those collected in inhibited conditions (reserpine or 
dTBZ) or TetR-HEK cells from four independent experiments (six images per condition per 
experiment). 
5.3.3 Imaging Noradrenergic Neuronal Cell Bodies with FFN270 in Acute Brain Slice (4.2.4) 
 All acute slices were prepared as described in 5.1.1, and specifically for the locus 
coeruleus, as described in 5.2.2. Acute murine brain slices from TH-GFP mice containing the 
noradrenergic cell bodies of the locus coeruleus, as identified by GFP signal, were incubated 
with 10µM FFN270 for 30min. After a 10min washing period, FFN270 was imaged with two-
photon laser excitation set to a wavelength of 760nm (near the protonated excitation maximum), 
and emitted light between 440-500nm was collected. GFP was imaged with an excitation 
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wavelength of 920nm and emitted light between 570-640nm was collected.  Images were of a 
112x112µm FOV (1024x1024 pixels) taken with a 10µs dwell time. 
For quantification of colocalization in coronal midbrain slices, cells were considered 
positive for either fluorophore if their mean fluorescence intensity was above 2 times the SD of 
the mean background fluorescence intensity, which was determined in an area devoid of 
fluorescent puncta/cells. The number of cells was manually counted in images from at least three 
different positions per slice, 2-3 slices per animal, from 3 different animals. 
5.3.4 Imaging Noradrenergic Projections in Layer 1 of the Barrel Cortex in Acute Brain Slice 
(4.2.4) 
All acute slices were prepared as described in 5.1.1. For these experiments, acute coronal 
slices containing the barrel cortex were used. FFN270 was loaded into noradrenergic axonal 
projection through a 30min incubation at 10µM. Slices were then washed for 10min prior to 
imaging. FFN270 was imaged using an excitation wavelength of 760nm and emission collection 
of 440-500nm. Due to the sparse nature of these projections, 112x112µm images at 512x512 
pixels (10µs dwell time) of 20 z-planes separated 1µm apart were acquired and then later z-
projected in ImageJ. 
To determine if NET was required for loading in the barrel cortex, FFN270 loading was 
repeated in the presence of nomifensine (2µM) or reboxetine (500nM). For each inhibitor 
condition, slices were pre-incubated with the inhibitor for 15min, followed by a co-incubation 
with FFN270 and inhibitor. After FFN270 loading, the inhibitor was also included in the 
perfusing ACSF during the wash step. This was repeated for 2-3 slices per animal for 3 different 
animals per condition. 
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Quantification of fluorescent puncta in cortical slices with and without inhibitors was 
preformed using Volocity image software version 4.4 (Improvision, PerkinElmer). By defining a 
threshold of intensity as well as size and shape parameters (see Volocity user guide for a more 
detailed description of the object identification tasks) puncta objects were automatically selected. 
After an automatic selection of the objects by the program, a manual inspection was performed, 
where each object was visually inspected to confirm its validity. Selected objects that did not 
conform to a certain number of properties (appropriate size, rounded shape, and well-delimited 
boundaries) were discarded. 
For colocalization experiments, this process was repeated in TH-GFP mice. All FFN270 
loading and imaging conditions, as described above (except the excitation wavelength was 
lowered to 740nm to deter crosstalk between the fluorophores), remained the same. GFP images 
were acquired with an excitation wavelength of 920nm and emission collection of 570-640nm. 
For quantification, Volocity software was again used. After puncta selection described above, the 
colocation feature was used, as described in 5.2.3, to determine colocalization of FFN270 puncta 
to GFP. 
5.3.5 Release of FFN270 from Noradrenergic Release Sites with KCl and Electrical Stimulation 
in Acute Brain Slice (4.2.5) 
 All acute slices were prepared as described in 5.1.1. For depolarization with KCl 
experiments, images were collected as described in 5.3.4. Due to the physical deformations of 
the slice caused by 40mM KCl treatment, no time course was collected, only pre- and 5min post-
KCl treatment images were collected. After the washing period, ACSF with 40mM KCl 
(prepared by isotonic replacement of NaCl) was perfused over the slice for 5min. The FFN270 
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labeling of noradrenergic axonal puncta before and after treatment was then compared to the 
fluorescent labeling in blood vessels or non-axonal puncta. 
 For electrical destaining experiments, FFN270 was loaded and imaged as described in 
5.3.4, except only 5 z-planes spaced 1µm apart were collected to improve imaging rate (image 
every 15s). Electrical stimulation was performed as described in 5.1.2 (10Hz local stimulation 
for 3600 pulses). FFN270 puncta were imaged for 3min prior to stimulation and for 5min after 
stimulation started. The set of images was then analyzed using a MATLAB macro that registered 
and identified destaining puncta. Registration in the z-dimension was performed by choosing a 
group of z-planes that correlated well with each other based on a two-dimensional cross-
correlation in frequency. X/Y registration was performed using a subpixel fast Fourier transform 
algorithm. After final registration each image was thresholded using a multiple thresholding 
methods that incrementally forms ROIs over puncta. These ROIs were then slightly enlarged 
based on the interpunctal distance using a seeded watershed transform to account for any puncta 
movement not corrected by registration. Any ROIs present throughout the pre-stimulation 
baseline had there fluorescence measured throughout the whole time course. The background-
subtracted intensity for each ROI was normalized to the time point prior to stimulation and 
corrected for the baseline rundown using an exponential best fit. Puncta were then classified as 
destaining based on their weightings in the first principal component, using k-means clustering in 
order to minimize the total variance within each cluster. TO identify outliers, a Z-score was 
calculated for each intensity value after stimulation relative to the mean and standard deviation 
of the baseline values. The puncta post-stimulation needed to have a Z-score below -2 standard 
deviations of the mean baseline. Destaining puncta were identified that met both principal 
component and outlier tests. This MATLAB macro will be described in more detail in the 
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submitted paper of our laboratory3. Destaining puncta were identified from 2-3 slices per animal 
for 3 different animals. This experiment and analysis was repeated in 200mM CdCl2 condition to 
block calcium channels, and the number of identified destaining puncta was compared to 
conditions without cadmium ions. 
5.3.6 Optimization of in vivo FFN270 loading condition in Layer 1 of the Barrel Cortex (4.2.6) 
 For in vivo experiments, mice were anesthetized with isoflurane prior to surgery. The 
head was shaved and disinfected with alternating alcohol and betadine swabs. The skull was 
exposed and 2mm diameter circle of bone, centered over the barrel cortex (from bregma: AP: -
1.5-2.5mm, ML: 1.0-2.0mm), was removed with a high speed drill. We applied gel foam soaked 
in sterile cortex buffer to stop any bleeding. For initial “bath loading” the dura was removed and 
50µM FFN270 was directly applied in a small drop to the open brain tissue. For injection 
loading, a glass pipette on a Nanoject II (Drummond Scientific) was used to inject 100µl of FFN 
at each 100µm and 50µm measured from the surface. Injections were delivered in 10µl boluses 
spaced by 30 seconds. A headpost was affixed to the skull with cyanoacrylate and small plastic 
ring was glued around the window to hold ACSF during imaging. The mouse was anesthetized 
with ketamine and xylazine for imaging. Images were collected at 512x512 pixels (10µs dwell 
time) over a 112x112µm FOV. Due to the increased movement observed in vivo, 30 z-planes 
spaced 1µm apart were imaged over the time course. After registering using the 3-D 
colocalization registration macro included with the FIJI version of ImageJ, this usually resulted 
in about 15-20 z-planes that remained consistent over the whole time course. These registered 
images were then z-projected and used for analysis. 
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5.3.7 Release of FFN270 in vivo with Amphetamine (4.2.7) 
 FFN270 was loaded into the barrel cortex of anesthetized mice through injection as 
described in 5.3.6. 30min post FFN270 loading injection, the mouse was help in place under the 
microscope and imaged as described in 5.3.6. Stacks of images were collected every 5min 
starting at 30min post-loading. After 15min of imaging, amphetamine was I.P. injected into the 
mouse at 1mg/kg or 10mg/kg. The time point right before and 5min after amphetamine injection 
were registered using the 3-D colocalization registration macro included with the FIJI version of 
ImageJ. Next, the Multiple Thresholds plug-in (created by Damon Poburko, Simon Fraser 
University, Burnaby, BC, Canada) was used for fluorescent puncta identification at each time 
point. The percent change in the number of puncta after amphetamine injections were compared 
to control mice that only received an I.P. injection of PBS. This was repeated for 3 different 
animals for each AMPH condition and 6 control animals. 
5.3.8 DREADDs and Optogenetics in vivo setup and preliminary evaluation (4.2.8) 
 For the preliminary experiment with DREADDs, the noradrenergic specific DREADDs 
virus (AAV9 PRSx8-hM3DQ DREADD, gift from Gary Aston-Jones, Rutgers University) was 
injected into the locus coeruleus (from bregma: AP: -9.0-10.0mm, ML: 1.5mm, DV: 7.5mm) at 
least two weeks prior to imaging. After waiting for two weeks for adequate viral protein 
expression, FFN270 was injected-loaded in the barrel cortex as described in 5.3.6. 30min post-
FFN270 injection, imaging as described in 5.3.7 was conducted every 5min. After 15min of 
imaging, clozapine-N-oxide was injected at 10mg/kg. Each time point was registered as 
described in 5.3.7 and the average intensity of identified puncta were compared throughout the 
time course. Further analysis is required to rigorously understand FFN270 changes in this 
system. The data presented is only from one animal. Optogenetics experiments have also started, 
but not ready for data collection. For these experiments, mice were injected in the locus 
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